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INTRODUCTION 
 
 
Cancer and AIDS are today two of the leading causes of death in the world. Statistical data show 
about six million new cases of cancer per year in all over the world and about one in four people 
will get it in some form during their life time. The World Health Organization (WHO) estimated 
that, in 2009, 33.4 million people of the world population was suffering from AIDS, the new cases 
of HIV infections were 2.7 million per year and the annual deaths due to AIDS were 2.0 million. 
These data confirm the importance of these diseases both from the social and the purely scientific 
points of view, since the research aim to the identification of new efficacious therapeutic strategies. 
Cancer belongs to that class of diseases in which a group of cells display uncontrolled growth 
forming a tumour that can involve also the adjacent tissues and eventually bits of this tumour break 
off and form new tumours (this is known as metastasis).  
These features make possible to differentiate cancer from benign tumors which show a limited 
growth, do not exhibit invasive properties nor give rise to metastasis. 
Most cancers are initially recognized either because signs or symptoms appear or through cancer 
screening but definitive diagnosis requires histological examination and evaluation of specific 
markers that can be useful to establish prognosis and individual treatments. 
Once diagnosed, patients may undergo surgery and/or radiotherapy and/or chemotherapy. Which 
treatment is used depends on the type of cancer, the location and grade of the tumor, and the stage 
of the disease, as well as the general state of a person's health. 
Many progress have been made in the development of effective and selective treatments in order to 
limit the damage over the normal cells. 
The most effective treatment used for the complete removal of the cancer is the surgical removal of 
affected part, even if the effectiveness of treatment is often limited by the ability of the tumor to 
metastasize. 
Radiation and chemotherapy can provide valuable tools to fight the disease, but they can also cause 
damage to normal tissue and have several side effects such as myelosuppression. 
For these reasons the search for new anticancer drugs is one of the main objectives of scientific 
research. 
Anticancer drugs can be generally divided into two broad categories: cytotoxic and cytostatic. Both 
lead to a reduction in the tumour size by preventing the reproduction of the cancer cells. 
The cytostatic drugs act by interfering with DNA replication. Because cancer cells rapidly divide, 
rapidly synthesize new DNA  and if this is damaged the cell will die.   
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These drugs are divided into three main classes: 
• Antimetabolites: molecules, similar to the nucleotides, that fit the normal metabolic pathways 
causing alterations or block. 
• Alkylating agents and intercalators: molecules that bind (not covalently) the DNA, causing 
changes in its shape. 
• Strand breakers: highly reactive species that lead to breakage of the double helix DNA strands. 
Among cytotoxic drugs are those that interact with the mitotic spindle that express their action by 
acting mainly on microtubules. Microtubules are filamentous proteins formed by - and -tubulin 
dimers that by assembling themselves, during the cell division, form the mitotic spindle which 
cause the separation of sister chromatids by carrying the chromosomes. The role of microtubules is 
essential for the proper distribution of the genetic material in daughter cells. (Fig.1) 
 
  
   Figure 1 
 
 
 
The drugs that interfere with microtubule prevent the proper functioning of the mitotic spindle 
resulting in a non-cell division and subsequent apoptosis. Reference molecules are definitely the 
well-known vinca alkaloids (Vincristine 1 e Vinblastine 2) and taxanes (Paclitaxel 3 e Docetaxel 4). 
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Examples of compounds showing antitumor activity are also polycondensed nitrogen heterocycles. 
From several years the research group where I carried out my PhD was interested in the synthesis 
and biological evaluation of polycondensed nitrogen heterocycles. In this regard they already 
synthesized new heterocyclic systems with antitumor activity, such as pyrrolo[2,1-c][1,2,4]triazines 
5 [1], indolo[4,3-a][1,2,4]triazines 6 [2], indolo[3,2-c]cinnolines 7 [3], indolo[1,2-
c]benzo[1,2,3]triazines 8 [1], pyrrolo[2,1-d][1,2,3,5]tetrazines 9 [4] and indolo[5,4-
a][1,2,3,5]tetrazines 10. [5] (Fig.2) 
 2 
Vinblastine 
1 
Vincristine 
 
3 
Paclitaxel 
4 
Docetaxel 
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All derivatives screened in vitro showed a good antineoplastic activity showing IC50 values in 
micromolar range and in some cases from submicromolar to nanomolar range (indole[3,2-
c]cinnoline IC50 = 0.08-7.0 M; indole[1,2-c]benzo[1,2,3]triazine IC50 = 0.2-10 M; pyrrolo[2,1-d] 
[1,2,3,5]tetrazine IC50 <0.01-56 M). 
 
 
 
Figure 2 
 
 
Considering the results obtained with pyrrole and indole compounds,  new heterocyclic systems 
containing the isoindole nucleus were also synthesized and in particular isoindole[2,1-a] 
quinoxaline derivatives 11 and 12 (Tab.1).  
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Compd R R1 R2 R3 R4 R5 R6 R7 
11a H Me Me H H H OH H 
11b F H H H H H OH H 
12a H H H H H OMe H H 
12b H H H H OMe H H OMe 
12c H Me Me H H H OMe H 
12d H OMe OMe H H H OMe H 
12e F H H H H H OMe H 
12f H OMe H H H H OMe H 
12g H H OMe H H H OMe H 
12h H OMe OMe H H H OH H 
12i H OMe H H H H OH H 
12l H H OMe H H H OH H 
                         Table 1 
Some of these compounds, screened on a panel of approximately 60 human tumor cell lines derived 
from nine different tumor types (leukemia, melanoma, lung cancer, colon cancer, kidney cancer, 
ovarian cancer, breast cancer, prostate cancer and tumors of the CNS), showed inhibitory activity 
against all the lines tested from micro- to nanomolar concentrations (Tab.2). 
 
   pGI50 
Compd N
[1]
 N
[2]
 Range MG_MID 
11a 60 60 >8.00-5.18 7.03 
11b 60 60 6.52-5.11 5.73 
12a 46 46 6.86-5.81 6.38 
12b 59 58 7.14-5.64 5.91 
12c 58 56 >8.00-5.42 5.83 
12d 59 56 >8.00-4.81 7.75 
12e 58 54 7.68-4.97 6.95 
12f 58 54 >8.00-5.92 7.87 
12g 58 56 >8.00-5.98 7.70 
12h 60 57 >8.00-5.49 7.45 
12i 59 58 7.49-4.96 6.63 
12l 60 59 7.57-4.91 6.75 
 
 
N
[1]
 : number of the cell lines investigated 
N
[2]
 : number of the cell lines giving a positive pGI50 values 
 
Table 2 
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Test carried out on rats with tumor cells Ovcar-3, showed that the compound 12d (NSC747526) (it 
was decided to use this compound that is not the most active because it was the easiest to be 
prepared) determined a significant reduction of the tumor mass at the dose of 15mg/kg with a 
concomitant decrease in body weight of the animal. It also showed significant anti-angiogenic 
effects in Ovcar-3 tumors. It was observed a dose dependent significant reduction of the micro 
vessel number, micro vessel ratio and size.  
Immunohistochemical studies were also performed regarding the expression of tumor markers 
CD31 and Ki67. Biological results showed that the compound 12d caused a dose-dependent 
decrease of the expression of Ki67 and CD31. (Fig.3)  
 
 
 
Figure 3 
 
 
Preliminary tests also showed interactions between isoindolol-quinoxaline derivatives and G-
quadruplex telomeric DNA, containing nucleic acid sequences rich in guanine, capable of forming 
structures with four strands in the telomeres, structures that are located at the end of chromosomes 
and necessary for their stability and involved in approximately 85% of all forms of cancer. The 
shortening of telomeres is implicated in cellular senescence. Telomerase is an enzyme that 
synthesizes the filaments rich in guanine of telomeric DNA. The activity of telomerase is highly 
correlated with the cancer and may allow cancer cells to avoid senescence. Considering these 
observations, a promising new approach for the treatment of tumors is based on the identification of 
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small molecules that can inhibit telomerase having as target DNA G-quadruplex structures involved 
in the function of telomeres and the related enzyme. 
This approach would lead to the discovery of drugs which would affect selectively cancer cells and 
not normal cells, bypassing the substantial problems of toxicity of current drugs that are not able to 
discern between healthy cells and cancer cells. The preliminary results of the assays of G-
quadruplex telomeric showed that isoindolol-quinoxaline derivatives had a remarkable selectivity 
against these forms of DNA, suggesting these compounds as " lead compound " to treat a high 
number of tumor forms. 
 
The agent responsible for Acquired Immunodeficiency Syndrome, or more commonly known as 
AIDS, that affects the immune system, is the human immunodeficiency virus (HIV). Currently the 
two viral strains known are HIV-1 and HIV-2. They have a different geographical location, the 
former, initially called LAV (lymphadenopathy-associated virus), is mainly widespread in Europe, 
Asia and Africa, and the second one, mostly in West Africa and Asia, causes a syndrome clinically 
more moderate compared to the previous strain. [6] 
The virion has a spherical structure with a diameter of about 100 nm, with two external membranes 
(pericapsid) produced by the cell; they are a conoid capsid and an envelope in which the 
glycoproteins gp120 and gp41 are located. In the central core there is the RNA genome and  
different enzymes such as reverse transcriptase, integrase and protease. (Fig. 4) 
 
 
 
        Figure 4 
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The replicative cycle of HIV-1 or HIV-2 (Fig.5) starts when the gp120 protein, located on the 
external membrane of the virus, recognizes the homologue receptor on the surface of target cells, a 
particular protein known as CD4. Human cells with more CD4 receptors are CD4
+
 T lymphocytes, 
which are crucial in the process of immune defense. The virus replication process destroys these 
cells, in particular when new viruses leave the cell by budding that often causes the lysis of the 
latter. Once the bond occurred, the fusion of the viral membrane with the host cell starts and a 
fundamental role is played by the gp41 protein. 
Completed the fusion, inside the host cell the reverse transcriptase transcribes DNA from the viral 
RNA (Fig.5), and this DNA is then transported within the cell nucleus and inserted, via integrase, 
into the genome of the host cell to be subsequently transcribed into genomic and messenger RNA, 
essential for the synthesis of viral proteins necessary for the maturation of the virus.  
 
 
 
                    Figure 5 
 
 
These viral proteins produced are assembled together to proviral RNA to form the internal 
components of the structure of the virion. After that the membrane of the infected cell forms a lipid 
bilayer around the viral matrix (containing gp41 and gp120) and new infectious particles are 
released into the extracellular medium by a process of budding. Lastly the stage of maturation of the 
virion consists on the acquisition of the ability to infect other cells. (Fig. 6) [7] [8] 
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       Figure 6 
 
 
Currently, the anti-AIDS drugs commercially available are different: reverse transcriptase 
inhibitors, protease inhibitors, integrase inhibitors and fusion inhibitors; although the most used 
treatment is surely multidrug, which has the purpose of reduce the resistance that commonly occur 
and delay the progression of the disease. [9]  
Considering the key role of reverse transcriptase in this disease, it is not surprising the interest 
moved over the years to the development of new inhibitors. 
HIV reverse transcriptase (RT) is a crucial enzyme responsible for the synthesis of double-stranded 
DNA from the single-stranded RNA genome.  
HIV-1 RT is a protein dimer consisting of  two subunits of 66 kDa (p66) and 51 kDa (p51). [10] 
The p66 and p51 subunits are composed of three subdomains called thumb, palm and fingers. The 
p66 subunit also contains an RNase H active site. NNRTIs bind to a common hydrophobic site 
(NNIBP) in the p66 palm subdomain 10 Ǻ away from the polymerase. (Fig. 7) [11] [12] 
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Figure 7 
 
The frequent mutations that occur in this enzyme of the amino acid residues Y181, Y188 and K103 
led to the identification of four highly conserved residues of the binding pocket for NNRTIs: F227, 
W229, L324 and Y318. With the exception of Y318 the other three are part of the "hairpin" β12-
β13 responsible for maintaining the correct orientation of the enzyme for the nucleophilic attack on 
the incoming dNTP. [13] 
The mutation in this region of the enzyme compromise the activity of the enzyme, in particular, the 
mutation of the fragment W229 reduces the activity of reverse transcriptase to less than 2%, 
highlighting the vital importance of this residue for the enzyme. [14] The mutation of this fragment 
has never been observed in combination with other, indicating that the compensatory mutations to 
restore the enzyme activity of reverse transcriptase in the mutated residue W229 does not happen 
easily. [15] 
The reverse transcriptase inhibitors can be classified into two main groups: nucleoside RT inhibitors 
(NRTIs) and non-nucleoside RT inhibitors (NNRTIs). [16] [17] [18] [19]  
NRTIs compete with the natural deoxynucleoside triphosphate (dNTP) substrate for RT binding, 
and thus inhibit HIV replication by terminating chain elongation. NNRTIs bind to an allosteric site 
in HIV-RT and indirectly interefere with dNTP incorporation, probably by altering the 
conformation of residues located in the active site and inducing structural distortion of RT.  
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A competitive inhibitor (NRTI) currently used in the treatment of AIDS is Zidovudine (AZT) 13, 
but its therapeutic usefulness is limited by poor brain penetration, viral resistance, toxicity and low 
specificity. [20] [21] [22] 
 
O
N3
HO
HN
O
O
13  
            
HN
N
N N
O
14                      
O
H
NO
Cl
F3C C
C
11  
 
NNRTIs can bypass some of these disadvantages inherent to nucleoside inhibitors and the 
representative compounds of this class are Nevirapine 14 and Efavirenz 15. 
Beacuse of their generally good tollerability and low toxicity, [23] these drugs are essential 
component of highly active antiretroviral therapy (HAART), with nucleoside reverse transcriptase 
inhibitors (NRTI) and/or protease inhibitors (PI). [11]  The multidrug therapy provides a substantial 
delay in disease progression compared to mono therapy or dual therapy, allowing significant 
immune system function restoration and retarding the emergence of resistant viral strains. [23] [24] 
Mutation to RT rapidly emerge and they confer resistance to all known NNRTIs, reducing the 
efficiency of the drugs. It is necessary to understand the interactions of the inhibitor with RT in 
order to design more effective drugs.  
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In order to identify new molecules with antiviral and/or antitumor properties, 
pyrrolo[1,5]benzoxazepine (PBOX) derivatives are reported. In fact, these compounds showed both 
anti-HIV (derivatives of type 16) and anticancer (derivatives of type 17) activity depending on the 
substitution on the benzoxazepine core.  
 
O
N
O
R
16
O
N
17
O
R
R1
O
R = phenyl, naphtyl, p-OMephenyl, p-tolyl
R1= Me, N(Me)2, N(Et)2  
 
PBOXs 16 represent a new class of non-nucleoside inhibitors of reverse transcriptase of the 
immunodeficiency virus type 1 (HIV-1) that is also capable of preventing cytopathogenicity in the 
T4 lymphocytes. Their activity was influenced by the substituents in the 6-position on the fused 
aromatic ring. Small  lipophilic substituents on the C-6 were preferred, while substitutions on the 
benzo-fused ring were found to be useless for the activity, compared to not substituted compounds. 
Changes to the system to the C-6 were well tolerated, on the contrary the replacement of the 
benzo-fused ring with a [2,3]naphtho-system led to less active compounds. Finally, the best activity 
and specificity were obtained when in position 6 of the pyrrole-benzoxazepine system a phenyl 
group or ethyl alcohol were inserted. Furthermore, through enzyme assays the activity of these 
derivatives was compared with the activity of nevirapine and it was found that the latter is even less 
active, bringing an IC50 value of 0.5 M versus 0.25 M of pyrrole-benzoxazepines. The cell 
culture assays also showed a specificity of action against HIV-1 than HIV-2. [25]                                                                         
The same pyrrolo[1,5]benzoxazepines ring 17, variously substituted, showed antiproliferative 
activity in a wide range of tumor cell lines at micromolar concentrations. Many 
pyrrolo[1,5]benzoxazepines caused apoptosis as confirmed by cell shrinkage, by chromatin 
condensation and by the DNA fragmentation in three tumor cell lines, such as HL-60 promyelocytic 
cell line, Jurkat T lymphoma and Hut-78 lymphoma. The pro-apoptotic effect appeared to be due to 
an activation of caspase-3-like. Studies showed that the mitochondrial protein cytochrome c 
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induced apoptosis when it was accumulated in the cytosol in response to different stress inducers. It 
was also analyzed this aspect on the three tumor cell lines and it was found that this release of 
cytochrome c, which subsequently activates the caspase 3, had an important role in the induction of 
apoptosis by the PBO. [26] Interesting IC50 values (1.7-1.9 M), related to cytotoxic activity of 
benzoxazepine derivatives, were found on the cell lines of colon carcinoma HT29 and lung 
carcinomas NCI-H460 and M109. The cell death process appeared to be triggered by the activation 
of the proapoptotic MAP kinase JNK, suggesting that the molecular target of the 
pyrrolo[1,5]benzoxazepines was intracellular, since it was also found that their analogues, unable to 
penetrate inside the cell, did not induce apoptosis or activation of JNK. [27] 
Evidence also showed that the antitumor activity in different tumor cell lines, such as ovarian 
cancer and chronic myelogenous leukemia, was explicated through targeted action on both the 
tumor cells and their vasculature. The pro-apoptotic effect, shown for example on the A2780 
ovarian carcinoma cell line (IC50 = 0.23-3.58 M) or K562 chronic myeloid leukemia (IC50 = 0.37-
6.49 M), was mediated by the cell arrest in G2/M phase, due to the binding of these compounds to 
tubulin site not yet characterized, different from the one that binds colchicine and vinca alkaloids. 
This causes the formation of anomalous microtubules, unable to complete the cell division process 
resulting in apoptosis. Moreover, PBOXs showed an anti-angiogenic activity targeting cells 
vasculature. In particular, in the Human Umbilical Vein Endothelial Cells (HUVEC) the formation 
of capillaries and the migratory activity of the cells was inhibited (IC50 = 0.06-0.70 M). (Fig.8) 
[28] 
 
 
 Figure 8 
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It was also found, in the breast cancer cell line MCF-7 and in the chronic myeloid leukemia K562, 
an arrest in prometaphase, an accumulation of B1 cyclin and an activation of B1 cyclin/CDK1 
kinase, similar to the more representative antimicrotubular agents such as nocodazole and 
paclitaxel. Thanks to indirect immunofluorescence studies, depolymerization of microtubules was 
in fact detected in the cell lines treated with the benzoxazepine derivatives and, in vitro, the 
inhibition of tubulin assembly was also underlined. [29] 
Moreover, compound 18 showed antiproliferative effect by arresting the cell cycle in G1 phase 
avoiding cytotoxic effects. It seemed to enhance the apoptotic effectiveness of STI571 (Imatinib) in 
chronic myeloid leukemia. The induction of apoptosis by PBO/STI751 resulted in the activation of 
caspase 8, cleavage of PARP (Poly (ADP-ribose) polymerase) and Bcl-2 (antiapoptotic protein), up-
regulation of the proapoptotic protein Bim and down-regulation of Bcr-Abl. [30] 
 
N
O
O
N
O
18
 
 
Moreover, in literature there are some variously condensed oxazines 19 showing an interesting in 
vitro antiproliferative activity against the highly metastatic osteosarcoma LM8G7 and two ovarian 
cancer cell lines OVSAHO and SHOV-3 by binding some growth factors/cytokines VEGF 
(vascular endothelial growth factor), TNF-α (tumor necrosis factor), HB-EGF (heparin-binding 
epidermal growth factor-like growth factor) that appeared to be involved in cancer progression. 
 
N
H
O
A B
19  
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They also inhibited the proliferation of LM8G7 cells that express VEGF, of OVSAHO cells 
expressing TNF-α and of SHOV-3 cells that express HB-EGF in a micromolar range concentration. 
And finally they seemed to be also able to inhibit in vitro the LM8G7 migration and invasion, the 
angiogenic events, such as endothelial cells proliferation and migration, and the formation of 
capillary-like structures. (Fig.9) [31] 
 
 
Fig. 9 Oxazines (0.5-5 mM) or heparin effects (100 mg/mL) on migration (A) and invasion (B) of LM8G7 cells. The 
data shown represent the mean values ± SD of two different experiments. 
 
 
Considering the interesting results shown by both the pyrrolo[1,2-d][1,5]benzoxazepine derivatives 
and the isoindolo[2,1-a]quinoxalines as well as the experience gained in the synthesis of the 
isoindole nucleus, the purpose of the project was the synthesis of new isoindolo[1,2-
d][1,5]benzoxazepine heterocycle in order to evaluate if the substitution of the pyrrole ring with a 
isoindole ring could influence the antitumor and antiviral activities. 
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RESULTS AND DISCUSSION 
 
The synthetic pathway involved the synthesis of the 2-(2'-hydroxyphenyl)-2H-isoindole-1-
carbonitrile intermediates 23a-c, prepared by Strecker like reaction between different ortho-
phthaldialdehydes 20a-c and 2-aminophenol 21 in the presence of sodium hydrogensulfite and 
potassium cyanide. 
 
 
H
O
H
O
NH2
OH
+ + +NaHSO3 KCN
H2O
H
O
N
H
HO
HNC
N
CN
HO
20a-c
23a-c
21
R
R1
a R=R1=H
b R=R1=Me
c R=R1=OMe
22
R
R1
R
R1
 
 
 
We initially focused on the synthesis of ortho-phthaldialdehydes 20b-c not commercially available. 
A large number of papers reports the oxidation of alcohols to aldehydes using activated dimethyl 
sulfoxide (DMSO). The most widely used procedure in oxidation reactions is known as "Swern 
oxidation", it involved the use of oxalyl chloride (CO2Cl2) as activating agent of DMSO. 
Farooq in a work of 1994 reported the synthesis of the dimethyl-ortho-phthaldialdehyde 20b by 
oxidation of the corresponding 1,2-dimethanol 28. [32] 
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The mechanism of the oxidation could be explained through two primary steps: the activation of 
DMSO and the following oxidation. 
In the first step, the reaction between the DMSO (29b) and the CO2Cl2 (30) led to the formation of 
the intermediate 31, which quickly decomposed to form the dimetilclorosulfonil chloride 32. 
 
1) DMSO Activation
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ClCl
O O
29a 29b
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-CO S
Cl
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32
 
 
 
In the second step the formed dimetilclorosulfonil chloride 32 reacted with the 1,2-dimethanol 28 to 
generate first the alkyl sulfonium ion 33 which, after treatment with a base (triethylamine), 
underwent deprotonation to give the ylide 34. The subsequent elimination of two molecules of 
dimethylsulfide led to the formation of the aldehyde 20b. 
24   
20b 
27 
28 
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2) Oxidation
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It was therefore necessary to synthesize the 1,2-dimethanol 28 through the reduction of the 
corresponding dimethylester 27. 
This latter compound 27 was synthesized using 2,3-dimetilbutan-1,3-diene 24 as starting material. 
The Diels Alder reaction between derivative 24 and dimethyl acetylene dicarboxylate 25 in toluene 
refluxing for 24 hours, led to the isolation, in high yield (95%), of intermediate 26. The subsequent 
oxidation of derivatives 26 with DDQ (2,3-dichloro-5,6-dicyano-benzo-1,4-quinone) in 
chlorobenzene refluxing for 24 hours, led to the isolation of the desired ester 27 in high yield 
(92%). The reduction of the derivative 27 with borane in tetrahydrofuran refluxing for 20 hours led 
to the formation of the alcohol 28 with 80% yield. 
The oxidation of the alcohol group, using dimethyl sulfoxide, oxalyl chloride and triethylamine as 
base in dichloromethane under an argon atmosphere at -78 ° C gave the 4,5-
dimethylphthaldialdehyde 20b. (87%) 
The synthetic route necessary to obtain the 4,5-dimethoxyphthaldialdehyde 20c involved the 
reduction of the 2-bromo-4,5-dimethoxy benzoic acid 35 to the corresponding alcohol 36, followed 
by its oxidation to give the aldehyde 40. The aldehyde group of the latter had to be protected, 
lithiated and deprotected to give the desired ortho- phthaldialdehyde 20c. 
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Reduction of the suitable bromo-benzoic acid 35 was carried out using a solution of borane in 
tetrahydrofuran. From the reaction mixture, after stirring at room temperature for 2 hours and 
following acidification, it was possible to isolate the corresponding alcohol 36 in excellent yield 
(90%). [33] 
The alcohol 36 underwent oxidation using Dess-Martin periodinane (1,1,1-triacetoxy-1,1-dihydro-1 
,2-benziodossol-3(1H)-one) in dichloromethane at room temperature for 2 hours under argon 
atmosphere, to furnish the corresponding aldehyde 40 in excellent yield (90%). 
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The obtained aldehydes were protected with ethylene glycol in the presence of a catalytic amounts 
of p-toluensulfonic acid in toluene refluxing for 24 hours using the Dean-Stark apparatus that, by 
removing the water formed in the reaction process, improve the rate of the reaction giving the acetal 
42 in high yield (90%). [34] 
The subsequent litiation of the derivative 42 with n-BuLi (solution 1.6M in n-hexane) in presence of  
dimethylformamide in tetrahydrofuran at -78° C for 1 hour led to the aldehyde 43 in quantitative 
yield. Deprotection of the aldehyde group of the latter compound with p-toluensulfonic acid in 
acetone at room temperature, afforded the ortho-phthaldialdehyde derivative 20c in excellent yield 
(88%). 
All phthaldialdehydes 20a-c were reacted with the commercially available 2-aminophenol 21 in the 
presence of sodium hydrogen sulfite and potassium cyanide to give the corresponding 2-(2'-
hydroxyphenyl)-2H-isoindoles-1-carbonitrile 23a-e in very good to quantitative yields (84-100%). 
The reaction mechanism provided that the amino group attacks one of the two aldehyde functions of 
ortho-phthaldialdehydes. The following addition of an aqueous solution of potassium cyanide led 
the formation of a non-isolable intermediate 22, that after a further nucleophilic attack and 
subsequent intramolecular rearrangement, gave the desired isoindole derivatives. 
Starting from 2-(2'-hydroxyphenyl)-1-cyano-isoindoles 23a-c it was possible to obtain the esters 
45a-d by O-alkylation using ethyl -bromoesters 44a,b in the presence of sodium hydride as base, 
in tetrahydrofuran refluxing, in good yields (52-76%). 
 
 
N
CN
HO R2
Br
OEt
O
N
CN
OEtOOC
R2
NaH
a R=R1=H, R2=phenyl
b R=R1=Me, R2=phenyl
c R=R1=OMe, R2=phenyl
d R=R1=H, R2=p-tolyl
23a-c 44a,b 45a-d
R
R1
R
R1
a R=R1=H
b R=R1=Me
c R=R1=OMe
a  R2=phenyl
b R2=p-tolyl
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The p-tolyl-ethyl-bromoester 44b, not commercially available, was prepared starting from the 
ethyl p-tolylacetate 46 by reaction with NBS (N-bromosuccinimide) in carbon tetrachloride in the 
presence of  HBr 48% refluxing for 26 hours, with 75% yield. 
          
O
OEt
O
OEt
Br
NBS/HBr 48%
CCl4/
46 44b  
The saponification of the ester group of 45a-d derivatives with an aqueous NaOH 5% solution in a 
mixture of EtOH/THF (1:1) at room temperature for 15 minutes, allowed the formation of the 
corresponding acids 47a-d from good to high yields (73-95%). 
The acids thus obtained were reacted with thionyl chloride in toluene refluxing to generate the 
benzoxazepine nucleus of derivatives 48a-d, through intramolecular cyclization in moderate yields 
(35-44%).
N
CN
OEtOOC
R2
N
CN
OHOOC
R2
NaOH 5%
EtOH/THF
N
CN
O
O
R2
SOCl2/toluene
45a-d
47a-d
48a-d
a R=R1=H, R2=phenyl
b R=R1=Me, R2=phenyl
c R=R1=OMe, R2=phenyl
d R=R1=H, R2=p-tolyl
R
R1
R
R1
R
R1
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The isondolo[1,5]benzoxazepine derivatives 48a-d were functionalized by the insertion of an acetyl 
group by reacting with acetyl chloride and a suitable base at room temperature; to obtain derivatives 
49a-d, the reaction was carried out in the presence of triethylamine as a base (64-90%) while 
sodium hydride was used for derivatives 50a,b in tetrahydrofuran (50-54%). 
 
N
CN
O
O
R2
N
CN
O
O
R2
N
OO
R2
CN
O
O
Et3N/DCM NaH/THF
O
Cl
O
Cl
48a-d
49a-d 50a,b
a R=R1=H, R2=phenyl
b R=R1=Me, R2=phenyl
c R=R1=OMe, R2=phenyl
d R=R1=H, R2=p-tolyl
R
R1
R
R1
R
R1
 
 
Moreover the same isondolo[1,5]benzoxazepine derivatives 48a-d were functionalized by the 
insertion of an ethyl group using ethyl iodide and triethylamine as base for derivative 51a (30%) 
and sodium hydride for derivatives 52a-d (24-55 %). 
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Et3N/DMF NaH/DMFEtI EtI
48a-d
51a 52a-d
R
R1
R
R1
R
R1
a R=R1=H, R2=phenyl
b R=R1=Me, R2=phenyl
c R=R1=OMe, R2=phenyl
d R=R1=H, R2=p-tolyl  
 
 
Finally, starting from the 2-(2'-hydroxyphenyl)-2H-isoindoles-1-carbonitrile intermediates 23a-e it 
was also possible to obtain the isoindole[1,4]benzoxazinones 53a-c by refluxing in acetic acid and 
subsequent hydrolysis (10 -20%). 
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All derivatives obtained 48a-d, 49a-d, 50a-b, 51a, 52a-d and 53a-c were submitted to evaluate 
their biological activity as antitumor and/or antiviral agents. 
Biological screenings were performed on seven isondolo[1,5]benzoxazepines (48a, 48b, 48c, 50a, 
51a, 52a, 52d), selected by the National Cancer Institute (Bethesda), at one dose concentration (10
-5
 
M), for the in vitro disease-oriented antitumor screenings against a panel of about 60 human tumor 
cell lines grouped in disease sub-panel including leukemia, non-small cell lung cancer, colon 
cancer, central nervous system cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and 
breast cancer cell lines. 48a, 48b, 48c showed the most interesting results were. These results take 
into consideration the percentage of growth inhibitory power. The three screened derivatives 
showed a very good selectivity towards the non-small lung cancer cell line NCI-H522 (range -
43.73% - -32.37%) and also a good selectivity towards the BT-549 breast cancer cell line (16.96% - 
-7.13%) and the SR leukemia cell line (12.51% - -7.43%). (Fig.10, 11, 12) 
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Figure 10 
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Figure 11 
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Figure 12 
 
 
These most interesting compounds 48a, 48b and 48c were selected for the total-screening at five 
dose concentrations (10
-4
-10
-8
 M). 
All of them resulted active at micromolar concentration with a range of IC50 value of 1.8-18.2  
for 48a, 1.6-5.5  for 48b and 1.6-91  for 48c. 
In particular they showed a particular selectivity towards some tumor cell line such as the leukemia 
cell line CCRF-CEM, the non-small lung cancer cell lines HOP-92 and NCI-H522, the CNS cancer 
cell line SNB-75 and the breast cancer cell line MDA-MB-2231 with the best activity observed for 
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the HOP-92 cell line with an IC50 value between 1.5-2.0 M. (Tab.3)  
 
TUMOR CELL LINE  
48a 
IC50
48b 
 
48c 
CCRF-CEM       (Leukemia Cell Line) 2.7 2.5 2.7 
HOP-92              (Non-Small Lung Cancer Cell Line) 2.0 1.6 1.5 
NCI-H522          (Non-Small Lung Cancer Cell Line) 2.1 1.6 1.6 
SNB-75              (CNS Cancer Cell Line) 2.2 2.3 4.4 
MDA-MB-231   (Breast Cancer Cell Line) 2.8 2.6 4.6 
 
Table 3 
 
Moreover, all compounds were submitted to the University of Padova to investigate their antiviral 
activity.  
They were solubilized in dimethylsulfoxide at 10 mM concentration. Initially it was determineted 
the molar extinction coefficient by spectrophotometric titration. It was used the TN 10/20 (10 mM 
Tris HCl and 20 mM NaCl) buffer for the analysis and the range of wavelengths of the spectra was 
between 250 and 550 nm. To evaluate the molar extinction coefficient the compound was added in a 
increasing way and the spectrum was recorded after each add. The data are shown in table. (Tab.4) 
 
Compound EPSILON 
(cm
-1
M
-1
) 
(nm) 
48a 15343 ± 380 427.00 
48b 16646 ± 473 352.53 
48d 7025 ± 493 335.31 
49c 14822 ± 286 398.92 
49d 18079 ± 661 404.12 
50a 13495 ± 489 393.76 
52b 10854 ± 1476 370.95 
53b 6524.3 ± 203 367.50 
53c 11427 ± 197 276.69 
 
  Table 4 
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It was not possible to evaluate the molar extinction coefficient of the compounds missing in the 
table as they tumbled in the cuvette. 
It was also examined whether the compounds emitted in the same range of emission of fluorescein 
as this could compromise the subsequent tests. The analysis was carried out with the multi-plate 
reader VICTORIII. 
96-well plates were used and the final volume for each well was 100 l adding the buffer TN 10/20, 
water and the compound tested with a final concentration of 100 M. The analysis was carried out 
by exciting the derivatives at 485 nm and observing the possible emission at 535 nm, that is the 
emission wavelength of fluorescein. 
Once demonstrated that all compounds were suitable to the following tests, it was analyzed their 
activity by FRET using the multi-plate reader VICTORIII. 
The purpose of the test was to evaluate the inhibition of the nucleocapsid protein (NC protein) 
through the analysis of the variation of fluorescence.  
The NC protein is a very small, basic protein containing two retroviral zinc finger which are 
connected by a short basic peptide linker. (Fig.13)  
 
 
           Figure 13 
 
 
It is initially synthesized as part of part of the Gag polyprotein. It takes part in the selection of the 
genomic RNA for encapsidation into the new virus particle. [35] It also act as a nucleic chaperone, 
unfolding a cellular tRNA molecule and promoting the hybridization of a part of the tRNA to the 
viral genome, where it serves as a primer for reverse transcription, a critical process to the 
replicative cycle of the virus. [36] [37] 
To evaluate the activity of compounds the oligonucleotide cTAR FAM- DAB labeled (Fluorescein 
and Dabcyl) was used; in his folded conformation the radiation of  fluorescein was quenched by the 
acceptor of fluorescence Dabcyl and no signal could be registered; when the NC protein promoted 
the unfolding of the oligonucleotide, a process of denaturation of cTAR took place, with a 
consequent separation of the two markers which resulted in a fluorescence signal. When the protein 
31 
 
inhibitor was added it was possible to notice a decrease in the fluorescence signal due to the 
inhibition of the process of unfolding of the oligonucleotide. 
The analysis was performed with increasing concentrations of all compounds to understand at 
which concentration the activity began to appear.  
The solution of the oligonucleotide was prepared by diluting the cTAR in TNMg (1M Tris HCl, 1M 
NaCl and Mg(ClO4)2 1M) and water to obtain a final concentration in the well of  0.1 . The 
solution was heated for 5 minutes in a water bath and then brought to room temperature to promote 
the folding of the cTAR. 
The protein was diluted in water to a concentration of 0.8 , after that the solutions with the 
increasing concentrations of sample in dimethylsulfoxide were prepared: 0.1  0.5 , 1.0  
5.0 , 10 , 50 M and 100 . 
The results was processed using the following equation: 
Fluorescence = (Fx-F0)/(Fm-F0) 
 Where Fx is the fluorescence in the presence of the compound, cTAR and NC 
 F0 is the fluorescence of cTAR  
 Fm is the fluorescence of cTAR together with NC. 
 
By analyzing the variation of fluorescence as a function of the logarithm of molarity we obtained 
the curves (for example 48b Fig.14 and 49b Fig.15) from which it was possible to obtain the IC50 
values reported in the table (Tab.5). 
 
 
Figure 12 
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Figure 13 
 
 
COMPOUND IC50 (M) 
48a >100 
48b >100 
48c >100 
48d >100 
49a >100 
49b >100 
49c >100 
49d >100 
50a >100 
50b >100 
51a >100 
52a >100 
52b >100 
52c >100 
52d >100 
53a >100 
53b >100 
53c >100 
 
Table 5 
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Unfortunately none of the 18 derivatives showed inhibition activity of the cTAR melting by the NC 
protein of HIV-1 up to a concentration of 100 . Further studies are still in progress. 
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INTRODUCTION 
 
In attempt to overcome drug resistance, lesser toxicity, good patient adherence, and better 
pharmacokinetic properties of NNRTIs and find more potent inhibitor several cocrystals of HIV-1 
RT with NNRTIs have been studied, showing that the structural features that appear to be important 
for the binding to the allosteric site include the presence of a double plane and the ability of those 
systems to adopt two conformations which were called “butterfly like” [38] [39] or “horseshoe” 
[40] conformation. 
In particular hypothetical 3-D pharmacophore models were built by using a combined ligand- and 
structure-based molecular modeling approach to understand which were the main features that an 
NNRTI should incorporate. 
For example in the past years, seven NNRTIs have been marketed or are undergoing clinical trials, 
etravirine 54, rilpivirine 55, RDEA806 56, [41] UK-453061 57, [42] IDX-899 58, [43] MK-4965 
59, [44] and the drug candidate BILR 355 60. [45] 
 
 
N
NO NH
CN
Br
NH2
CN
54
N
NHN NH
CN
CN
55  
 
35 
 
56
N
N N
S
O
N
H
Cl
OK
O
Br
 
 
O
N
N
OH
CNNC
57
N
H
P
CN
O
NH2
O
O
Cl
58  
 
O O
N
NH
N
Cl CN
Cl
NH2
59  
 
36 
 
N
N
N N
O
Cl
O
N
O
60  
 
 
According with the known bind information of these 7 compounds, a pharmacophore model was 
built. (Fig.14) 
 
 
Figure 14 
 
 
In this model F and B are the hydrophobic region that interact with the the residues Y181 (Tyr), 
Y188 (Tyr), W229 (Trp), F227 (Phe), V106 (Val), P236 (Pro), L100 (Leu), L234 (Leu), and Y318 
(Tyr). D is the region that is responsible for the adaptability, aryl or alkyl groups, single ring or 
double ring, phosphonate or sulfonyl group for example. C is the part of the molecule responsible of 
the hydrogen bonding interaction with K101 (Lys), K103 (Lys) and P236 (Pro). A is the polar 
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moiety that interact with the solvent interface. The linkers between B and F (C and E) are 
responsible for the molecular flexibility. (Fig.15) [46] 
 
 
 
Figure 15 
 
Moreover further information were given by a pharmacophore model built using the crystal 
structure of RT with 7 different ligands which were able to establish hydrogen bonding interactions 
with the backbone of the aminoacids K101 and/or K103: efavirenz 61, emivirine 62, HBY097 63, 
MSC204 64, UC781 65, 739W94 66, and TMC120 67. 
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The final model contained three lipophilic parts and two hydrophobic region, one hydrogen bond 
acceptor and one hydrogen bond donor. 
The figure 16 showed the alignment of the 3D coordinates of the bound ligand efavirenz 61 onto the 
five feature hypothesis built. 
 
 
Figure 16 
 
The HBA (hydrogen bond acceptor) and HBD (hydrogen bond donor) are mapped by the 
carboxiamide group (Lys101), while the three hydrophobic sites HYs are mapped by the 
cyclopropyl group (HY1, Trp229, Tyr181, Tyr188, Pro95), the benzene-fused ring (HY2, Val106, 
Phe227, Leu234, Pro236), and the chlorine atom (HY3, Leu100, Val106, Tyr318, Leu234, Pro236). 
[47] 
Considering the necessary features described, a series of compounds that had most of them was 
observed to be the indole-3-sulfonamides. The 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide 68 
has been reported as a potent NNRTI against wild type RT (IC50= 3 nM), it also showed a sub-
micromolar activity against K103N (IC50= 116 nM) and Y181C (IC50= 71 nM), two HIV-RT 
mutants observed clinically with high frequency. [48] 
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Considering these results different series of new indole-3-sulfonamides 69, 70, 71, 72 have been 
developed showing IC50 values at nanomolar concentrations. [49] 
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In light of these results, the purpose of the project was the synthesis of new classes of indole 73, 74, 
75 and 76 in order to improve the activity of the indole-3-sulfonamides compounds through the 
insertion of a group that is able to form hydrogen bonds as it was described in the pharmacophore 
models. 
 
 
N
H
O
O
X R
73 X = S, SO2
74 X = CO, CH2, O
N
H
X R
OMe
OMe 75 X = S, SO2
76 X = CO, CH2, O
R = H, 2-Br, 2-Cl, 2-F, 2-Me, 2-OMe, 2-NO2, 3-Me, 3-OMe, 3-NO2, 4-Cl, 4-OMe, 4-NO2, 2,6-dimethyl, 2,6-dimethyoxy, 2,6-
diCl, 2,6-diF, 2,4-diNO2, 3,4-diNO2, 2,4,6-trimethyl, 3,4,5-trimethoxy, 4-Cl-3-NO2
 
 
 
DOCKING STUDY 
 
With the aim of gaining an insight into the binding mode and interactions of indole derivatives with 
HIV-1 RT and to improve the development of more active inhibitors, it was performed a docking 
study of these derivatives with HIV-1 RT. 
For docking studies the X-ray crystallographic structure of HIV-1 RT protein with PDB code 1RT2 
was selected. In this structure RT is constituted by two different subunits (chain A and B) and is co-
crystallized with TNK 651 that bind just one of the two subunits. (Fig.17)  
This structure was used to design new NNRTIs in several works present in literature. [50] [51] [52]  
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       Figure 17 
 
 
To validate the model, non nucleoside structures, similar to our compounds, with antiviral activity 
on RT, were docked. [48] [49] [53] [54] 
A number of 57 compounds 77a-v, 78a-y, 79a-j with a molecular scaffold showed in table 6 were 
docked using different conditions: standard and extra precision mode, using Lys101 as constraints 
for hydrogen bond an using different crystallographic structures. 
The best docking was that one in which the X-ray structure 1RT2 and extra precision Glide mode 
was used. 
34 active compounds showed H-bond interaction between  N of indole portion and Lys101  residue 
(Tab.6) that seems to be very important for antiviral activity as reported in literature. [50] [51] [52] 
[55]  
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         Figure 18 
 
 
The total number of active compounds showed hydrophobic interactions between R1 substituents 
and Tyr 181, Trp 229, Phe227, Tyr181 residues. Furthermore the indole portion establish 
hydrophobic interaction with Leu 234, Pro236, Tyr318 an Leu100 residues. (Fig.18) 
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Compd X R R1 R2 Docking 
Score 
H-bond 
interaction 
77a SO2 Cl Phenyl 
N
H
N
 
-10.008 K101 
77b SO2 Cl Phenyl 
N
H
N
 
-8.673 - 
77c SO2 Cl Phenyl 
N
H
N
 
-8.718 K101 
77d SO2 Cl Phenyl 
N
H
N
 
-7.901 - 
77e SO2 Cl Phenyl 
N
H
N
 
-8.715 - 
77f SO2 Cl Phenyl 
N
H
N
 
-8.583 - 
77g SO2 Cl Phenyl 
N
S
 
-8.407 - 
77h SO2 Cl Phenyl 
N
H
N
 
-8.780 - 
77i SO2 Cl Phenyl 
N
HN
 
-4.931 - 
77j SO2 Cl Phenyl 
N
H
N
 
-8.611 - 
77k SO2 Cl Phenyl 
N
H
N
 
- - 
77l SO2 Cl Phenyl CONH2 -12.447 K101 
77m S H Phenyl CH2S(O)Ph -7.167 K101 
77n S Cl Phenyl CH2S(O)Ph -10.037 K101 
77o SO H Phenyl CH2S(O)Ph -12.100 K101 
77p S H Phenyl CO2CH3 -11.877 K101 
77q S Cl Phenyl CO2CH3 -11.230 K101 
77r S Cl Phenyl CONH2 -12.595 K101 
77s S H Phenyl CON(CH3)2 - - 
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77t S H Phenyl CONHCH3 -12.218 K101 
77u S Cl Phenyl CONHCH3 -12.420 K101 
77v SO Cl Phenyl CONH2 -12.869 K101 
78a SO2 Cl 
N
 
CONH2 -10.464 K101 
78b SO2 CN 
N
 
CONH2 -10.203 K101 
78c SO2 
 N
 
CONH2 -10.847 K101 
78d SO2 
 
N
 
CONH2 - - 
78e SO2 Phenyl 
N
 
CONH2 - - 
78f SO2 
N  
N
 
CONH2 - - 
78g SO2 
N
Cl
 
N
 
CONH2 -12.436 K101 
78h 
 
SO2 Br 
N
 
CONH2 -10.344 K101 
78i SO2 Br 
N
 
N
H
O
OH
 
-9.042 K101 
78j SO2 Br 
N
 
N
H
O
F
Cl
 
-8.068 - 
78k SO2 Br 
N
 
N
H
O
HO
 
-8.372 - 
78l SO2 Br 
N
 
N
H
O
N
 
-8.818 K101 
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78m SO2 Br 
N
 
N
H
O
HN N
 
-9.837 K101 
78n SO2 Br 
N
 
N
H
O
S
N
 
-9.254 K101 
78o SO2 Br 
N
 
N
H
O
S
N
 
-9.053 K101 
78p SO2 Br 
N
 
N
H
O
N
 
-9.250 K101 
78q SO2 Br 
N
 
N
H
N
 
-6.258 - 
78r SO2 Br 
N
 
N
H
N
OH
 
-7.291 K101 
78s SO2 Br 
N
 
N
H
N
OMe
 
-8.295 K101 
78t SO2 Br 
N
 
N
H
N Ph
 
-3.028 - 
78u SO2 Br 
N
 
N
H
N
OH
 
-5.761 - 
78v SO2 Br 
N
 N
H
N
 
-6.185 - 
78w SO2 Br 
N
 
N
H
N
OMe
 
-6.301 - 
78x SO2 Br 
N
 N
H
N
F
 
-6.339 - 
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78y SO2 Br 
N
 N
H
N N
 
-7.161 - 
79a SO2 Br 
H
N
 
CONH2 -9.201 K101 
79b SO2 Br 
H
N
 
CONH2 -9.615 K101 
79c SO2 Br 
H
N
 
CONH2 -11.040 K101 
79d SO2 Br 
H
N
 
CONH2 -10.698 K101 
79e SO2 Br 
N
 
CONH2 -10.377 K101 
79f SO2 Br 
N
 
CONH2 -11.652 K101 
79g SO2 Br H
N
F
F
 
CONH2 -12.396 K101 
79h SO2 Br 
N
F
F
 
CONH2 -12.892 K101 
79i SO2 Cl 
 
N
H
O
N
O
O
 
-8.583 - 
79j SO2 Cl 
 
N
H
O
H
N
 
-11.312 K101 
 
      
      Table 6 
 
The same crystallographic structure with PDB code 1RT2 was used to dock compounds 73-76. 
Also in this case structures were docked in different conditions: standard and extra precision mode, 
using Lys 101 as constraints for hydrogen bond and using different crystallographic structures. 
The best docking was that one in which Lys101 was used as constraint. 
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All compounds interact with RT in a butterfly like mode showing a very good superimposition 
(Fig.19) and good docking score values between -12.108 and -7.040. (Tab.7, 8, 9, 10) One of the 
wings of this butterfly is made of -electron rich moiety that interact with a hydrophobic pocket 
formed by the side chains of aromatic amino acids such as  Tyr181, Tyr188, Phe227, Trp229, 
Tyr318. 
On the other hand the other wing is constituted by the quinone or indole moiety bearing a donating 
hydrogen bond  with Lys101.  
 
 
 
 
 
 
 
 
 
Figure 19 
 
In some cases halogenated atoms on R substituents establish additional H-bond accepting 
interaction with Lys103 residue. (Tab.8, 9, 10) 
 
N
H
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O
R
73a-r
O
n
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Compound n R Docking Score H-bond 
interaction 
73a 0 H -9.373 K101 
73b 0 4-Cl -9.984 K101 
73c 0 3-OMe -9.388 K101 
73d 0 3-Me -10.272 K101 
73e 0 2-Cl -9.583 K101 
73f 0 2-Br -9.582 K101 
73g 0 2-OMe -9.494 K101 
73h 0 2,4,6-triMe -8.121 K101 
73i 2 2,4,6-triMe -7.221 K101 
73j 2 2-Me -8.455 K101 
73k 2 2-F -7.743 K101 
73l 2 2-Br -7.711 K101 
73m 2 2-Cl -8.542 K101 
73m 2 3-Me -8.455 K101 
73o 2 2-OMe -8.621 K101 
73p 2 4-Cl -8.152 K101 
73q 2 3-OMe -8.929 K101 
73r 2 H -7.986 K101 
                Table 7 
 
 
N
H
X
O
O
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74a-x
 
 
 
Compound X R Docking Score H-bond 
interaction 
74a CO 4-OMe -10.310 K101 
74b CO 4-Cl -10.736 K101 
74c CO 2-Me -9.556 K101 
74d CO 3-Me -9.619 K101 
74e CO 3,4,5-triOMe -7.350 K101 
74f CO 2,6-diF -7.870 K101 
74g CH2 4-Cl -11.181 K101 
74h CH2 2,6-diOMe -8.933 K101 
74i CH2 H -10.399 K101 
74j CH2 4-OMe -11.418 K101 
74k CH2 2,6-diF -9.924 K101 
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74l CH2 3-Me -11.060 K101 
74m CH2 2-Me -10.134 K101 
74n O 2,6-diOMe -7.448 K101 
74o O 3-OMe -9.251 K101 
74p O 4-Cl-3-NO2 -10.280 K101-K103 
74q O 4-OMe -9.443 K101 
74r O 4-Me-2-NO2 -10.195 K101 
74s O 2,4-diMe -9.129 K101 
74t O H -9.436 K101 
74u O 3,4-diMe -10.111 K101 
74v O 3-Me-4-Cl -9.251 K101 
74w O 3-NO2 -10.390 K101-K103 
74x O 4-Me -10.076 K101 
      Table 8 
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Compound n R Docking Score H-bond 
interaction 
75a 0 H -10.067 K101 
75b 0 4-Cl -10.935 K101 
75c 0 3-OMe -10.246 K101 
75d 0 3-Me -11.113 K101 
75e 0 2-Cl -10.918 K101 
75f 0 2-Br -10.496 K101 
75g 0 2-OMe -9.893 K101 
75h 0 2-F -10.639 K101-K103 
75i 0 2-Me -10.318 K101 
75j 2 2-F -10.623 K101 
75k 2 2-Br -9.330 K101 
75l 2 2-Cl -9.616 K101-K103 
75m 2 2-OMe -9.070 K101-K103 
75n 2 3-Me -10.985 K101 
75o 2 3-OMe -10.453 K101 
75p 2 H -10.441 K101 
      Table 9 
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N
H
X
O
O
R
76a-z
 
 
 
 
 
Compound X R Docking Score H-bond 
interaction 
76a CO H -10.363 K101-K103 
76b CO 4-Cl -10.741 K101 
76c CO 3-NO2 -10.038 K101-K103 
76d CO 4-OMe -11.418 K101 
76e CO 2-NO2 -10.143 K101-K103 
76f CO 2,6-diMe -9.523 K101-K103 
76g CO 2,6-diF -11.575 K101-K103 
76h CO 2,6-diCl -8.593 K101-K103 
76i CH2 4-Cl -11.171 K101 
76j CH2 2,6-diOMe -9.081 K101-K103 
76k CH2 H -10.641 K101 
76l CH2 4-NO2 -11.424 K101 
76m CH2 4-OMe -12.108 K101 
76n CH2 2-NO2 -9.975 K101-K103 
76o CH2 2,6-diF -10.549 K101-K103 
76p O 3-NO2 -11.180 K101-K103 
76q O 2,6-diOMe -8.479 K101-K103 
76r O 3,4-diNO2 -7.040 K101-K103 
76s O 3-OMe -10.265 K101 
76t O 4-Cl-3-NO2 -10.199 K101 
76u O 4-OMe -10.102 K101 
76v O 4-NO2 -10.056 K101 
76w O 2-NO2 -10.480 K101 
76x O 4-Cl-2-NO2 -11.461 K101-K103 
76y O 4-Me-2-NO2 -11.347 K101-K103 
76z O 5-Me-2-NO2 -10.166 K101-K103 
    Table 10 
 
 
Considering the results showed by both the docking studies and the activity of compounds reported 
in the literature, we started with the synthesis of 73 and 75 derivatives. 
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RESULTS AND DISCUSSION 
 
The 4,7-dimethoxyindole 83 is the key intermediate for the synthesis of all compounds desired. 
Starting from the 2,5-dimethoxybenzaldehyde 79 which reacted in presence of sodium in ethanol 
with the ethyl azidoacetate 78, previously prepared from the ethyl bromoacetate 77 with sodium 
azide in a quantitative yield, it was possible to obtain compound 80 (48%). This latter compound 
was converted into the the dimethoxyindole 81 through intramolecular cyclization in toluene 
refluxing with a 66% yield. The hydrolysis of the ester group of compound 81 was performed with 
an 5% aqueous solution of sodium hydroxide refluxing (74%) [56] and the so formed acid 82 was 
decarboxylated at high temperature with copper in N-methylpyrrolidinone to afford the 4,7-
dimethoxyindole 83 in very good yield (78%). 
  
Br
OEt
O
N3
OEt
O
OMe
OMe
O
N3
OEt
OOMe
OMe
N
H
OMe
OMe
COOEt
N
H
OMe
OMe
COOH
N
H
OMe
OMe
NaN3
+ Na/EtOH toluene
5% NaOH
Cu/NMP
77
78 79 80 81
8283
 
 
 
Starting from the 4,7-dimethoxyindole 83 it was possible to obtain compound 73a-h through C-S 
cross coupling reaction copper catalyzed with variously substituted tiophenol 84, using copper 
iodide, 2,2 '-bipyridyl and sodium carbonate as base in dimethylformamide. 
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R = H, 2-Br, 2-Cl, 2-F, 2-Me, 2-OMe, 2-NO2, 3-Me, 3-OMe, 3-NO2, 4-Cl, 4-OMe, 4-NO2, 2,6-dimethyl, 2,6-dimethyoxy, 2,6-
diCl, 2,6-diF, 2,4-diNO2, 3,4-diNO2, 2,4,6-trimethyl, 3,4,5-trimethoxy, 4-Cl-3-NO2
N
H
OMe
OMe
HS
R+
N
H
S
OMe
OMe
R
83 84 73a-h
CuI, 2,2'-bipyridyl
Na2CO3/DMF
 
 
Phenylsulfonylindoles 73a-h could be oxidized to phenylsulfonylindoles 73i-r using 3-
chloroperbenzoic acid in dichloromethane, these latter compounds could be then oxidized by 
reacting with 90% solution of nitric acid and silver(II)oxide in tetrahydrofuran to obtain quinones 
75j-p.  
 
R = H, 2-Br, 2-Cl, 2-F, 2-Me, 
2-OMe, 2-NO2, 3-Me, 3-
OMe, 3-NO2, 4-Cl, 4-OMe, 4-
NO2, 2,6-dimethyl, 2,6-
dimethyoxy, 2,6-diCl, 2,6-
diF, 2,4-diNO2, 3,4-diNO2, 
2,4,6-trimethyl, 3,4,5-
trimethoxy, 4-Cl-3-NO2
N
H
S
OMe
OMe
R
73a-h
N
H
S
OMe
OMe
R
73i-r
N
H
S
O
O
R
75j-p
O
O
3-chloroperbenzoic acid
DCM
AgO/HNO3 90%THF
O
O
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In the table are reported all compounds synthesized at the moment. (Tab.11) 
 
N
H
S
O
O
R
75a-p
O
n
N
H
S
O
O
R
73a-r
O
n
 
 
 
 
Compound n R 
73a 0 H 
73c 0 3-OMe 
73d 0 3-Me 
73f 0 2-Br 
73m 2 3-Me 
73r 2 H 
75n 2 3-Me 
75p 2 H 
                 
 
 
All derivatives thus obtained will be biologically tested in order to evaluate their antitumor antiviral 
activity. 
 
 
 
 
 
 
Table 11 
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EXPERIMENTAL DATA 
 
All melting points were taken on a Buchi B-540 apparatus. IR spectra were determined in 
bromoform with a spectrophotometer Shimadzu FT / IR 8400S. 
1
H and 
13
C NMR spectra were 
measured at 200 and 50.3 MHz, respectively, on DMSO-d6 or CDCl3 ssolution, using a Bruker AC 
200 MHz (TMS as internal standard). Chromatography column was performed with MERK silica 
gel 230-400 mesh ASTM or FLASH40i Biotage chromatography or with Buchi Sepacore 
chromatography module (prepacked cartridge reference). 
 
CHEMISTRY 
 
Synthesis of dimethyl-4,5-dimethylcycloesa-1,4-diene-1,2-dicarboxylate 26 
To a solution of dimethyl acetylene dicarboxylate 25 (25g, 0.17 mol) in toluene (100 ml) 2,3-
dimethylbutan-1,3-diene 24 (13.1g, 0.16 mol) was added under nitrogen atmosphere. The reaction 
mixture was stirred under reflux for 24 hours. The solvent was evaporated under reduced pressure. 
Mp 64-65°C; Yield 95%; IR 1732 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 1.69 (3H, s, CH3), 3.77 (2H, 
s, CH2), 3.84 (3H, s, CH3). 
 
Synthesis of dimethylbenzene-1,2-dicarboxylate 27 
To a solution of compound 26 (30g, 0.13 mol) in chlorobenzene (500 ml) DDQ (2 eq) was added. 
The mixture was stirred under reflux for 24 hours. After cooling, diethyl ether was added and the 
mixture was filtered on celite. Evaporated the solvent under reduced pressure, the crude was 
purified by chromatography using dichloromethane as eluent. 
Mp 49-50°C; Yield 92%; IR 1728 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.29 (3H, s, CH3), 3.81 (3H, 
s, CH3), 7.47 (1H, s, CH). 
 
Synthesis of (4,5-dimethyl-1,2-phenylen)dimethanol 28 
To a solution of borane (1.5M in THF/diethyl ether, 50ml) at 0°C under argon atmosphere, a 
solution of ester 27 (24 mmol) in THF (40 ml) was added. The mixture was stirred at 0°C for 2 
hours and then under reflux for 20 hours. After cooling methanol was added to the mixture and the 
solvent evaporated under reduced pressure. The resulting crude was dissolved in ethyl acetate and 
washed with a saturated solution of sodium hydrogen carbonate. The organic layer was dried on 
Na2SO4 and evaporated. 
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Mp 103°C; Yield 80%; 
1
H NMR CDCl3 (ppm): 2.24 (3H, s, CH3), 3.33 (1H, bs, OH), 4.61 (2H, d, 
CH2), 7.08 (1H, s, CH). 
 
Synthesis of 4,5-dimethylphtalaldehyde 20b 
To  a mixture of dichloromethane (100 ml) and oxalyl chloride (8ml, 88 mol) at -78°C and under 
argon atmosphere, a mixture of dimethyl sulfoxide (13.6 ml, 0.18 mol) and dichloromethane (25 
ml) was added dropwise. After 3-5 min a solution of the 1,2-dimethanol 28 (40 mol) in 
dichloromethane-dimethyl sulfoxide (10 ml) was added dropwise. After 30 min 100 ml of 
triethylamine were added dropwise. After stirring for 10 min the mixture was warmed to room 
temperature and poured in water and ice. It was extracted in dichloromethane and the organic layer 
dried and evaporated. The crude was purified in column using dichloromethane as eluent. 
Mp 95-100°C; Yield 87%; IR 1688 (CHO) cm
-1
; 
1
H NMR CDCl3 (ppm): 1.77 (3H, s, CH3), 7.28 
(1H, s, CH), 10.3 (1H, s, CHO). 
 
Synthesis of (2-bromo-4,5-dimethoxyphenyl)methanol 36 
To a solution of benzoic acid derivative 35 (20 mmol) in tetrahydrofuran (50 ml), a solution of 
borane (solution 1.0 M in THF, 28.0 ml, 30 mmol) was added dropwise and the mixture was 
stirred at room temperature for 2 hours. After cooling at 0°C a solution of hydrochloric acid 1M 
was added and the mixture was extracted with diethyl ether. The organic layer was washed with 
water and saturated solution of sodium hydrogen carbonate.  
Mp 95°C; Yield 90%; IR 3498 (OH) cm
-1
; 
1
H NMR DMSO (ppm): 3.77 (3H, s, CH3), 3.77 (3H, s, 
CH3), 4.45 (2H, d, J = 5.5 Hz, CH2), 5.35 (1H, t, J = 5.5 Hz, OH), 7.10 (1H, s, Ar-H), 7.12 (1H, s, 
Ar-H); 
13
C NMR DMSO-d6 (ppm): 55.5 (CH3),  55.9 (CH3), 62.3 (CH2), 110.7 (C), 111.6 (CH), 
115.2 (CH), 132.9 (C), 148.1 (C), 148.2 (C). 
 
Synthesis of 2-bromo-4,5-dimethoxybenzaldehyde 40 
To a solution of the appropriate phenyl methanol derivative 36 (1.7 mmol) in dichloromethane, 2.4 
g (1.9 mmol) of Dess-Martin periodinane were added under argon atmosphere. The mixture was 
stirred for 2 hours. Diethyl ether was added and the organic phase was washed with 5% solution of  
sodium thiosulfate and saturated solution of sodium hydrogen carbonate. The organic phase was 
dried using Na2SO4 and evaporated. The crude was purified in column using dichloromethane as 
eluent. 
Mp 148-149 °C; Yield 90%; IR (CHO) 1676 cm
-1
; 
1
H NMR DMSO-d6 (ppm): 3.83 (3H, s, CH3), 
3.91 (3H, s, CH3), 7.31 (1H, s, Ar-H), 7.32 (1H, s, Ar-H), 10.06 (1H, s, CHO); 
13
C NMR DMSO-
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d6 (ppm): 55.6 (CH3), 56.4 (CH3), 110.4 (CH), 115.9 (CH), 119.3 (C), 125.7 (C), 148.6 (C), 154.4 
(C), 190.1 (CH). 
 
Synthesis of 2(1,3-dioxolan-2-yl)-4,5-dimethoxy-bromobenzene 42 
To a solution of 2-bromo-benzaldehyde derivative 40 (3.3 mmol) in toluene, ethylene glicole 41 
(9.2 mmol, d= 1.113, 0.6 ml) and a catalytic amount of p-toluensulfonic acid were added. The 
mixture was stirred at reflux for 24 hours using Dean-Stark trap. After cooling, the organic phase 
was washed with a saturated solution of sodium hydrogen carbonate and dried and evaporated. The 
crude was purified by BIOTAGE chromatography using cyclohexane:ethyl acetate (98:2) as 
eluent. 
Mp 98-99°C; Yield 90%; 
1
H NMR DMSO-d6 (ppm): 3.76 (3H, s, CH3), 3.79 (3H, s, CH3),  3.95-
4.11 (4H, m, 2xCH2), 5.85 (1H, s, CH), 7.05 (1H, s, Ar-H), 7.14 (1H, s, Ar-H); 
13
C NMR DMSO-
d6 (ppm): 56.1 (CH3), 56.4 (CH3),  65.3 (2xCH2), 102.3 (CH), 111.1 (CH), 113.0 (C), 115.9 (CH), 
128.5 (C), 148.6 (C), 150.5 (C). 
 
Synthesis of 2-(1,3-dioxolan-2-yl)-4,5-methoxybenzaldehyde 43 
To a solution of benzaldehyde derivative 42 (2.5 mmol) in tetrahydrofuran (8ml) at -78°C, n-butyl 
lithium (solution 1.6 M in n-hexane, 2.5 mmol, 1.6 ml) was added during 1 hour. The mixture was 
stirred for 1 hour at -78°C. After that, 0.3 ml of dimethylformamide were added and the mixture 
was warmed to room temperature during 1 hour. A saturated solution of ammonium chloride was 
added and the mixture extracted in dichloromethane. The organic layer was dried with Na2SO4 and 
evaporated. The crude was purified in column using dichloromethane as eluent. 
Mp 77-78°C; Yield 100%; IR (CHO) 1680 cm
-1
; 
1
H NMR DMSO-d6 (ppm): 3.98 (3H, s, CH3), 
3.99 (3H, s, CH3), 4.00-4.12 (4H, m, 2xCH2), 6.33 (1H, s, CH), 7.22 (1H, s, Ar-H), 7.41 (1H, s, 
Ar-H), 10.30 (1H, s, CHO); 
13
C NMR DMSO-d6 (ppm): 55.6 (CH3), 55.8 (CH3), 64.8 (2xCH2), 
99.9 (CH), 109.5 (CH), 110.0 (CH), 127.2 (C), 134.0 (C), 149.1 (C),  153.0 (C), 189.9 (CH). 
 
Synthesis of 4,5-dimethoxyphtaldehyde 20c 
To a solution of ortho-benzylaldehyde derivative 43 (1.5 mmol) in acetone (17 ml) a catalytic 
amount of p-toluensulfonic acid was added. The solution was stirred for 15 minutes at room 
temperature. Evaporated the solvent, the resulting residue was dissolved in dichloromethane and it 
was washed with a solution of sodium carbonate and brine. The crude was purified by 
chromatography using dichloromethane as eluent.  
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Mp 169,4-170,0; Yield 88%; IR (CHO) 1680   cm
-1
; 
1
H NMR CDCl3 (ppm): 3.94 (3H, s, CH3), 
7.54 (1H, s, CH), 10.5 (1H, s, CHO); 
13
C NMR CDCl3 (ppm): 11.7 (CH), 131.2 (C), 153.2 (C), 
191.7 (CH). 
 
Synthesis of 2-(2-hydroxyphenyl)-2H-isoindole-1-carbonitriles 23a-c  
General procedure: 
To a solution of sodium hydrogen sulfite (0.71 g, 0.004 mol) in water (18 ml), the suitable 
phthalaldehyde 20a-c (0.004 mol) was added. The mixture was stirred until the solid was dissolved, 
and the 2-aminophenol 21 (0.004 mol) was added. The reaction was heated on a steam bath for 30 
min at 40°C, then potassium cyanide (0.81 g, 0.012 mol) in water (5 ml) was added, and the mixture 
was heated for an additional 90 min. The solid formed upon cooling was filtered and used as crude 
for the subsequent reaction. 
 
2-(2-Hydroxyphenyl)-2H-isoindoles-1-carbonitrile 23a: Mp 143°C; Yield 100%; IR: 3299 (OH), 
2256 (CN) cm
-1
; 
1
H NMR CDCl3 (ppm): 7.17-7.35 (6H, m, 6xAr-H), 7.68-7.74 (2H, m, 2xAr-H), 
7.91 (1H, bs, OH), 8.28 (1H, d, J=8.4 Hz, Ar-H); 
13
C NMR CDCl3 (ppm): 107.6 (C), 107.8 (CH), 
115.4 (CH), 117.6 (CH), 120.0 (CH), 120.9 (CH), 122.4 (C), 123.7 (CH), 123.9 (CH), 125.6 (CH), 
126.2 (C), 126.5 (C), 127.6 (CH), 144.2 (C), 152.1 (C). 
 
2-(2-Hydroxyphenyl)-5,6-dimethyl-2H-isoindoles-1-carbonitrile 23b: Mp 146.1-147.5°C; Yield 
84%; IR: 3301 (OH), 2256 (CN) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.36 (3H, s, CH3), 2.40 (3H, s, CH3), 
7.24 (4H, m, 4xAr-H), 7.44 (1H, s, Ar-H), 7.68 (1H, d, J=7.3 Hz, Ar-H), 7.76 (1H, s, Ar-H), 8.28 
(1H, bs, OH); 
13
C NMR CDCl3 (ppm): 20.7 (CH3), 20.9 (CH3), 107.0 (CH), 115.3 (CH), 117.4 
(CH), 118.8 (CH), 119.6 (CH), 119.7 (C), 122.7 (C), 123.6 (CH), 125.8 (C), 126.0 (C), 127.1 (CH), 
134.0 (C), 136.2 (C), 141.0 (C), 144.0 (C). 
 
2-(2-Hydroxyphenyl)-5,6-dimethoxy-2H-isoindoles-1-carbonitrile 23c: Mp 131.4-132.7°C; 
Yield 100%; IR: 3410 (OH), 2257 (CN) cm
-1
; 
1
H NMR CDCl3 (ppm): 3.84 (3H, s, OCH3), 3.86 
(3H, s, OCH3), 7.02 (1H, s, Ar-H), 7.19-7.41 (3H, m, 3xAr-H), 7.53 (1H, s, Ar-H), 8.10-8.15 (1H, 
m, Ar-H), 8.33 (1H, s, Ar-H), 10.39 (1H, bs, OH); 
13
C NMR CDCl3 (ppm): 55.3 (CH3), 55.5 (CH3), 
93.4 (C), 95.5 (CH), 99.1 (CH), 116.1 (CH), 116.8 (CH), 118.8 (C), 119.2 (CH), 125.5 (C), 126.9 
(CH), 127.4 (C), 127.9 (CH), 148.0 (C), 148.9 (C), 150.9 (C), 152.2 (C). 
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Synthesis of ethyl-bromo(4-methylphenyl)acetate 44b 
To a solution of ethyl p-tolylacetate 46 (2g, 0.011 mol) in carbon tetrachloride (29 ml) N-
bromosuccinimide (2g, 0.011 mol) and a catalytic amount of aqueous HBr 48% solution were 
added. The mixture was stirred at reflux for 26 hours. After cooling, the excess N-
bromosuccinimide was removed by filtration. The solvent was evaporated under reduced pressure 
and the crude product is purified by chromatography using dichloromethane as eluent. 
Oil; Yield 75%; IR: 1681 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm):1.13 (3H, t, J=7.0 Hz, CH3), 2.30 (3H, 
s, CH3) 4.18 (2H, q, J=7.0 Hz, CH2), 5.87 (1H, s, CH), 7.20 (2H, d, J=7.5 Hz, 2xAr-H), 7.45  (2H, 
d, J=7.5 Hz, 2xAr-H); 
13
C NMR CDCl3 (ppm): 13.8 (CH3), 20.7 (CH3), 62.1 (CH2), 128.5 (2xCH), 
129.3 (2xCH), 132.3 (C), 138.7 (C), 139.6 (CH), 168.0 (C). 
 
Synthesis of ethyl [2-(1-cyano-2H-isoindol-2-yl)phenoxy]acetate compounds 45a-d 
General procedure:  
To a solution of suitable isoindoles 23a-c (0.004 mol) in tetrahydrofuran (20 ml) sodium hydride 
(0.004 mol) was added. The mixture was stirred at room temperature for 1 hour, then ethyl-α-
bromoester 44a,b (0.004 mol) was added. The mixture was stirred at reflux for 4-24 hours. After 
cooling, the solvent was evaporated at reduced pressure and the crude was purified by 
chromatography using dichloromethane as eluent. 
 
Ethyl [2-(1-cyano-2H-isoindol-2-yl)phenoxy](phenyl)acetate 45a: The mixture was stirred at 
reflux for 7 hours. Mp 98.6-100°C; Yield 76%; IR: 2200 (CN), 1746 (CO) cm
-1
; 
1
H NMR CDCl3 
(ppm): 1.12 (3H, t, J=7.1 Hz, CH3), 4.12 (2H, q, J=7.1 Hz, CH2), 5.65 (1H, s, CH), 7.04-7.18 (3H, 
m, 3xAr-H), 7.22-7.32 (6H, m, 6xAr-H), 7.45 (1H, dd, J=1.7, 7.9 Hz, Ar-H), 7.52 (1H, dd, J=1.7, 
7.9 Hz, Ar-H), 7.68-7.74 (3H, m, 3xAr-H); 
13
C NMR CDCl3 (ppm): 13.9 (CH3), 61.9 (CH2), 79.3 
(CH), 95.1 (C), 114.5 (C), 114.7 (CH), 118.2 (CH), 120.9 (CH), 121.7 (CH), 122.4 (CH), 122.9 
(CH), 124.1 (C), 125.7 (CH), 126.7 (2xCH), 128.1 (C), 128.3 (CH), 128.7 (2xCH), 129.0 (CH), 
130.7 (CH), 131.9 (C), 134.3 (C), 151.4 (C), 169.1 (C). 
 
Ethyl [2-(1-cyano-5,6-dimethyl-2H-isoindol-2-yl)phenoxy](phenyl)acetate 45b: The mixture 
was stirred at reflux for 4 hours. Mp 131-133°C; Yield 52%; IR: 2196 (CN), 1746 (CO) cm
-1
; 
1
H 
NMR CDCl3 (ppm): 1.13 (3H, t, J=7.1 Hz, CH3), 2.36 (3H, s, CH3), 2.40 (3H, s, CH3), 4.13 (2H, q, 
J=7.1 Hz, CH2), 5.63 (1H, s, CH), 7.04 (1H, dd, J=1.1, 8.3 Hz, Ar-H), 7.16 (1H, td, J=1.2, 7.7 Hz, 
Ar-H), 7.24-7.33 (5H, m, 5xAr-H), 7.36-7.52 (4H, m, 4xAr-H), 7.58 (1H, bs, Ar-H); 
13
C NMR 
CDCl3 (ppm): 13.9 (CH3), 20.6 (CH3), 20.9 (CH3), 61.9 (CH), 79.3 (CH), 99.9 (C), 114.7 (CH), 
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115.0 (C), 117.1 (CH), 119.5 (CH), 120.8 (CH), 122.3 (CH), 123.6 (C), 126.7 (2xCH), 128.3 (C), 
128.4 (CH), 128.7 (2xCH), 129.0 (CH), 130.4 (CH), 131.6 (C), 132.8 (C), 134.4 (C), 136.2 (C), 
151.4 (C), 169.1 (C). 
 
Ethyl [2-(1-cyano-5,6-dimethoxy-2H-isoindol-2-yl)phenoxy](phenyl)acetate 45c: The mixture 
was stirred at reflux for 6 hours. Mp 114.1-115.6°C; Yield 58%; IR: 2256 (CN), 1731 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 1.14 (3H, t, J=7.1 Hz, CH3), 3.94 (3H, s, CH3), 3.99 (3H, s, CH3), 4.13 (2H, 
q, J=7.1 Hz, CH2), 5.61 (1H, s, CH), 6.94 (2H, d, J=6.2 Hz, 2xAr-H), 7.04 (1H, dd, J=1.1, 8.3 Hz, 
Ar-H), 7.16 (1H, td, J=1.0, 8.2 Hz, Ar-H), 7.26-7.29 (5H, m, 5xAr-H), 7.35-7.48 (2H, m, 2xAr-H), 
7.52 (1H, bs, Ar-H); 
13
C NMR CDCl3 (ppm): 13.9 (CH3), 55.9 (CH3), 56.1 (CH3), 61.8 (CH2), 79.4 
(CH), 94.4 (C), 98.4 (CH), 100.0 (CH), 114.9 (CH), 115.0 (C), 119.4 (C), 120.8 (CH), 122.4 (CH), 
126.7 (2xCH), 128.3 (CH), 128.4 (C), 128.5 (C), 128.7 (2xCH), 129.0 (CH), 130.3 (CH), 134.5 (C), 
148.7 (C), 151.1 (C), 151.5 (C), 169.2 (C). 
 
Ethyl [2-(1-cyano-2H-isoindol-2-yl)phenoxy](4-methylphenyl)acetate 45d: The mixture was 
stirred at reflux for 24 hours. Mp 101.4-102.2°C; Yield 60%; IR: 2200 (CN), 1729 (CO) cm
-1
; 
1
H 
NMR CDCl3 (ppm): 1.10 (3H, t, J=7.1 Hz, CH3), 2.26 (3H, s, CH3), 4.11 (2H, q, J=7.1 Hz, CH2), 
5.58 (1H, s, CH), 7.00-7.29 (7H, m, 7xAr-H), 7.35-7.53 (3H, m, 3xAr-H), 7.63-7.73 (3H, m, 3xAr-
H); 
13
C NMR CDCl3 (ppm): 14.0 (CH3), 21.2 (CH3), 61.8 (CH2), 79.7 (CH), 100.2 (C), 115.2 (CH), 
118.5 (CH), 121.0 (CH), 121.7 (CH), 122.5 (CH), 123.0 (CH), 124.3 (C), 125.7 (CH), 126.9 
(2xCH), 127.4 (C), 128.5 (CH), 129.2 (C), 129.5 (2xCH), 130.8 (CH), 131.7 (C), 132.0 (C), 139.0 
(C), 151.9 (C), 169.3 (C). 
 
Synthesis of [2-(1-cyano-2H-isoindol-2-yl)phenoxy] acetic acids 47a-d 
General procedure: 
To a solution of proper derivative 45a-d (0.025 mol) in a mixture of tetrahydrofuran and ethanol 
(1:1) (30 ml) an aqueous sodium hydroxide 5% solution (25 ml) was added dropwise. The reaction 
mixture was stirred for 15 minutes at room temperature. The solvent was evaporated under reduced 
pressure, the remaining aqueous layer was acidified with 6N hydrochloric acid and extracted with 
ethyl acetate. The organic layer was dried with Na2SO4 and evaporated. The product obtained did 
not require further purification. 
 
[2-(1-Cyano-2H-isoindol-2-yl)phenoxy](phenyl)acetic acid 47a: Mp 181.8-183°C; Yield 90%; 
IR: 3566 (OH), 2211 (CN), 1733 (CO) cm
-1
; 
1
H NMR DMSO-d6 (ppm): 6.05 (1H, s, CH), 7.14-
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7.35 (9H, m, 9xAr-H), 7.53-7.67 (3H, m, 3xAr-H), 7.84 (1H, d, J=8.5 Hz, Ar-H), 8.05 (1H, d, J=0.7 
Hz, Ar-H), 13.35 (1H, bs, OH); 
13
C NMR DMSO-d6 (ppm): 77.7 (CH), 94.1 (C), 114.1 (C), 114.7 
(CH), 117.4 (CH), 121.6 (CH), 121.8 (CH), 122.7 (CH), 123.0 (CH), 123.6 (C), 126.0 (CH), 126.9 
(2xCH), 127.1 (C), 128.4 (2xCH), 128.5 (CH), 128.8 (CH), 131.0 (CH), 131.1 (C), 134.4 (C), 151.3 
(C), 170.2 (C). 
 
[2-(1-Cyano-5,6-dimethyl-2H-isoindol-2-yl)phenoxy](phenyl)acetic acid 47b: Mp 212-213.2°C; 
Yield 95%; IR: 3557 (OH), 2203 (CN), 1728 (CO) cm
-1
; 
1
H NMR DMSO-d6 (ppm): 2.33 (3H, s, 
CH3), 2.37 (3H, s, CH3), 6.04 (1H, s, CH), 7.21 (1H, td, J=0.9, 7.5 Hz, Ar-H), 7.25-7.36 (6H, m, 
6xAr-H), 7.42 (1H, bs, Ar-H), 7.51-7.61 (3H, m, 3xAr-H), 7.87 (1H, bs, Ar-H), 13.36 (1H, bs, OH); 
13
C NMR DMSO-d6 (ppm): 20.1 (CH3), 20.4 (CH3), 77.6 (CH), 92.9 (C), 114.4 (C), 114.6 (CH), 
116.2 (CH), 119.9 (CH), 121.7 (CH), 121.8 (CH), 123.0 (C), 126.9 (2xCH), 127.2 (C), 128.3 (CH), 
128.5 (2xCH), 128.7 (CH), 130.7 (C), 130.8 (CH), 132.3 (C), 135.4 (C), 136.1 (C), 151.2 (C), 170.2 
(C). 
 
[2-(1-Cyano-5,6-dimethoxy-2H-isoindol-2-yl)phenoxy](phenyl)acetic acid 47c: Mp 200-
201.5°C; Yield 80%; IR: 3021 (OH), 2204 (CN), 1751 (CO) cm
-1
; 
1
H NMR DMSO-d6 (ppm): 2.23 
(3H, s, CH3), 5.98 (1H, s, CH), 7.05-7.36 (8H, m, 8xAr-H), 7.52-7.67 (3H, m, 3xAr-H), 7.83 (1H, 
d, J=8.5 Hz, Ar-H), 8.03 (1H, s, Ar-H), 12.84 (1H, bs, OH); 
13
C NMR DMSO-d6 (ppm): 20.6 
(CH3), 77.6 (CH), 94.1 (C), 114.0 (C), 114.7 (CH), 117.4 (CH), 121.5 (CH), 121.6 (CH), 121.7 
(CH), 122.7 (CH), 122.9 (CH), 123.5 (C), 125.9 (C), 126.9 (2xCH), 127.1 (C), 128.3 (CH), 129.0 
(2xCH), 131.0 (CH), 132.4 (C), 138.2 (C), 151.3 (C), 170.3 (C). 
 
[2-(1-Cyano-2H-isoindol-2-yl)phenoxy](4-methylphenyl)acetic acid 47d: Mp 214.9-216.8°C; 
Yield 73%; IR: 3020 (OH), 2207 (CN), 1733 (CO) cm
-1
; 
1
H NMR DMSO-d6 (ppm): 3.83 (3H, s, 
OCH3), 3.88 (3H, s, OCH3), 6.03 (1H, s, CH), 6.92 (1H, s, Ar-H), 7.15 (1H, s, Ar-H), 7.20-7.38 
(7H, m, 7xAr-H), 7.54-7.57 (2H, m, 2xAr-H), 7.78 (1H, s, Ar-H), 13.30 (1H, bs, OH); 
13
C NMR 
DMSO-d6 (ppm): 55.4 (CH3), 55.5 (CH3), 77.6 (CH), 93.2 (C), 95.5 (CH), 99.1 (CH), 114.6 (CH), 
118.8 (C), 121.7 (CH), 126.6 (CH), 126.9 (2xCH), 127.4 (C), 127.6 (C), 128.1 (C), 128.3 (CH), 
128.5 (2xCH), 128.7 (CH), 130.6 (CH), 135.4 (C), 148.2 (C), 151.1 (C), 151.3 (C), 170.2 (C). 
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Synthesis of 7-oxo-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-carbonitriles 48a-d 
General procedure: 
To a suspension of proper 47a-d (0.0014 mol) in dichloromethane (30 ml) thionyl chloride (0.3 ml, 
0.0042 mol) was added and the reaction mixture was stirred at reflux for 30-90 min. After cooling, 
the mixture was basified with an aqueous sodium hydroxide 5% solution and extracted with 
dichloromethane. The solvent was evaporated under reduced pressure and the crude was purified by 
chromatography using dichloromethane as eluent. 
 
7-Oxo-6-phenyl-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-carbonitrile 48a: The 
mixture was stirred at reflux for 1 hour. Mp 152.8-154°C; Yield 35%; IR: 2256 (CN), 1652 (CO) 
cm
-1
; 
1
H NMR CDCl3 (ppm): 5.66 (1H, s, CH), 7.23-7.48 (10H, m, 10xAr-H), 7.82-7.94 (2H, m, 
2xAr-H), 8.18-8.25 (1H, m, Ar-H); 
13
C NMR CDCl3 (ppm): 92.9 (CH), 99.4 (C), 113.0 (C), 118.4 
(CH), 121.9 (CH), 124.5 (CH), 125.7 (CH), 126.5 (CH), 126.9 (C), 127.4 (CH), 128.1 (2xCH), 
128.2 (CH), 128.6 (C), 128.7 (2xCH), 129.2 (CH), 130.9 (CH), 131.4 (C), 131.7 (C), 135.9 (C), 
149.9 (C), 190.7 (C). 
 
9,10-Dimethyl-7-oxo-6-phenyl-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-carbonitrile 
48b: The mixture was stirred at reflux for 1 hour. Mp 223.8-225°C; Yield 38%; IR: 2228 (CN), 
1660 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.36 (3H, s, CH3), 2.41 (3H, s, CH3), 5.60 (1H, s, CH), 
7.19-7.24 (1H, m, Ar-H), 7.34-7.40 (7H, m, 7xAr-H), 7.58 (1H, bs, Ar-H), 7.85-7.89 (1H, m, Ar-
H), 8.02 (1H, bs, Ar-H); 
13
C NMR CDCl3 (ppm): 20.7 (CH3), 20.8 (CH3), 92.9 (CH), 100.2 (C), 
113.3 (C), 117.5 (CH), 121.0 (CH), 124.5 (CH), 125.8 (CH), 126.4 (CH), 128.3 (2xCH), 128.5 (C), 
128.6 (C), 128.7 (2xCH), 129.1 (CH), 130.5 (CH), 131.5 (C), 132.0 (C), 136.4 (C), 138.1 (C), 139.2 
(C), 150.2 (C), 190.4 (C). 
 
9,10-Dimethoxy-7-oxo-6-phenyl-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-
carbonitrile 48c: The mixture was stirred at reflux for 30 minutes. Mp 195-197°C; Yield 40%; IR: 
2256 (CN), 1658 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 3.95 (3H, s, OCH3), 4.02 (3H, s, OCH3), 5.60 
(1H, s, CH), 7.04 (1H, s, Ar-H), 7.19-7.24 (1H, m, Ar-H), 7.34-7.41 (7H, m, 7xAr-H), 7.57 (1H, s, 
Ar-H), 7.81-7.86 (1H, m, Ar-H); 
13
C NMR CDCl3 (ppm): 56.2 (CH3), 56.3 (CH3), 92.2 (CH), 96.1 
(CH), 98.9 (C), 99.6 (CH), 113.4 (C), 124.3 (CH), 125.3 (CH), 125.5 (C), 126.1 (C), 126.3 (CH), 
128.2 (2xCH), 128.3 (C), 128.7 (2xCH), 129.1 (CH), 130.1 (CH), 131.7 (C), 136.1 (C), 149.8 (C), 
152.0 (C), 153.0 (C), 190.3 (C). 
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6-(4-Methylphenyl)-7-oxo-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-carbonitrile 48d: 
The mixture was stirred at reflux for 1.5 hours. Mp 179.6-181°C; Yield 44%; IR: 2255 (CN), 1653 
(CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.35 (3H, s, CH3), 5.63 (1H, s, CH), 7.14-7.26 (4H, m, 4xAr-H), 
7.40-7.45 (4H, m, 4xAr-H), 7.83-7.92 (2H, m, 2xAr-H) 8.21-8.25 (2H, m, 2xAr-H); 
13
C NMR 
CDCl3 (ppm): 21.3 (CH3), 92.9 (CH), 113.0 (C), 118.4 (CH), 122.0 (CH), 124.6 (CH), 125.7 (CH), 
126.4 (CH), 127.0 (C), 127.1 (C), 127.4 (CH), 128.1 (2xCH), 128.2 (CH), 128.6 (C), 129.4 (2xCH), 
130.9 (CH), 131.5 (C), 131.7 (C), 132.3 (C), 133.1 (C), 164.5 (C), 191.0 (C). 
 
Synthesis of isoindolo[1,2-d][1,5]benzoxazepin-7-yl-12-carbonitrile acetate compounds 49a-d 
General procedure:  
To a solution of the suitable derivative 48a-d (0.0006 mol) in dichloromethane (5 ml) triethylamine 
was added (0.16 ml, 0.0012 mol) and the mixture was stirred for 1 hour at room temperature. After 
that acetyl chloride (0.0012 mol) was added, the mixture was maintained under stirring at room 
temperature for 5-24 hours. The mixture was poured onto ice and extracted with ethyl acetate. The 
organic phase was concentrated and the crude purified by chromatography using dichloromethane 
as eluent. 
 
6-Phenylisoindolo[1,2-d][1,5]benzoxazepin-7-yl-12-carbonitrile acetate 49a: The mixture was 
stirred at room temperature for 5 hours. Mp 211.8-212.8°C; Yield 90%; IR: 2196 (CN), 1765 (CO) 
cm
-1
; 
1
H NMR CDCl3 (ppm): 2.39 (3H, s, CH3), 7.30-7.63 (8H, m, 8xAr-H), 7.77-7.95 (4H, m, 
4xAr-H), 8.05-8.10 (1H, m, Ar-H); 
13
C NMR CDCl3 (ppm): 20.5 (CH3), 94.1 (C), 113.9 (C), 117.9 
(CH), 120.4 (CH), 122.2 (CH), 122.4 (C), 124.2 (C), 125.1 (CH), 125.8 (CH), 126.9 (2xCH), 127.0 
(CH), 127.4 (CH), 129.1 (2xCH), 129.9 (C), 130.1 (CH), 130.8 (C), 131.2 (CH), 131.6 (C), 131.7 
(C), 149.3 (C), 153.8 (C), 169.0 (C). 
 
9,10-Dimethyl-6-phenylisoindolo[1,2-d][1,5]benzoxazepin-7-yl-12-carbonitrile acetate 49b: 
The mixture was stirred at room temperature for 24 hours. Mp 248-249°C; Yield 64%; IR: 2256 
(CN), 1775 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.37 (3H, s, CH3), 2.38 (3H, s, CH3), 2.39 (3H, s, 
CH3), 7.49-7.64 (8H, m, 8xAr-H), 7.87-7.92 (3H, m, 3xAr-H); 
13
C NMR CDCl3 (ppm): 20.2 (CH3), 
20.3 (CH3), 20.5 (CH3), 93.0 (C), 99.5 (CH), 114.2 (C), 116.6 (CH), 118.8 (CH), 121.8 (C), 122.1 
(CH), 123.2 (CH), 125.6 (CH), 126.8 (2xCH), 126.9 (C), 129.0 (2xCH), 129.9 (CH), 130.1 (C), 
130.9 (CH), 131.2 (C), 131.8 (C), 135.2 (C), 138.0 (C), 148.7 (C), 153.6 (C), 168.9 (C). 
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9,10-Dimethoxy-6-phenylisoindolo[1,2-d][1,5]benzoxazepin-7-yl-12-carbonitrile acetate 49c: 
The mixture was stirred at room temperature for 24 hours. Mp 246.6-248°C; Yield 64%; IR: 2256 
(CN), 1768 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.29 (3H, s, CH3), 3.93 (3H, s, OCH3), 4.00 (3H, s, 
OCH3), 6.98 (1H, s, Ar-H), 7.05 (1H, s, Ar-H), 7.29-7.47 (6H, m, 6xAr-H), 7.78-7.81 (2H, m, 
2xAr-H), 7.89-7.94 (1H, m, Ar-H); 
13
C NMR CDCl3 (ppm): 20.7 (CH3), 55.9 (CH3), 56.2 (CH3), 
94.0 (C), 96.4 (CH), 98.1 (CH), 115.1 (C), 118.4 (C), 122.0 (CH), 123.5 (C), 125.3 (CH), 126.4 
(CH), 127.1 (2xCH), 128.6 (2xCH), 129.3 (C), 129.5 (CH), 129.6 (CH), 131.0 (C), 131.9 (C), 132.2 
(C), 149.4 (C), 149.6 (C), 151.7 (C), 153.9 (C), 168.3 (C). 
 
6-(4-Methylphenyl)isoindolo[1,2-d][1,5]benzoxazepin-7-yl-12-carbonitrile acetate 49d: The 
mixture was stirred at room temperature for 24 hours. Mp 239°C; Yield 64%; IR: 2196 (CN), 1763 
(CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.28 (3H, s, CH3), 2.42 (3H, s, CH3), 7.15-7.46 (7H, m, 7xAr-
H), 7.68-7.83 (4H, m, 4xAr-H), 7.94-7.99 (1H, m, Ar-H); 
13
C NMR CDCl3 (ppm): 20.8 (CH3), 21.5 
(CH3), 94.5 (C), 100.1 (C), 114.7 (C), 118.5 (CH), 120.4 (CH), 122.1 (CH), 122.9 (C), 124.4 (CH), 
124.9 (C), 125.7 (CH), 126.5 (CH), 126.7 (CH), 127.1 (2xCH), 129.0 (C), 129.4 (2xCH), 130.2 
(CH), 130.8 (C), 132.6 (C), 140.1 (C), 150.4 (C), 154.5 (C), 168.6 (C). 
 
Synthesis of 6-acetyl-7-oxo-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-carbonitriles 
50a,b 
General procedure:  
To a solution of the suitable derivative 48a,b (0.001 mol) in tetrahydrofuran (23 ml) sodium 
hydride (0.001 mol) was added and the reaction mixture was stirred for 1 hour at room temperature. 
Acetyl chloride (0.001 mol) was added and the reaction was stirred at room temperature for 1-24 
hours. Some drops of methanol were added and the solvent was evaporated under reduced pressure. 
The residue was dissolved in dichloromethane, washed with a saturated solution of ammonium 
chloride, dried and evaporated. The crude was purified by chromatography with dichloromethane as 
eluent. 
 
6-Acetyl-6-phenyl-7-oxo-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-carbonitrile 50a: 
The mixture was stirred at room temperature for 24 hours. Mp 126.4-127.9°C; Yield 50%; IR: 2256 
(CN), 1775 (CO), 1635 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.02 (3H, s, CH3), 7.24-7.68 (9H, m, 
9xAr-H), 7.81-7.93 (4H, m, 4xAr-H); 
13
C NMR CDCl3 (ppm): 20.4 (CH3), 106.2 (C), 111.3 (C), 
119.2 (CH), 120.8 (CH), 123.5 (CH), 123.9 (C), 126.6 (CH), 126.9 (CH), 128.4 (CH), 128.6 (CH), 
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128.7 (C), 128.9 (2xCH), 129.5 (C), 130.0 (2xCH), 130.1 (C), 131.6 (CH), 132.3 (C), 135.0 (CH), 
145.8 (C), 167.3 (C), 182.3 (C), 191.8 (C). 
 
6-Acetyl-9,10-dimethyl-6-phenyl-7-oxo-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-
carbonitrile 50b: The mixture was stirred at room temperature for 1 hour. Mp 97-98.6°C; Yield 
54%; IR: 2215 (CN), 1771 (CO), 1630 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 1.95 (3H, s, CH3), 2.29 
(3H, s, CH3), 2.38 (3H, s, CH3), 7.32 (1H, d, J = 8.1 Hz, Ar-H), 7.40-7.49 (2H, m, 2xAr-H), 7.55-
7.63 (3H, m, 3xAr-H), 7.69 (1H, s, Ar-H), 7.74-7.89 (4H, m, 4xAr-H); 
13
C NMR CDCl3 (ppm): 
19.8 (CH3), 19.9 (CH3), 20.8 (CH3), 99.5 (C), 105.3 (C), 111.4 (C), 117.8 (CH), 118.6 (CH), 122.0 
(C), 123.4 (CH), 126.7 (CH), 127.5 (C), 128.7 (CH), 128.9 (C), 129.3 (2xCH), 129.5 (C), 129.6 
(2xCH), 131.7 (CH), 135.5 (CH), 137.7 (C), 139.6 (C), 145.6 (C), 167.3 (C), 182.0 (C), 192.2 (C). 
 
Synthesis of 7-ethoxy-6-phenylisoindolo[1,2-d][1,5]benzoxazepine-12-carbonitrile 51a  
To a solution of 48a (0.0006 mol) in dimethylformamide (3 ml) triethylamine (0.0006 mol) was 
added and the mixture was stirred for 1 hour at room temperature. After that ethyl iodide (0.35 ml, 
0.0004 mol) was added, the mixture was maintained under stirring at room temperature for 1.5 
hours. The mixture was poured onto ice, the resulting precipitate was filtered off and purified by 
chromatography with dichloromethane as eluent. 
Mp 219.4-221°C; Yield 30%; IR: 2256 (CN) cm
-1
; 
1
H NMR CDCl3 (ppm): 1.19 (3H, t, J=7.1 Hz, 
CH3), 4.25 (2H, q, J=7.1 Hz, CH2), 7.26-7.37 (4H, m, 4xAr-H), 7.45-7.76 (8H, m, 8xAr-H), 8.13-
8.18 (1H, m, Ar-H); 
13
C NMR CDCl3 (ppm): 14.0 (CH3), 60.9 (CH2), 100.0 (C), 118.5 (CH), 119.1 
(C), 122.0 (CH), 123.4 (CH), 123.5 (C), 126.2 (CH), 126.4 (CH), 126.6 (CH), 127.2 (C), 127.3 (C), 
128.2 (C), 128.3 (CH), 128.5 (2xCH), 130.0 (2xCH), 130.1 (C), 130.5 (C), 131.1 (CH), 133.8 (CH), 
146.2 (C), 163.2 (C). 
 
Synthesis of 6-ethyl-7-oxo-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-carbonitriles 
52a-d 
General procedure: 
To a solution of 48a-d (0.0006 mol) in dimethylformamide (3 ml) sodium hydride (0.0006 mol) 
was added and the mixture was stirred for 1 hour at room temperature. After that ethyl iodide (0.04 
ml, 0.0006 mol) was added, the mixture was maintained under stirring at room temperaturefor 1-3 
hours. The mixture was poured onto ice and extracted with ethyl acetate. The organic phase was 
concentrated and the crude purified by chromatography using dichloromethane as eluent. 
 
66 
 
6-Ethyl-7-oxo-6-phenyl-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-carbonitrile 52a: 
The mixture was stirred at room temperature for 3 hours. Mp 99.1-100°C; Yield 55%; IR: 2213 
(CN), 1747 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 1.13 (3H, t, J=7.1 Hz, CH3), 4.23 (2H, q, J=7.1 Hz, 
CH2), 7.33-7.44 (4H, m, 4xAr-H), 7.56-7.81 (7H, m, 7xAr-H), 7.88 (1H, dd, J=1.5, 7.7 Hz, Ar-H), 
8.04-8.09 (1H, m, Ar-H); 
13
C NMR CDCl3 (ppm): 13.7 (CH3), 60.7 (CH2), 99.5 (CH), 101.8 (C), 
112.0 (C), 118.2 (CH), 118.6 (C), 121.4 (CH), 123.5 (CH), 126.3 (C), 126.7 (CH), 126.8 (CH), 
127.4 (C), 128.5 (2xCH), 128.9 (CH), 129.2 (2xCH), 129.3 (C), 130.3 (C), 131.3 (CH), 134.3 (CH), 
145.6 (C), 158.6 (C), 162.7 (C). 
 
6-Ethyl-9,10-dimethyl-7-oxo-6-phenyl-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-
carbonitrile 52b: The mixture was stirred at room temperature for 1 hour. Mp 116-118°C; Yield 
24%; IR: 2211 (CN), 1746 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 1.16 (3H, t, J=7.1 Hz, CH3), 2.37 
(6H, s, 2xCH3), 4.23 (2H, q, J=7.1 Hz, CH2), 7.30 (2H, t, J=7.8 Hz, 2xAr-H), 7.45-7.64 (6H, m, 
6xAr-H), 7.74-7.79 (2H, m, 2xAr-H), 7.90 (1H, bs, Ar-H); 
13
C NMR CDCl3 (ppm): 14.0 (CH3), 
20.7 (CH3), 20.9 (CH3), 60.7 (CH2), 101.6 (C), 112.6 (C), 117.3 (CH), 118.2 (C), 120.7 (CH), 123.4 
(CH), 126.2 (CH), 127.0 (C), 128.3 (C), 128.4 (CH), 128.5 (2xCH), 129.8 (C), 130.0 (2xCH), 130.7 
(C), 130.8 (CH), 133.7 (CH), 137.0 (C), 137.1 (C), 146.3 (C), 159.6 (C), 163.2 (C). 
 
6-Ethyl-9,10-dimetoxy-7-oxo-6-phenyl-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-
carbonitrile 52c: The mixture was stirred at room temperature for 1 hour. Mp 118.8-120°C; Yield 
40%; IR: 2211 (CN), 1681 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 1.17-1.24 (5H, m, CH3, CH2), 4.01 
(6H, s, 2xCH3), 6.58-7.11 (3H, m, 3xAr-H), 7.18-7.79 (8H, m, 8xAr-H); 
13
C NMR CDCl3 (ppm): 
14.5 (CH3), 56.2 (CH3), 56.3 (CH3), 64.0 (CH2), 96.8 (CH), 100.1 (C), 100.2 (CH), 112.3 (CH), 
112.4 (C), 120.2 (CH), 124.7 (C), 125.6 (C), 126.2 (C), 128.4 (2xCH), 129.4 (2xCH), 130.1 (C), 
130.9 (C), 132.0 (CH), 132.6 (C), 134.3 (CH), 151.4 (C), 152.9 (C), 154.3 (C), 184.2 (C), 191.6 
(C). 
 
6-Ethyl-7-oxo-6-(4-methylphenyl)-6,7-dihydroisoindolo[1,2-d][1,5]benzoxazepine-12-
carbonitrile 52d: The mixture was stirred at room temperature for 1 hour. Oil; Yield 25%; IR: 
2213 (CN), 1740 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 1.18 (3H, t, J=7.1 Hz, CH3), 2.33 (3H, s, CH3), 
4.25 (2H, q, J=7.1 Hz, CH2), 7.08 (2H, d, J=8.0 Hz, 2xAr-H), 7.30-7.35 (2H, m, 2xAr-H), 7.46-7.76 
(7H, m, 7xAr-H), 8.14-8.19 (1H, m, Ar-H); 
13
C NMR CDCl3 (ppm): 14.0 (CH3), 21.7 (CH3), 60.9 
(CH2), 102.6 (C), 112.3 (C), 118.5 (CH), 119.1 (C), 122.0 (CH), 123.5 (CH), 125.4 (C), 126.1 
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(CH), 126.4 (CH), 126.5 (CH), 127.3 (C), 128.2 (CH), 129.2 (2xCH), 130.0 (2xCH), 130.1 (C), 
130.5 (C), 131.0 (CH), 144.7 (C), 146.3 (C), 159.4 (C), 163.2 (C). 
 
Synthesis of 6H-isoindolo[1,2-c][1,4]benzoxazin-6-ones 53a-c  
General procedure:  
A solution of the intermediates 23a-c (0.0009 mol) in acetic acid (2 ml) was heated under reflux for 
2 hours. After cooling the mixture was poured onto ice and the resulting precipitate filtered off and 
purified by chromatography using dichloromethane as eluent. 
 
6H-isoindolo[1,2-c][1,4]benzoxazin-6-one 53a: Mp 213-214.1°C; Yield 20%; IR: 1710 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 7.29-7.50 (5H, m, 5xAr-H), 7.76-7.85 (2H, m, 2xAr-H), 8.10 (1H, s, Ar-H), 
8.34 (1H, dd, J=0.9, 8.4 Hz, Ar-H); 
13
C NMR CDCl3 (ppm): 106.2 (C), 110.1 (CH), 115.4 (CH), 
118.7 (CH), 120.2 (CH), 120.6 (CH), 122.1 (C), 124.6 (CH), 124.7 (CH), 126.6 (C), 127.0 (CH), 
128.2 (CH), 129.0 (C), 144.3 (C), 153.4 (C). 
 
8,9-dimethyl-6H-isoindolo[1,2-c][1,4]benzoxazin-6-one 53b: Mp 244.4-246°C; Yield 10%; IR: 
1717 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.37 (3H, s, CH3),  2.40 (3H, s, CH3),  7.27-7.46 (3H, m, 
3xAr-H), 7.49 (1H, s, Ar-H), 7.74-7.78 (1H, m, 1xAr-H), 7.92 (1H, s, Ar-H), 8.06 (1H, s, Ar-H); 
13
C NMR CDCl3 (ppm): 20.7 (CH3), 20.9 (CH3), 110.3 (CH), 115.2 (CH), 118.6 (CH), 119.1 (CH), 
119.5 (CH), 122.3 (C), 124.5 (CH), 124.6 (C), 126.0 (C), 127.7 (CH), 128.6 (C), 134.8 (C), 137.7 
(C), 137.8 (C), 144.2 (C). 
 
8,9-dimetoxy-6H-isoindolo[1,2-c][1,4]benzoxazin-6-one 53c: Mp 212°C; Yield 15%; IR: 1710 
(CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 3.87 (3H, s, OCH3),  3.90 (3H, s, OCH3), 7.18 (1H, s, Ar-H), 
7.39-7.50 (4H, m, 4xAr-H), 8.34 (1H, dd, J=1.8, 6.1 Hz, Ar-H), 8.63 (1H, s, Ar-H); 
13
C NMR 
CDCl3 (ppm): 55.4 (2xCH3), 97.5 (CH), 99.0 (CH), 104.5 (C), 112.7 (CH), 116.1 (CH), 117.8 (CH), 
121.5 (C), 122.2 (C), 124.5 (C), 124.8 (CH), 127.4 (CH), 143.2 (C), 149.1 (C), 151.6 (C), 152.8 
(C). 
 
Synthesis of ethyl azidoacetate 78:  
To a solution of ethyl bromoacetate 77 (6.64 ml, 0.06 mol) in acetone (64 ml) sodium azide (9.8g, 
0.14 mol) dissolved in water (50 ml) was added with an ice bath. The reaction mixture was stirred 
under reflux for 4 hours. The solvent is evaporated under reduced pressure. A saturated solution of 
sodium hydrogen carbonate  was added and the aqueous phase was extracted with ethyl acetate. The 
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solvent was evaporated under reduced pressure and the product obtained was used without further 
purification. 
Oil; Yield 100%; IR: 2108 (N3), 1740 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 1.32 (3H, t, J=7.1 Hz, 
CH3), 3.87 (2H, s, CH2), 4.27 (2H, q, J=7.1 Hz, CH2); 
13
C NMR CDCl3 (ppm): 14.2 (CH3), 50.4 
(CH2), 61.9 (CH2), 168.3 (C). 
 
Synthesis of ethyl (2Z)-2-azido-3-(2,5-dimethoxyphenyl)prop-2-enoate 80: 
0.55 g of sodium were added, under inert atmosphere, to 23 ml of ethanol and the mixture stirred at 
room temperature until complete dissolution. 24 mmol of  compound 78 (3.1 g), dissolved in 
ethanol (5 ml) were added dropwise to the sodium ethylate thus formed at -20°C. The mixture 
stirred at -20°C for 2 hours then the 2,5-dimethoxybenzaldehyde 79 (1 g, 6 mmol) dissolved in 
ethanol (7 ml) was added. The mixture was stirred at -20°C for additional 2.5 hours, then it was 
cooled to room temperature, the solvent evaporated under reduced pressure and the residue 
dissolved in ethyl acetate and washed with water. The organic phase was concentrated and the crude 
purified by column chromatography using dichloromethane as eluent. 
Mp 68.7-70°C; Yield 48%; IR: 2116 (N3), 1704 (CO) cm
-1
; cm
-1
; 
1
H NMR CDCl3 (ppm): 1.40 (3H, 
t, J=7.1 Hz, CH3), 3.81 (3H, s, OCH3), 3.82 (3H, s, OCH3), 4.37 (2H, q, J=7.1 Hz, CH2), 6.78-6.91 
(2H, m, 2xAr-H), 7.36 (1H, s, CH), 7.82 (1H, d, J=2.8 Hz, Ar-H); 
13
C NMR CDCl3 (ppm): 14.3 
(CH3), 55.8 (CH3), 56.2 (CH3), 62.2 (CH2), 111.5 (CH), 115.8 (CH), 116.1 (CH), 119.1 (CH), 122.7 
(C), 125.5 (C), 152.2 (C), 153.0 (C), 163.7 (C). 
 
Synthesis of ethyl 4,7-dimethoxy-1H-indole-2-carboxylate 81:  
A solution of compound 80 (2.6 mmol) in toluene (15 ml) was refluxed for 2 hours. The solvent 
was evaporated under reduced pressure and the crude purified by column chromatography using 
dichloromethane as eluent. 
Mp 113.6 °C; Yield 66%; IR: 3442 (NH), 1695 (OH) cm
-1
; 
1
H NMR CDCl3 (ppm): 1.33 (3H, t, 
J=7.1 Hz, CH3), 3.83 (3H, s, OCH3), 3.86 (3H, s, OCH3), 4.30 (2H, q, J=7.1 Hz, CH2), 6.40 (1H, d, 
J=8.3 Hz, Ar-H), 6.67 (1H, d, J=8.3 Hz, Ar-H), 7.08 (1H, d, J=2.2 Hz, Ar-H), 11.92 (1H, bs, NH); 
13
C NMR CDCl3 (ppm): 14.2 (CH3), 55.2 (CH3), 55.6 (CH3), 60.2 (CH2), 98.8 (CH), 104.6 (CH), 
105.7 (CH), 119.3 (C), 126.6 (C), 129.2 (C), 141.2 (C), 147.6 (C), 160.8 (C). 
 
Synthesis of 4,7-dimethoxy-1H-indole-2-carboxylic acid 82: 
An aqueous solution of 5% sodium hydroxide (31 ml) was added to indole 81 (4.1 mmol) and the 
mixture was refluxed for 1 hour. Then, the mixture was cooled in an ice-bath and neutralized with 
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6N hydrochloric acid. The precipitate obtained was filtered and it was used without any further 
purification.   
Mp 204 °C; Yield 74%; IR: 3486 (NH), 3480 (OH), 1675 (CO) cm
-1
; 
1
H NMR CDCl3 (ppm): 3.83 
(3H, s, OCH3), 3.85 (3H, s, OCH3), 6.39 (1H, d, J=8.3 Hz, Ar-H), 6.65 (1H, d, J=8.3 Hz, Ar-H), 
7.03 (1H, d, J=2.2 Hz, Ar-H), 11.71 (1H, bs, NH), 12.80 (1H, bs, OH); 
13
C NMR CDCl3 (ppm): 
55.1 (CH3), 55.6 (CH3), 98.6 (CH), 104.4 (CH), 105.4 (CH), 119.4 (C), 127.6 (C), 129.1 (C), 141.2 
(C), 147.6 (C), 162.3 (C). 
 
Synthesis of 4,7-dimethoxy-1H-indole 83:  
The indole-2-carboxylic acid 82 (0.2 g, 0.9 mmol), copper powder (0.2 g, 3.6 mmol), and N-
methylpyrrolidinone (11 ml) were heated at reflux (250°C) for 2 hours under nitrogen atmosphere. 
The mixture was poured into ice and water and extracted with ethyl acetate, the crude was purified 
by column chromatography using dichloromethane as eluent.    
Mp 127.7-128.6°C; Yield 78%; IR: 3368 (NH) cm
-1
; 
1
H NMR CDCl3 (ppm): 3.91 (6H, s, 2xOCH3), 
6.38 (1H, d, J=8.2 Hz, Ar-H), 6.51 (1H, d, J=8.2 Hz, Ar-H), 6.63 (1H, s, Ar-H), 7.10 (1H, s, Ar-H), 
8.39 (1H, bs, NH); 
13
C NMR CDCl3 (ppm): 55.7 (2x CH3), 98.7 (CH), 100.3 (CH), 101.4 (CH), 
119.9 (C), 122.6 (CH), 127.6 (C), 141.1 (C), 147.7 (C). 
 
Synthesis of 4,7-dimethoxy-3-(phenylsulfanyl)-1H-indoles 73a, c, d, f: 
General procedure:  
To a solution of indole 83 (1.7 mmol) and suitable thiophenol 84 (1.7 mmol) in dimethylformamide 
(8 ml) copper iodide (1.7 mmol), 2,2 '-bipyridyl (1.7 mmol) and sodium carbonate (4.3 mmol) were 
added. The mixture was heated at reflux for 1.5-2 hours then the mixture was cooled to room 
temperature and poured into water and ice. The precipitate obtained was filtered and purified by 
column chromatography using dichloromethane as eluent. 
 
4,7-Dimethoxy-3-(phenylsulfanyl)-1H-indole 73a: The mixture was stirred at reflux for 1.5 hours. 
Mp 115.2-116.5°C; Yield 68%; IR: 3451 (NH) cm
-1
; 
1
H NMR CDCl3 (ppm): 3.65 (3H, s, OCH3), 
3.92 (3H, s, OCH3), 6.40 (1H, d, J=8.3 Hz, Ar-H), 6.55 (1H, d, J=8.3 Hz, Ar-H), 7.04-7.30 (6H, m, 
6xAr-H), 8.56 (1H, bs, NH); 
13
C NMR CDCl3 (ppm): 55.7 (CH3), 56.2 (CH3), 100.0 (C), 101.0 
(CH), 102.5 (CH), 103.0 (C), 124.6 (CH), 126.4 (2xCH), 128.4 (2xCH), 128.7 (C), 129.3 (CH), 
140.6 (C), 140.9 (C), 148.8 (C). 
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4,7-Dimethoxy-3-[(3-methoxyphenyl)sulfanyl]-1H-indole 73c: The mixture was stirred at reflux 
for 2 hours. Mp: 194.4-194.9°C; Yield 35%; IR: 3441 (NH) cm
-1
; 
1
H NMR CDCl3 (ppm): 3.92 (9H, 
m, CH3, 2xOCH3), 6.40 (1H, d, J = 8.3 Hz, Ar-H), 6.56 (1H, d, J = 8.3 Hz, Ar-H), 6.70-6.84 (4H, 
m, 4xAr-H), 7.28 (1H, m, Ar-H), 8.61 (1H, bs, NH); 
13
C NMR CDCl3 (ppm): 55.7 (CH3), 55.8 
(CH3), 56.2 (CH3), 100.8 (CH), 100.9 (C), 102.5 (CH), 109.7 (CH), 110.1 (C), 110.3 (C), 120.9 
(CH), 125.1 (CH), 126.7 (CH), 129.5 (C), 129.6 (C), 129.7 (C), 129.8 (CH), 141.3 (C). 
 
4,7-Dimethoxy-3-[(3-methylphenyl)sulfanyl]-1H-indole 73d: The mixture was stirred at reflux 
for 2 hours. Mp 111.4-112.3°C; Yield 35%; IR: 3454 (NH) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.23 (3H, 
s, CH3), 3.67 (3H, s, OCH3), 3.91 (3H, s, OCH3), 6.40 (1H, d, J =  8.4 Hz, Ar-H), 6.55 (1H, d, J = 
8.4 Hz, Ar-H), 6.83 -7.21 (4H, m, 4xAr-H), 7.26 (1H, d, J = 2.6 Hz, Ar-H), 8.55 (1H, bs, NH); 
13
C 
NMR CDCl3 (ppm): 21.4 (CH3), 55.7 (CH3), 56.2 (CH3), 101.0 (CH), 102.5 (CH), 103.3 (C), 123.7 
(CH), 125.6 (CH), 127.1 (CH), 128.3 (CH), 128.7 (C), 129.3 (CH), 138.1 (C), 140.3 (C), 140.9 (C), 
148.9 (C), 177.0 (C). 
 
3-[(2-Bromophenyl)sulfanyl]-4,7-dimethoxy-1H-indole 73f: The mixture was stirred at reflux for 
2 hours. Mp 126-127°C; Yield 47%; IR: 3447 (NH) cm
-1
; 
1
H NMR CDCl3 (ppm): 3.64 (3H, s, 
OCH3), 3.93 (3H, s, OCH3), 6.41 (1H, d, J=8.3 Hz, Ar-H), 6.57 (1H, d, J=8.3 Hz, Ar-H), 6.70-7.19 
(4H, m, 4xAr-H), 7.34-7.76 (1H, m, Ar-H), 8.61 (1H, bs, NH); 
13
C NMR CDCl3 (ppm): 55.7 (CH3), 
56.2 (CH3), 100.0 (CH), 101.2 (CH), 102.0 (C), 102.6 (C), 102.7 (CH), 119.4 (C), 125.4 (CH), 
127.2 (CH), 128.9 (C), 130.0 (CH), 132.1 (CH), 140.9 (C), 142.2 (C), 148.8 (C).  
 
Synthesis of 4,7-dimethoxy-3-(phenylsulfonyl)-1H-indoles 73m, r: 
General procedure: 
To a solution of 3-chloroperbenzoic acid (4.2 mmol) in dichloromethane (20 ml) at 0°C a solution 
of suitable 4,7-dimethoxy-3-(phenylsulfanyl)-1H-indoles compounds (1.05 mmol) in 
dichloromethane (10 ml) was added dropwise. Immediately a solid separated from the reaction 
mixture.  A saturated solution of sodium hydrogen carbonate (10 ml) was added and aqueous phase 
was extracted with dichloromethane. The solvent was evaporated under reduced pressure and the 
product obtained was purified by column chromatography. 
 
4,7-Dimethoxy-3-[(3-methylphenyl)sulfonyl]-1H-indole 73m: The crude was purified using a 
mixture of dichloromethane and ethyl acetate (99:1) as eluent. Mp: 173.8-174.3°C; Yield 48%; IR: 
1141 (SO2), 3438 (NH) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.36 (3H, s, CH3), 3.62 (3H, s, OCH3), 3.85 
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(3H, s, OCH3), 6.40 (1H, d, J = 8.3 Hz, Ar-H), 6.55 (1H, d, J = 8.3 Hz, Ar-H), 7.39 (1H, s, Ar-H), 
7.71 (3H, bs, 3xAr-H), 7.91 (1H, s, Ar-H), 12.40 (1H, bs, NH); 
13
C NMR CDCl3 (ppm): 20.7 
(CH3), 55.0 (CH3), 55.7 (CH3), 101.5 (CH), 103.7 (CH), 116.1 (C), 124.6 (CH), 127.6 (CH), 128.5 
(C), 128.7 (C), 131.6 (CH), 132.9 (CH), 138.2 (C), 140.8 (C), 143.2 (C), 146.5 (C).  
 
4,7-Dimethoxy-3-(phenylsulfonyl)-1H-indole 73r: The crude was purified using a mixture of 
dichloromethane and ethyl acetate (95:5) as eluent. Mp 192.6-194°C; Yield 70%; IR: 1141 (SO2), 
3313 (NH) cm
-1
; 
1
H NMR CDCl3 (ppm): 3.69 (3H, s, OCH3), 3.87 (3H, s, OCH3), 6.40 (1H, d, J = 
8.3 Hz, Ar-H), 6.55 (1H, d, J = 8.3 Hz, Ar-H), 7.04-7.46 (3H, m, 3xAr-H), 7.96-8.02 (3H, m,3x Ar-
H), 8.98 (1H, bs, NH); 
13
C NMR CDCl3 (ppm): 55.6 (CH3), 55.8 (CH3), 100.0 (C), 102.2 (CH), 
103.8 (CH), 117.9 (C), 127.8 (2xCH), 128.3 (2xCH), 128.9 (C), 130.2 (CH), 132.2 (CH), 140.7 (C), 
143.2 (C), 147.3 (C). 
 
Synthesis of 3-(phenylsulfonyl)-1H-indole-4,7-dione compounds 75n, p: 
General procedure: 
4,7-Dimethoxy-3-(phenylsulfonyl)-1H-indole compound 73m, r (0.32 mmol) was dissolved in 
tetrahydrofuran (3 ml) and a 90% solution of nitric acid (0.12 ml) and silver(II)oxide (0.12 g) were 
added at 0°C. The mixture was stirred at room temperature for 30 minutes, then it was poured into 
ice and water and extracted with dichloromethane. The solvent is evaporated under reduced 
pressure and the product obtained was purified by column chromatography using a mixture of 
dichloromethane and ethyl acetate (95:5) as eluent. 
 
3-[(3-Methylphenyl)sulfonyl]-1H-indole-4,7-dione 75n: Mp: 183.8-184.3°C; Yield 80%; IR: 
1142 (SO2), 1593,1664 (CO), 3557 (NH) cm
-1
; 
1
H NMR CDCl3 (ppm): 2.42 (3H, s, CH3) 6.64 (2H, 
m, 2xAr-H), 7.27-7.39 (2H, m, 2xAr-H), 7.87-7.97 (3H, m, 3xAr-H), 10.57 (1H, bs, NH); 
13
C NMR 
CDCl3 (ppm): 21.4 (CH3), 89.2 (CH), 125.7 (CH), 128.7 (CH), 129.5 (CH), 132.9 (C), 133.8 (C), 
134.4 (CH), 134.9 (CH), 138.8 (CH), 139.1 (C), 140.0 (C), 140.6 (C), 177.7 (C), 180.0 (C). 
 
3-(Phenylsulfonyl)-1H-indole-4,7-dione 75p: Mp 197.6-198.7°C; Yield 65%; IR: 1142 (SO2), 
1662, 1679 (CO), 3313 (NH) cm
-1
; 
1
H NMR CDCl3 (ppm): 6.68 (2H, q, J = 10.2 Hz, 2xAr-H), 7.55-
7.70 (3H, m, 3xAr-H), 7.96 (1H, s, Ar-H), 8.06 (2H, d, J = 6.9 Hz, 2xAr-H), 13.64 (1H, bs, NH); 
13
C NMR CDCl3 (ppm): 119.8 (C), 123.1 (C), 127.6 (2xCH), 128.9 (2xCH), 130.7 (CH), 133.4 
(CH), 135.5 (CH), 137.9 (CH), 141.3 (C), 148.0 (C), 177.6 (C), 180.4 (C).  
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Docking studies were performed for all designed compounds by Glide 8.0  (Schrodinger Inc., 2008) 
installed on a 3.4 GHz Pentium 4 processor with 1 GB RAM and 250 GB Hard Disk with Windows 
XP operating system. 
The X-ray crystallographic structure of HIV-1 RT protein (PDB code 1RT2) was downloaded from 
Protein Data Bank ( www.rcsb.org/pdb). 
For Glide docking studies, chain A was retained and the protein was minimized by the protein 
preparation wizard. Partial atomic charges were assigned according to the OPLS_AA force field. A 
radius of 20 Å was selected for active site cavity during receptor grid generation. 
All compounds used in the docking study with Glide were built within maestro by using build 
module of Schrodinger Inc., (2008).  
All docking calculations were performed using the Extra Precision (XP) mode of Glide Program 
8.0. A grid box was prepared with the center defined by the co-crystallized ligand TNK 651 of 
1RT2. 
To validate the Glide docking protocol, TNK 651, the co-crystalized ligand was docked into the 
binding site. The docking structure was compared to the crystal structure showing that this protocol 
successfully reproduces the crystal TNK 651- RT complex. 
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SYNTHESIS OF TRIAZOLES AND OXAZOLES DERIVATIVES AS G-QUADRUPLEX 
LIGANDS (UCL, SCHOOL OF PHARMACY) 
 
INTRODUCTION 
 
During my PhD, I spent 6 months at the University College of London under the supervision of 
Professor Stephen Neidle, where I carried out a project based on the synthesis of potential ligand of 
G-quadruplex DNA. 
Telomeres are specialized sequences at the end of chromosomes, comprising tandem repeats of 
simple DNA sequences, they serve to protect chromosome integrity and ensure complete replication 
of essential genes. 
Human telomeric DNA consist of tandem repeats of the sequence 5’-TTAGGG with single-stranded 
3’-end overhang (Fig.1). [1] 
 
Figure 1 [2] 
 
 
This single stranded DNA can be recognized as a damage so it is not usually exposed to the cell 
environment, but is associated with proteins to organize it in a ordered structure, called T-loop, in 
which the G-rich sequence loops back on itself and is inserted in the duplex telomeric DNA, paring 
with the C-rich strand replacing its complementary counterpart, which thus forms a D-loop. [3] 
77 
 
This arrangement is maintained by the “Shelterin complex”: a complex of six proteins assembled at 
the telomeric DNA. [4] Three components of this complex, TRF1 (telomeric-repeat-binding factor 
1), TRF2 (telomeric-repeat-binding factor 2) and POT1 (protection of telomeres 1) specifically 
recognize the sequence TTAGGG, TRF1 and 2 bind the double stranded DNA while POT1 
recognizes the single stranded DNA. The structure is stabilized by a bridging protein chain made by 
the other three subunits TIN2, TPP1 and RAP1 (Fig.2). [5] 
 
 
 
 
Figure 2 [6] 
 
 
 
 
Due to replication problem after every round of cell division the telomere is shortened by 50-200 
nucleotides: DNA polymerase is unable to replicate until the end of the chromosome and after a the 
loss of a number of nucleotides (known as Hayflick) the telomere becomes critically short causing 
the cells’ senescence and apoptosis. [7] 
In the majority of the tumour cells the telomeres are maintained at a constant length by the 
activation of the enzyme telomerase causing cell immortalization. [8] This enzyme  is up-regulated 
in 80-85% of human tumours [9] but the enzyme does exist in stem cells. [10] 
The telomerase enzyme complex is a reverse transcriptase that adds bases onto the 3’ single 
stranded telomeric overhang; it consists of a (catalytic subunit hTERT and a ribonucleic acid 
subunit hTR, which carries a 11-bp RNA template, scaffold for DNA retrosynthesis (Fig.3). [11] 
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Figure 3 [2] 
 
 
 
 
Zahler and co-workers demonstrated that for the activity of the telomere the single stranded 3’ end 
has to be unfolded, thus it was shown that induction of the telomere folding to form four-stranded 
quadruplex structures results in inhibition of telomerase activity. [12] 
DNA can form other tertiary structures besides the well-known double helix. The G-quadruplex is a 
stable four-stranded structure characteristic of nucleic acid sequences rich in guanine. 
Four coplanar guanine bases can be linked through Hoogsteen hydrogen bonding to generate a 
square planar arrangement called G-tetrad (o G-quartet): two or more G-tetrads can stack on top of 
each other by  interactions to generate a G-quadruplex, whose structure is stabilized by the 
presence of cations, such as K
+
 or Na
+
, which coordinates the carbonyl groups in the centre of the 
quartets (Fig.4). [13] 
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Figure 4 
 
The stacked bases exist as quadruple helix, because of the steric constraints they cannot stay 
directly on each other but are twisted.  
G-quadruplexes can be formed by the association of four DNA strands that can run parallel and 
anti-parallel: both intra- and intermolecular arrangement are possible, in the second case the 
quadruplex formed will be dimeric or tetrameric, it depends in how many different strands are 
involved (Fig.5).  
 
Figure 5 [14] 
 
 
Depending on whether loops connect strands which are either adjacent or opposite, they can be 
lateral, diagonal o external and the guanines can have relative syn or anti conformation  (Fig.6). 
[15] 
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Figure 6 [13] 
 
 
Regions with G-rich sequences, that can form G-quadruplexes, were found in many different areas 
of the genome other than telomeres.  
It was found that the gene of the human heat shock protein 90 (Hsp 90) contains a guanin-rich 
sequence upstream of the transcription start site, analogous to the c-kit promoter sequence. [16] 
The human proto-oncogene c-kit encodes a receptor tyrosine kinase that, upon activation by its 
ligand, stimulates cell proliferation, differentiation and survival. [17] 
Activating mutations or overexpression can result in aberrant function and oncogenic cellular 
transformation.  
Two G-rich sequences were found in c-kit promoter region, they occur between position -87 and -
109 base pairs (Kit 1) and between -140 and -160 base pairs (Kit 2) relative to the transcription start 
site. Both of them were shown to form stable G-quadruplexes in vitro, and the three-dimensional 
structures was solved for each sequence. [18] 
Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that regulates the late-
stage maturation, activation, and stability of different kind of proteins, many of them are involved in 
signal transduction and other pathways important in the malignancy. [19] 
It was found that Hsp90 proteins are required to obtain a functionally active telomerase in vitro [20] 
and the essential sites for the function are the N-terminal ATP-binding site [21] and a putative C-
terminal ATP-binding site, they act cooperatively allowing cross-talk mediated by a central charged 
domain between the two termini. [22] 
G-quadruplex structure can be stabilized by organic molecules through the combination of 
electrostatic and hydrophobic force and the formation of hydrogen bonds. 
Through molecular modeling and crystallographic data, [13] it was possible to identified some 
features required for the interaction, including a flat aromatic surface, the presence of cationic 
charges, amino groups which are protonated at physiological pH and the ability to interact with the 
G-quartets through  force. 
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The first G-quadruplex binding ligand was the 2,6-diamidoanthraquinone 1, [23] it was developed 
after a series of anthraquinones that showed to act as selective DNA triplex interacting compounds, 
with reduced affinity for duplex DNA. [24] [25] 
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N
CH2OH
1  
 
 
 
This compound demonstrated telomerase inhibitory ability (IC50 = 23 µM) but there was an almost 
complete inhibition of telomerase activity at 100 µM.  
Structure-activity relationship studies on anthraquinone compounds showed the effect of 
chromophore, chain linker and regioisomerism on telomerase activity. Based on these studies, a 
series of analogous 3,6-disubstituted acridine derivatives were developed since the acridine moiety 
is an inherently planar chromophore, but contains a heterocyclic nitrogen atom with the ability to be 
protonated at physiological pH.  
The acridine derivatives examined showed a telomerase inhibitory activity with the most potent 
inhibitor 2 having a IC50  value of 1.35 µM. [26] 
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Ligands based on the acridine skeleton were subsequently developed by derivatizing the 9-position 
of the 3,6-disubstituted acridine ring system. The lead compound, BRACO-19 3, showed an IC50  
value of 0.06 µM. [27] 
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This compound inhibited cell growth at subcytotoxic concentrations after days rather than weeks, 
by inducing senescence and displacement of POT1 from telomeres. [28] 
Evidence of telomere shortening in UXF1138L cells (uterine carcinoma cell line) was discovered; 
with an IC50 of 2.5 µM and an IC100 of 5 µM, and the concentration that would cause zero growth 
inhibition was found 1µM, in a 5 day proliferation assay. [29] 
 In vivo activity against a human tumor xenograft was also found, where the cytotoxic agent taxol 
was used to produce tumor regression and BRACO-19, given after debulking, was able to suppress 
tumor regrowth. [30] 
The most potent and specific telomerase inhibitor known is a natural compound produced by 
Streptomyces Anulatus 3533-SV4; Telomestatine 4 showed an IC50 value of 0.005 µM and it was 
proved to be a specific telomerase inhibitor since it showed weak activities against reverese 
transcriptases such as HIV- and MMLV- (moloney murine leukemia virus), with IC50 values of 19.4 
µM and 13.4 µM respectively. [31] 
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In the porphyrine family the most active compound was TMPyP4 5 (5,10,15,20-tetra-(N-methyl-4-
pyridyl)porphine) with an IC50 values of 6.5 µM, by stacking on the G-quartet surface setting up 
 interactions. [32] 
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Berberine 6 is an antibiotic alkaloid originating from Chinese herbal medicine, [33] it was 
subsequently screened for anticancer activity showing evidence of antineoplastic properties. [34] 
It was after shown to inhibit telomere elongation and to bind G-quadruplex DNA with an IC50 
values of 35 µM. [35] 
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Based on data and in vitro and in vivo knowledge gathered from previous G-quadruplex ligands and 
chemotypes, two series of compounds were developed:  phenyl bis-triazole and phenyl bis-oxazole 
derivatives. 
The triazole compounds 7 are the first generation of G-quadruplex binding ligand synthesised via 
“click chemistry” and they showed high affinity for G-quadruplex over duplex DNA, along with 
some telomerase inhibition in vitro (best IC50 value is 13.2 µM). [36] 
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The phenyl bis-oxazole 8 derivative showed high selectivity for Hsp90A and Hsp90B G-quadruplex 
DNA. 
 
 
N
O O
N
R2N NR2n n8
n =1, 2
NR2  = pyrrolidinyl-, piperidinyl-, dimethylamino-, diethylamino- 
 
 
The lead compound 9 was evaluated in cell-based assays to investigate the cell growth inhibitory 
ability and gave IC50 values in cancer cell lines (Tab.1) [37] 
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Cell line IC50 (µM) 
A549 1.02 
MCF7 1.32 
RCC4 0.94 
786-O 1.33 
MiaPaCa 1.25 
WI38 2.59 
Table 1 
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Considering the results shown by the former ligands, the purpose of the project was the synthesis of 
naphthalene bis-triazole derivatives 10, and phenyl and naphthalene bis-oxazole derivatives 11 and 
12 and the derivatisation occurred with the linker of the appropriate length and with a different 
panel of amines. 
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X = O, NH 
n = 2,3 
 NR2 = diethylamino-, pyrrolidinyl-, N-methyl-piperazinyl- 
   
 
RESULTS AND DISCUSSION 
 
The synthesis of the bis-triazole compounds was based on a convergent approach of the alkyne 13 
and azide 14 building blocks, the final compounds were the result of a formation of two triazole 
rings via Huisgen 1,3-dipolar cycloaddition. 
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The alkyne building block was synthesized in three steps. 
 
 
HO OH
TfO OTf
TMS TMS
1315
16 17
DMAP, 2,6-lutidine, 
TfO2, DCM/THF
CuI, PPh3, Pd(PPh3)4, 
ethyniltrimethylsilane
piperidine
NaOH 1M, THF
 
 
The first step was the conversion of naphthalene-2,7-diol 15 into the corresponding di-triflate 16 
using triflic anhydride,  that was substituted by the nuclophilic hydroxyl group of the naphthalene. 
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The second was the formation of the protected alkyne 17 through Sonogashira coupling reaction 
using tetrakis(triphenylphosphine)palladium, copper iodide and piperidine as base under reflux 
overnight to give the desired compound with 90% yield. 
The mechanism was based on Pd and Cu cycles; the first one goes through the oxidative insertion of 
the alkyne, transmetallation, tran-cis isomerisation and reductive elimination with formation of the 
desired product and regeneration of Pd(0); the Cu cycle provides the formation of a alkyne-Cu 
complex, the formation of the alkynyl copper, the transmetallation and the regeneration of copper 
iodide (Fig.7). 
 
 
 
 
 
Figure 7 [38] 
 
 
The final step is an easy deprotection of the trimethylsilane with aqueous sodium hydroxide 
solution obtaining the compound 13 in a quantitative yield. 
The azide building block 14a-i was synthesized starting from the corresponding amino-compound 
18a-i through diazotization with one pot azide substitution. 
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X NR2
NR2n n
14a-i
18a-i
a X=NH, n=2, NR2=diethylamino-, m-substitued
b  X=NH, n=3, NR2=diethylamino-, m-substitued
c   X=NH, n=3, NR2=N-methyl-piperazinyl-, p-substitued
d X=NH, n=3, NR2=N-methyl-piperazinyl-, m-substitued
e  X=NH, n=3, NR2=pyrrolidinyl-, m-substitued
f  X=NH, n=2, NR2=pyrrolidinyl-, m-substitued
g  X=O, n=3, NR2=N-methyl-piperazinyl-, m-substitued
h  X=O, n=2, NR2=diethylamino-, m-substitued
i  X=O, n=3, NR2=pyrrolidinyl-, m-substitued  
 
 
The reactive cation NO
+
 was formed using tert-butyl nitrite and hydrochloric acid, the formed aryl 
diazonium salt was a good leaving group replaced by the azide, introduced as the sodium salt. 
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The amino compounds 18a-i were prepared starting from the m- or p-phenylendiamine 19a-b or 
from the 3-aminophenol 21 depending on whether X is –O- or –NH-. For the preparation of the 
compound 18a-f the m- or p-phenylendiamine 19a-b was added to a solution of the chlorinated side 
chains 20a-e in acetonitrile in the presence of potassium iodide under microwave irradiation for 10 
minutes at 110°C to give the desired compound in good yields.  
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19a-b 20a-e 18a-f
KI, CH3CN
MW, 110°C, 10 mins
a n=3, NR2=diethylamino-
b n=3, NR2=N-methyl-piperazinyl-
c n=3, NR2=pyrrolidinyl-
d n=2, NR2=diethylamino-
e n=2, NR2=pyrrolidinyl-
a m-substituted
b p-substituted
 
 
If X was –O-, the 3-aminophenol 21 reacted with chlorinated side chains 20b-d in DMF using 
sodium hydride as base to give the compounds 18g-i. 
 
Cl NR2
n
20b-d
NaH, DMF
NH2
OH
NH2
O NR2
n
21 18g-i  
 
 
The chlorinated side chains 20a-c, not commercially available, were prepared starting from the 
corresponding amine 22a-c by reaction with the iodo- or bromo-chloropropane. 
 
N NHN
H
NH
22a 22b 22c  
 
Once the two building blocks were synthesized, the final compounds were obtained via Huisgen 
1,3-dipolar cycloaddition, [39] reaction of a dipolarophile with a 1,3-dipolar derivative that led to 5-
membered cycle. 
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The risk of forming both regioisomers was avoided using the so called “click reaction” that was first 
fully described by K. Barry Sharpless whose purpose was to train a set of small molecules that 
could generate compounds by joining together heteroatom links. He established some criteria for an 
ideal click reaction that shloud be modular, wide in scope, work at high yields, produce only 
harmless byproducts and be stereospecific.  
The azide-alkyne Huisgen reaction combined Cu(I) catalysis with  the cycloaddition making the 
reaction regioselective for the 1,4-disubstituted isomer. [40] 
The reaction was performed by producing Cu(I) in situ through a mixture of CuSO4
.
5H2O and 
sodium ascorbate in a ratio of 1:10; bathophenanthrolinedisulfonic acid disodium salt hydrate was 
used for catalysing the multiple click reactions and an excess of the appropriate amine was added in 
order to avoid elimination of the amino-side chains. The desired compounds 10a-i were obtained by 
purification of the crude products using a semi-prep C-18 reversed phase HPLC.  
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10a-i
a X=NH, n=2, NR2=diethylamino-, m-substitued
b X=NH, n=3, NR2=diethylamino-, m-substitued
c X=NH, n=3, NR2=N-methyl-piperazinyl-, p-substitued 
d X=NH, n=3, NR2=N-methyl-piperazinyl-, m-substitued
e X=NH, n=3, NR2=pyrrolidinyl-, m-substitued
f X=NH, n=2, NR2=pyrrolidinyl-, m-substitued
g X=O, n=3, NR2=N-methyl-piperazinyl-, m-substitued
h X=O, n=2, NR2=diethylamino-, m-substitued
i X=O, n=3, NR2=pyrrolidinyl-, m-substitued  
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The synthesis of the bis-oxazole compounds was based on an arylation, using the substituted 
arylbromides, of the phenyl and naphthalene bis-oxazole.  
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O O
N
24
Br
X NR2
29a-e
n
+
11a X=NH, n=2, NR2=diethylamino-
11b X=NH, n=3, NR2= N-methyl-piperazinyl- 
11c  X=NH, n=2, NR2= pyrrolidinyl- 
11d X=O, n=2, NR2= diethylamino-
11e X=O, n=2, NR2=pyrrolidinyl-
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12a X=NH, n=2, NR2=diethylamino-
12b X=NH, n=3, NR2= N-methyl-piperazinyl-
 
 
 
Before  this step the phenyl bis-oxazole 24 was synthesized from the isophathalaldehyde 23 using 
the tosylmethylcyanate-procedure described by van Leusen with potassium carbonate in methanol. 
[41]  
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The synthesis of the naphthalene bis-oxazole 27 was based on the Strotman’s paper, [42] starting 
from the 2,7-dibromonaphtalene 25 by reaction with the oxazole 26 in the presence of potassium 
carbonate, palladium acetate, pivalic acid and the proper ligand (2-di-tert-butylphosphino-3,4,5,6-
tetramethyl-2’,4’,6’-triisopropyl-1,1’-biphenyl) in DMA under reflux for 72 hours. 
 
N O O N
Br Br
N O
+
K2CO3, Pd(OAc)2, 
Pivalic acid,
2-Di-tert-butylphosphino-3,4,5,6-tetramethyl-
2',4',6'-triisopropyl-1,1'-biphenyl, 
DMA
25 26
27  
 
The meta-substitued arylbromides 29a-e were prepared using two different pathways.  
If X was –NH-, 3-bromoaniline 28 were added to a solution of the chlorinated side chains 20b,d,e 
in acetonitrile in the presence of potassium iodide under microwave irradiation for 10 minutes at 
110°C to give the compounds 29a-c. 
 
Br
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Cl NR2
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20b,d,e
KI, CH3CN
MW, 110°C, 10 mins
Br
N
H
NR2n
28 29a-c
29a n=2, NR2=diethylamino-
29b n=3, NR2= N-methyl-piperazinyl-
29c n=2, NR2= pyrrolidinyl-  
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If instead X was –O- the synthesis started from the 3-bromophenol 30 by reaction with chlorinated 
side chains 20d,e using potassium carbonate as base in DMF, stirring at room temperature overnight 
to give the arylbromides 29d,e. 
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Br
OH
Br
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n
29d  n=2, NR2=diethylamino-
29e n=2, NR2= pyrrolidinyl-  
 
The phenyl and naphthalene bis-oxazole were then arylated twice with the arylbromides under 
Strotman’s conditions using a different ligand (2-dicyclohexylphosphino-2’,6’-
diisopropoxybiphenyl) in toluene to make the reaction selective for the C-5 arylation of the oxazole 
obtaining the derivatives 11a-e and 12a,b.  
All compounds obtained 10a-i, 11a-e, 12a,b were analyzed by FRET (Fluorescence Resonance 
Energy Transfer), which evaluated the distance-dependent interaction between the electronic 
excited states of two molecules in which excitation was transferred from a donor molecule to an 
acceptor molecule through non-radiative dipole–dipole coupling, resulting in the return of the donor 
to its ground state causing a fluorescent emission (Fig.8). [43] 
 
 
 Figure 8 
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Primary conditions were that donor and acceptor molecules must be in close proximity (typically 
10–100 Å) and the absorption spectrum of the acceptor must overlap the fluorescence emission 
spectrum of the donor (Fig.9). 
 
 
Figure 9 [44] 
 
The FRET efficiency (E) was described in the empirical Förster equation and depends on the donor-
to-acceptor separation distance (r) with an inverse 6th power law due to the dipole-dipole coupling 
mechanism: 
 
R0 is the Förster distance of this pair of donor and acceptor, i.e. the distance at which the energy 
transfer efficiency is 50%. 
DNA can be synthesized with its 3’ and 5’ ends tagged with fluorescent dyes, at the 5’ end 6-
carboxyfluorescein (FAM) 31 the donor, and tetramethyl-6-carboxyrhodamine (TAM) 32 at the 3’ 
end as the acceptor, using 6 carbon linkers. 
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COOH
NH
O
31                                   
ON N
COOH
NH
O
32  
97 
 
When nucleotides are folded in the G-quadruplex structure, the fluorophores are closer in space and 
the FRET efficiency is high. 
Using this property, by increasing the temperature while measuring the fluorescence intensity, 
melting experiments could be done on DNA and the melting temperature of the labelled 
oligonucleotides could be monitored to screen the G-quadruplex stabilising ability of small 
molecules. [45] 
The experiment was performed with four different sequences of labelled DNA: 
 
 
F21T: 5’-FAM-GGG TTA GGG TTA GGG TTA GGG-TAMRA-3’ 
C-Kit 2: 5’-FAM-CCC GGG CGG GCG CGA GGG AGG GGA GG-TAMRA-3’ 
Hsp90A: 5’-FAM-GGG CCA AAG GGA AGG GGT GGG-TAMRA-3’ 
TLoop: 5’-FAM-TAT AGC TATA TTT TTT TATA GCT ATA-TAMRA-3’  
 
 
The experiments were all run in potassium cacodylate buffer 60 mM (pH 7.4), in which the DNA 
sequences have the melting point shown in the table. (Tab.2) 
 
 
DNA-sequences Tm (°C) 
F21T 58.4 ± 0.9 
C-kit 2 53.5 ± 0.5 
Hsp90A 57.5 ± 0.5 
TLoop 53.5 ± 0.5 
                  Table 2 
 
 
The Tm values obtained for all the derivatives (at 1µM and 5 µM concentrations) were reported in 
the table. (Tab.3)  
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 ΔTm(°C) F21T ΔTm(°C) C-kit 2 ΔTm(°C) Hsp90A ΔTm(°C) TLoop 
 1 µM 5 µM 1 µM 5 µM 1 µM 5 µM 1 µM 5 µM 
10a 1.7 8 1.5 6.8 1.1 10.9 1 0.7 
10b 0.2 3.2 0.5 5.4 1.3 9.5 0 0.5 
10c 0.6 5 0.1 3.8 1.9 9 0.2 0.4 
10d 2.5 9.4 2.4 7.8 5.8 15.7 0.1 0.7 
10e 3.9 15.8 3 17.7 10.8 20.5 0.6 1.6 
10f 0.3 21.2 0 16.74 <2 26 0.2 3.2 
10g 4 22 4.2 18.5 10.5 24.9 0.3 2.5 
10h 4.2 20.1 2.2 22.9 8.8 23.6 0.3 5 
10i 0.8 26.5 1.3 29.9 6 28.2 0.1 5.8 
11a 0.5 13.3 0 13.6 1.2 19.5 0.1 0.2 
11b 0.6 20 0 18.3 <2 25 0.2 1.8 
11c 0.6 24.7 0.7 17 <2 26 0.4 6.8 
11d 0.7 17.6 0.9 12.8 3 23 0.3 1.3 
11e 1 25.9 1 20.3 3.4 27.7 0.1 5.3 
12a 1.1 3.4 1 5 2.7 11.3 0.3 0.6 
12b 1.5 11.3 1 12.6 2.5 14.6 0 0 
                  Table 3 
 
All the compounds showed a general preference for G-quadruplex DNA over duplex DNA but the 
best result was obtained with bis triazole compounds 10g and 10i, as it is evident from the graphs 
(Fig.10 and 11), in which the general trend showed a gradual increase of Tm increasing the 
concentration of the ligand. 
 
 Figure 10 
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Figure 11 
 
 
 
In particular the compound 10g showed Tm values equal to 4°C (1 M) and 22°C (5 M) for 
F21T, 4.2°C (1 M) and 18.5°C (5 M) for C-kit 2, 10.5°C (1 M) and 24.9°C (5 M) for Hsp90A 
and 0.3°C (1 M) and 2.5°C (5 M) for the duplex DNA. 
The naphthalene bis triazole compound 10i instead showed Tm values equal to 0.8°C (1 M) and 
26.5°C (5 M) for F21T, 1.3°C (1 M) and 29.9°C (5 M) for C-kit2, 6°C (1 M) and 28.2°C (5 
M) for Hsp90A and 0.1°C (1 M) and 5.8°C (1 M) for the duplex DNA. 
All compounds were screened against a panel of cancer and a non-cancer cell lines (referred to as 
normal fibroblast cell line, WI38). The cancer-derived cell lines studied were A549 (human lung 
adenocarcinoma), MCF7 (human breast adenocarcinoma), MiaPaCa (pancreatic cancer) and RCC4 
and 786-O (renal cancer cell lines). 
The experiment was based on a short cell exposure (up to 96 hours) to different concentrations of 
ligand in order to evaluate the IC50 value of each of them. 
The assay used is the sulforhodamine B calorimetric assay (SRB). It is based on the ability of the 
purple dye SRB 33 to interact with the basic amino acid residues of cellular proteins. This molecule 
is UV active and the quantification of the dye bound to the cells at 540 nm is an indirect measure of 
the amount of viable cells. 
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Cells were seeded in a 96-well plate and incubated for 24 hours, and then with different 
concentrations of ligand for 96 hours. The supernatant was removed and the remaining cells were 
fixed with trichloroacetic acid and stained with sulforhodamine B. 
The results obtained were adjusted by the negative control (cells without ligand and without SRB) 
and normalized by the positive control (cells only with SRB) to obtain the rate of viable cells. The 
IC50 values were calculated as the concentration responsible for a 50% decrease of cell viability. 
The results obtained are shown in the following table. (Tab.4) 
 
 A549 (µM) MCF7 (µM) MiaPaCa (µM) RCC4 (µM) 786-O (µM) WI38 (µM) 
10a 5.8 8.8 5.7 4 8.8 13.4 
10b 14.1 >25 16.3 >25 8.9 7.8 
10c >25 >25 >25 >25 >25 >25 
10d >25 >25 15.8 8.4 8.7 15.3 
10e 1.7 2.8 5.1 2.5 1.1/2.2 1.7 
10f 1.2 1.1 n/a 1.2 2.9/2.3 2.4 
10g 3.4 10.6 5.6 >25 10.2 7.2 
10h 4.1 >25 5 5 10.1 13.9 
10i 2 3.2 2.1 2/2.5 3.6/2.3 2.6 
11a 2.5 3.1 1.2 1 1.3 2.8 
11b 1.2 1 n/a 1.2 0.9 1.1 
11c 0.6 2.1 n/a 1.1 1.1 0.95 
11d 2.3 4.1 n/a 2.8 1.5 3.2 
11e 0.95 1.2 n/a 1.3 0.7 1 
12a 8.3 5 3.6 3 5 4.1 
12b 1.9 1.9 1 2.1 1.2 3.1 
 
      Table 4 
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The table showed that, with the exception of the derivative 10c that appeared to be completely 
inactive on all the tested cell lines, all the others were found to be cytotoxic for almost all the tumor 
cell lines, with the IC50 values in the micromolar range. In particular, the most active compounds 
were found to be the bis phenyl oxazoles 11c and 11e but they still do not show a particular 
selectivity for tumor cells over the normal cells.  
It was showed that in this series of compounds what could determinanted an anti-proliferative 
activity were the presence of a central phenyl ring ,two attached phenyl-oxazole rings that should be 
meta attached to the phenyl rings and the length of the linker and nature of the terminal group is of 
lesser importance. 
It is not possible to assume that the cellular mode of action involves G-quadruplex stabilization 
since only at high concentration there was a strong stabilization in the FRET assay; they could act at 
other quadruplex loci that are yet to be determined, or that the compounds act by non-quadruplex 
mechanism. [46] 
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EXPERIMENTAL DATA 
 
All chemicals, reagents and solvents were purchased from Sigma-Aldrich, Alfa Aesar, Lancaster 
Synthesis and Fluorochem (UK) and used without further purification. Solvents were supplied by 
VWR and Fisher scientific. Column chromatography was performed using BDH silica gel (BDH 
153325P). HPLC analysis was carried out with a Gilson apparatus combining a 322 PUMP and an 
Agilent 1100 SERIES detector, using a C18 5μ (100 x 4.6 mm) column (41622271 (W), YMC, 
Japan), at a flow of 1 mL/min. Preparative HPLC was carried out with a Gilson apparatus 
combining a 322 PUMP and a UV/VIS-155 detector with detection at 280 nm, using a C18 5μ (100 
x 20 mm) column (201022272) (W), YMC, Japan, at a flow of 20 mL/min. Water and methanol 
with 0.1 % formic acid were used as solvents for HPLC. For the purification of compounds X the 
following method was used: 100 % aqueous for 2 min after injection, gradually decreased to 50 % 
aqueous over 20 min to 5% aqueous after 30 min and then increased to 100% aqueous after 33 min. 
NMR spectra were recorded at 400 MHz (
1
H NMR) or 500 MHz (
13
C NMR) on a Bruker 
spectrometer in CDCl3 (with 0.05 % TMS, Cambridge Isotope Laboratories, USA). NMR spectra 
were analyzed with MestReC 4.5.6.0 with chemical shifts using TMS as a standard (δ = 0 ppm). 
NMR multiplicity abbreviations are s (singlet), bs (broad singlet), d (doublet), t (triplet), q (quartet), 
5q (quintet), and m (multiplet). Coupling constants J are reported as observed in Hertz (Hz). High 
Resolution Mass spectra (HRMS) were measured on a Micromass Q-TTOF Ultima Global tandem 
mass spectrometer run under electrospray ionisation (ESI), and processed using the MassLab 3.2 
software.  
 
CHEMISTRY 
 
Synthesis of naphthalene-2,7-diyl bis(trifluoromethanesulfonate)16 
A mixture of 2,7-dihydroxynaphtalene 15 (1.35 g, 8.43 mmol), 4-(Dimethylamino)pyridine (0.21 g, 
1.69 mmol), and 2,6-lutidine (2.2 ml, 18.53 mmol) was suspended in anhydrous dichloromethane 
(13.5 ml) and anhydrous tetrahydrofuran (13.5 ml) under argon atmosphere at 
-78°C. Triflic anhydride (5 g, 17.7 mmol) was added dropwise to this stirred mixture over 15 
minutes and the reaction was stirred at -78°C for 2 hours, then for 5 hours at 0°C. After that time, 
the reaction was carefully neutralized with saturated aqueous sodium hydrogen carbonate solution, 
extracted with dichloromethane, dried over MgSO4, filtered and the solvent removed in vacuo. The 
oil thus obtained was purified by column chromatography (dichloromethane) to give the compound 
16 as a white solid. Mp 60-62°C; Yield 61%;  
1
H NMR (ppm): 7.40 (2H, dd, J=2.4, 8.8 Hz, 2xAr-
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H), 7.73 (2H, d, J=2.4 Hz, 2xAr-H), 7.92 (2H, d, J= 9.2 Hz, 2xAr-H); 
13
C NMR (ppm): 118.8 
(CF3), 119.5 (2xCH), 121.1 (2xCH), 130.8 (2xCH), 131.3 (C), 133.6 (C), 148.3 (2xC). 
Spectroscopic data are in accordance with those reported in literature (Yao et al., 1998).  
 
Synthesis of (naphthalene-2,7-diyldiethyne-2,1-diyl)bis(trimethylsilane) 17 
A mixture of 16 (1 g, 2.36 mmol), copper iodide (0.046 g, 0.24 mmol), 
tetrakis(triphenylposphine)palladium(0) (0.28 g, 0.24 mmol), and Triphenylposphine (0.13 g, 0.48 
mmol) was dissolved in piperidine (15 ml) under argon atmosphere. Ethynyltrimethylsilane (1.98 
ml, 14 mmol) was added and the stirred mixture heated at reflux for 24 hours. The solvent was 
evaporated in vacuo and the resulting brown oil was purified by column chromatography (hexane: 
ethyl acetate 95:5).  Mp 127-129°C; Yield 90%;  
1
H NMR (ppm): 0.28 (18H, s, 6xCH3),  7.50 (2H, 
m, 2xAr-H), 7.71 (2H, d, J=8.4 Hz, 2xAr-H), 7.91 (2H, s, 2xAr-H); 
13
C NMR (ppm): -0.03 
(6xCH3Si), 95.2 (C), 105.0 (C), 121.2 (2xC), 127.7 (2xCH), 129.5 (2xCH), 131.6 (2xCH), 132.2 
(C),  132.3 (C). (Crisp et al., 1997). 
 
Synthesis of 2,7-diethynylnaphthalene 13 
Compound 17 (0.45 g, 1.39 mmol) was dissolved in tetrahydrofuran (80 ml) and 1M sodium 
hydroxide solution (80 ml) and the mixture stirred for 2 hours at room temperature. The reaction 
was extracted with dichloromethane, dried over MgSO4 and concentrated in vacuo. The pale yellow 
solid obtained did not require further purification.  Mp 124-126°C; Yield 100%;  
1
H NMR (ppm): 
3.17 (2H, s, 2xCH), 7.54 (2H, dd, J=1.6, 8.4 Hz, 2xAr-H), 7.78 (2H, d, J=8.9 Hz, 2xAr-H), 7.97 
(2H, s, 2xAr-H); 
13
C NMR (ppm): 78.0 (2xCH), 83.6 (2xC), 120.3 (2xC), 127.9 (2xCH), 129.6 
(2xCH), 132.0 (2xCH), 132.3 (C), 132.6 (C). (Crisp et al., 1997). 
 
Synthesis of 3-chloro-N,N-diethylpropan-1-amine 20a  
1-Iodo-3-chloropropane 22a (1.1 ml, 10.5 mmol) were added to 4.26 ml of diethylamine (40.5 
mmol). The reaction mixture was stirred at room temperature for 1 hour and after that the same 
amount of 1-iodo-3-chloropropane (1.1 ml, 10.5 mmol) was added. The reaction was stirred for 1 
hour at room temperature and after that 25 ml of sodium hydroxide 5 M were added. The reaction 
mixture was extracted with dichloromethane, dried on MgSO4 and concentrated in vacuo. The oil 
obtained did not required further purification. Yield 20%; 
1
H NMR: 1.01 (6H, t, J=7.1 Hz, 2xCH3), 
1.89 (2H, 5q, J=6.6 Hz, CH2), 2.47-2.56 (6H, m, 3xCH2), 3.58 (2H, t, J=6.6 Hz, CH2); 
13
C NMR 
(ppm): 5.5 (2xCH2), 27.9 (CH2), 41.1 (CH2), 44.5 (2xCH3), 51.5 (CH2). 
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Synthesis of 1-(3-chloropropyl)-4-methylpiperazine 20b 
1-Methylpiperazine 22b (1g, 10 mmol) was dissolved in acetone (20 ml), 5 ml of 25% sodium 
hydroxide solution were added and after that 1-bromo-3-chloropropane (2ml, 20 mmol) was added. 
The mixture stirred for 24 hours at room temperature. The organic layer was evaporated in vacuo 
and the aqueous layer was extracted with ethyl acetate, dried over MgSO4 and concentrated. The oil 
obtained did not required further purification. Quantitative yield; 
1
H NMR: 1.91 (2H, 5q, J=6.6 Hz, 
CH2), 2.25 (3H, s, CH3), 2.34-2.47 (10H, m, 5xCH2), 3.56 (2H, t, J=6.6 Hz, CH2); 
13
C NMR (ppm): 
24.6 (CH2), 38.0 (CH2), 40.8 (CH2), 48.0 (2xCH2), 49.9 (2xCH2), 50.2 (CH3). 
 
Synthesis of 1-(3-chloropropyl)pyrrolidine 20c 
Pyrrolidine 22c (1.16 ml, 0.014 mol), acetone (10 ml), 5M sodium hydroxide solution (8.4 ml, 
0.042 mol) and 1-bromo-3-chloropropane (2.8 ml, 0.028 mol) were stirred together under nitrogen 
atmosphere for 24 hours. The organic layer was separated, dried over MgSO4 , concentrated in 
vacuo and purified via coloumn chromatography (dichloromethane:methanol 99:1). Yield 90%; 
1
H 
NMR (ppm):  1.75-1.79 (4H, m, 2xCH2), 1.97 (2H, 5q, J=6.7 Hz, CH2), 2.48-2.51 (4H, m, 2xCH2), 
2.58 (2H, t, J=7.4 Hz, CH2), 3.60 (2H, t, J=6.7 Hz, CH2); 
13
C NMR (ppm): 23.5 (2xCH2), 32.1 
(CH2), 43.4 (CH2), 53.6 (CH2), 54.2 (2xCH2). 
 
Synthesis of amino compounds 18a-f 
General procedure: 
To a solution of the chloro-compound 20a-e (1 eq) in acetonitrile in an oven dried microwave vial, 
potassium iodide (0.2 eq) and benzendiamine 19a-b (3 eq) were added. 
The vial was heated under microwave irradiation for 10 minutes at 110°C. The cooled reaction 
mixture was diluted with ethyl acetate, washed with aqueous saturated sodium hydrogen carbonate, 
dried over MgSO4, concentrated in vacuo and purified via coloumn chromatography. 
 
N-[2-(diethylamino)ethyl]benzene-1,3-diamine 18a: The crude was purified by chromatography 
(dichloromethane:methanol 8:2). Yield 67%; 
1
H NMR (ppm): 1.06 (6H, t, J=7.0 Hz 2xCH3), 2.65-
2.70 (6H, m, 3xCH2), 3.09 (2H, t, J=6.5 Hz, CH2), 4.76 (2H, bs, NH2), 5.85-5.89 (3H, m, 3xAr-H), 
6.77 (1H, t, J=8.2 Hz, Ar-H); 
13
C NMR (ppm): 11.3 (2xCH2), 46.6 (2xCH2), 51.3 (CH2), 1 CH2 is 
hidden underneath DMSO peak, 98.0 (CH), 101.3 (CH), 103.2 (C), 129.2 (CH), 149.2 (CH), 149.5 
(C). 
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N-[3-(diethylamino)propyl]benzene-1,3-diamine 18b: The crude was purified by chromatography 
(dichloromethane:methanol 8:2). Yield 53%; 
1
H NMR: 1.24 (6H, t, J=7.0 Hz, 2xCH3), 1.89-1.93 
(2H, m, CH2), 3.06-3.12 (8H, m, 4xCH2), 4.78 (2H, bs, NH2), 5.86-5.89 (3H, m, 3x Ar-H), 6.78 
(1H, t, J=7.8 Hz, Ar-H); 
13
C NMR (ppm): 10.9 (2xCH2), 25.7 (CH2), 42.8 (CH2), 46.7 (2xCH3), 
51.3 (CH2), 99.4 (CH), 104.0 (CH), 104.7 (CH), 130.0 (CH), 147.5 (C), 149.7 (C). 
 
N-[3-(4-methylpiperazin-1-yl)propyl]benzene-1,4-diamine 18c: The crude was purified by 
chromatography (dichloromethane:methanol 9:1). Yield 25%; 
1
H NMR (ppm): 1.79 (2H, 5q, J=6.4 
Hz, CH2), 2.32 (3H, s, CH3), 2.49-2.52 (10H, m, 5xCH2), 3.16 (2H, t, J=6.4 Hz, CH2), 4.35 (2H, bs, 
NH2), 6.56-6.58 (2H, m, 2xAr-H), 6.83-6.86 (2H, m, 2xAr-H); 
13
C NMR (ppm): 26.0 (CH2), 44.4 
(CH2), 45.8 (CH3), 52.9 (2xCH2), 55.0 (2xCH2), 57.1 (CH2), 114.5 (2xCH), 117.0 (2xCH2), 137.6 
(C), 141.9 (C). 
 
N-[3-(4-methylpiperazin-1-yl)propyl]benzene-1,3-diamine 18d: The crude was purified by 
chromatography (dichloromethane:methanol 8:2). Yield 40%; 
1
H NMR (ppm): 1.64 (2H, 5q, J=6.7 
Hz, CH2), 2.21 (3H, s, CH3), 2.39 (2H, t, J=5.5 Hz, CH2), 2.51 (8H, bs, 4xCH2), 2.91 (2H, t, J=6.5 
Hz, CH2), 5.54-5.46 (2H, m, 2xAr-H), 5.86-5.89 (1H, m, Ar-H), 6.74-6.76 (1H, m, Ar-H); 
13
C 
NMR (ppm): 25.9 (CH2), 43.2 (CH2), 45.9 (CH2), 53.0 (2xCH2), 55.1 (2xCH2), 57.0 (CH3), 99.4 
(CH), 104.1 (CH), 104.7 (CH), 130.0 (CH), 147.5 (C), 149.9 (C). 
 
N-[3-(pyrrolidin-1-yl)propyl]benzene-1,3-diamine 18e: The crude was purified by 
cromatography (dichloromethane:methanol 95:5). Yield 35%; 
1
H NMR (ppm): 1.82-1.88 (6H, m, 
3xCH2), 2.59-2.65 (6H, m, 3xCH2), 3.17 (2H, t, J=6.6 Hz, CH2), 3.53 (2H, bs, NH2), 5.95 (1H, t, 
J=2.14 Hz, Ar-H), 6.03-6.06 (2H, m, 2xAr-H), 6.94 (1H, t, J=7.9 Hz, Ar-H); 
13
C NMR (ppm): 23.5 
(2xCH2), 28.0 (CH2), 42.9 (CH2), 54.2 (2xCH2), 54.7 (CH2), 99.4 (CH), 104.0 (CH), 104.6 (CH), 
130.0 (CH), 147.5 (C), 149.8 (C). 
 
N-[2-(pyrrolidin-1-yl)ethyl]benzene-1,3-diamine 18f: The crude was purified by chromatography 
(dichloromethane:methanol 9:1). Yield 63%; 
1
H NMR (ppm): 2.00 (4H, 5q, J=3.9 Hz, 2xCH2), 
3.05-3.11 (6H, m, 3xCH2), 3.46 (2H, t, J=5.9 Hz, CH2), 6.06-6.08 (3H, m, 3xAr-H), 6.94 (1H, t, 
J=8.4 Hz, Ar-H); 
13
C NMR (ppm): 23.3 (2xCH2), 50.8 (CH2), 54.2 (2xCH2), 54.7 (CH2), 99.8 (CH), 
103.5 (CH), 105.3 (CH), 130.2 (CH), 147.7 (C), 148.4 (C). 
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Synthesis of amino compounds 18g-i 
General procedure:  
3-Aminophenol 21 (1 eq) was dissolved in dimethylformamide and cooled in an ice bath. Sodium 
hydride (1.1 eq) was added and the reaction was allowed to warm to room temperature and stirred 
for 45 mins. Then the chloro-compound 20b-d (1.1 eq) was added and the mixture stirred at room 
temperature for 24 hours. Ice and water were added and the mixture was extracted with ethyl 
acetate, dried over MgSO4, concentrated in vacuo and purified via column chromatography.   
 
3-[3-(4-Methylpiperazin-1-yl)propoxy]aniline 18g: The crude was purified by chromatography 
(dichloromethane:methanol 9:1). Yield 43%; 
1
H NMR:  1.81 (2H, 5q, J=6.6 Hz, CH2), 2.20 (3H, s, 
CH3), 2.39-2.42 (10H, m, 5xCH2), 3.87 (2H, t, J=6.6 Hz, CH2), 4.99 (2H, bs, NH2), 6.1 (1H, dd, 
J=2.1, 7.5 Hz, Ar-H), 6.11-6.13 (2H, m, 2xAr-H), 6.87 (1H, t, J=8.4 Hz, Ar-H); 
13
C NMR (ppm): 
26.2 (CH2), 45.3 (CH3), 52.3 (2xCH2), 54.3 (CH2), 54.4 (2xCH2), 65.2 (CH2), 99.9 (CH), 102.0 
(CH), 106.7 (CH), 129.4 (CH), 149.6 (C), 159.6 (C). 
 
3-[2-(Diethylamino)ethoxy]aniline 18h: The crude was purified by chromatography 
(dichloromethane:methanol 9:1). Yield 50%; 
1
H NMR:  1.08 (6H, t, J=7.2 Hz, 2xCH3), 2.67 (4H, q, 
J=7.2 Hz, 2xCH2), 2.76 (2H, t, J=6.0 Hz, CH2), 3.20 (2H, t, J=6.0 Hz, CH2), 4.43 (2H, bs, NH2), 
6.16-6.20 (3H, m, 3xAr-H), 7.00 (1H, t, J=7.9 Hz, Ar-H); 
13
C NMR (ppm): 10.9 (2xCH2), 40.8 
(CH2), 46.8 (2xCH3), 51.5 (CH2), 100.1 (CH), 104.8 (CH), 105.8 (CH), 130.2 (CH), 149.7 (C), 
157.2 (C). 
 
3-[3-(Pyrrolidin-1-yl)propoxy]aniline 18i: The crude was purified by chromatography 
(dichloromethane:methanol 9:1). Yield 40%; 
1
H NMR:  1.83 (4H, bs, 2xCH2), 2.03 (2H, 5q, J=6.4 
Hz, CH2), 2.62 (4H, bs, 2xCH2), 2.68 (2H, t, J=7.5 Hz, CH2), 3.65 (2H, bs, NH2 ), 3.97 (2H, t, J=6.4 
Hz, CH2), 6.23 (1H, t, J=2.2 Hz, Ar-H), 6.26-6.31 (2H, m, 2xAr-H), 7.03 (1H, t, J=8.1 Hz, Ar-H); 
13
C NMR (ppm): 23.4 (2xCH2), 28.5 (CH2), 53.3 (CH2), 54.2 (2xCH2), 66.0 (CH2), 101.6 (CH), 
104.6 (CH), 107.9 (CH), 130.1 (CH), 147.8 (C), 160.1 (C). 
 
Synthesis of azido compounds 14a-i 
General procedure:  
The amino compound 18a-i (1 eq) was dissolved in tetrahydrofuran and cooled in an ice bath. The 
mixture was treated sequentially with concentrated aqueous hydrochloric acid (5.5 eq) and then 
with tert-butyl nitrite (2.5eq). The reaction was stirred in an ice bath for 1.5 hours and after that 
107 
 
sodium azide (3 eq) was added, followed by addition of water until the reaction ceased to 
effervesse. The reaction was allowed to warm to room temperature and stirred for 24 hours. The 
mixture was neutralized with saturated aqueous sodium hydrogen carbonate  solution and 
tertrahydrofuran was evaporated in vacuo. The aqueous solution was extracted with ethyl acetate, 
dried on MgSO4, concentrated and purified by column chromatography. 
 
N'-(3-azidophenyl)-N,N-diethylethane-1,2-diamine 14a: The crude was purified by 
chromatography (dichloromethane:methanol 98:2). Yield 54%; 
1
H NMR (ppm): 2.52 (6H, t, J=7.1 
Hz, 2xCH3), 2.50-2.58 (6H, m, 3xCH2), 4.06 (2H, t, J=6.9 Hz, CH2), 7.01-7.03 (1H, m, Ar-H), 7.36-
7.46 (3H, m, 3xAr-H); 
13
C NMR (ppm): 11.9 (2xCH3), 43.7 (CH2), 47.5 (2xCH2), 48.9 (CH2), 
110.7 (CH), 115.9 (CH), 117.5 (CH), 130.6 (CH), 141.5 (C), 143.5 (C). 
 
N'-(3-azidophenyl)-N,N-diethylpropane-1,3-diamine 14b: The crude was purified by 
chromatography (dichloromethane:methanol 95:5). Yield 12%; 
1
H NMR (ppm): 1.06 (6H, t, J=7.2 
Hz , 2xCH3), 1.77 (2H, 5q, J=7.1 Hz, CH2 ), 2.52 (2H, t, J=7.1 Hz, CH2 ), 2.61 (4H, q, J=7.2 Hz , 
2xCH2 ), 4.06 (2H, t, J=7.1 Hz, CH2 ), 7.02 (1H, ddd, J=0.86, 2.1, 8.0 Hz, Ar-H), 7.29 (1H, t, J=2.1 
Hz, Ar-H), 7.33 (1H, ddd, J=0.86, 2.1, 8.0 Hz, Ar-H), 7.44 (1H, t, J=8.0 Hz, Ar-H); 
13
C NMR 
(ppm): 10.9 (2xCH2), 23.8 (CH2), 41.9 (CH2), 46.7 (2xCH3), 50.0 (CH2), 110.0 (CH), 115.3 (CH), 
117.5 (CH), 130.8 (CH), 141.7 (C), 142.9 (C). 
 
4-Azido-N-[3-(4-methylpiperazin-1-yl)propyl]aniline 14c: The crude was purified by 
chromatography (dichloromethane:methanol 95:5). Yield 64%; 
1
H NMR (ppm): 1.72 (2H, 5q, J=7.0 
Hz, CH2), 2.30-2.35 (5H, m, CH3,CH2 ), 2.48 (8H, bs, 4xCH2 ), 4.06 (2H, t, J=7.0 Hz, CH2 ), 7.10-
7.12 (2H, m, 2xAr-H), 7.56-7.59 (2H, m, 2xAr-H); 
13
C NMR (ppm): 23.6 (CH2), 42.3 (CH2), 45.8 
(CH2), 52.6 (CH3), 54.9 (2xCH2), 55.0 (2xCH2), 120.0 (2xCH), 120.9 (2xCH), 138.7 (C), 139.1 (C).  
 
3-Azido-N-[3-(4-methylpiperazin-1-yl)propyl]aniline 14d: The crude was purified by 
chromatography (dichloromethane:methanol 9:1). Yield 32%; 
1
H NMR (ppm): 1.70-1.74 (4H, m, 
2xCH2), 2.29-2.33 (5H, m, CH2, CH3), 2.45 (8H, bs, 4xCH2), 7.02-7.04 (1H, m, Ar-H), 7.29 (1H, t, 
J=2.1 Hz, Ar-H), 7.35-7.38 (1H, m, Ar-H), 7.44 (1H, t, J=8.1 Hz, Ar-H); 
13
C NMR (ppm): 23.7 
(CH2), 41.9 (CH2), 45.9 (CH2), 52.8 (CH3), 55.0 (4xCH2), 109.9 (CH), 115.2 (CH), 117.3 (CH), 
130.6 (CH), 141.6 (C), 143.2 (C). 
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3-Azido-N-[3-(pyrrolidin-1-yl)propyl]aniline 14e: The crude was purified by chromatography 
(dichloromethane:methanol 98:2). Yield 55%; 
1
H NMR (ppm): 1.76-1.81 (6H, m, 3xCH2), 2.48 
(2H, t, J=7.2 Hz, CH2), 2.55 (4H, bs, 2xCH2), 4.07 (2H, t, J=7.2 Hz, CH2), 7.00-7.02 (1H, m, Ar-H), 
7.26 (1H, t, J=2.1 Hz, Ar-H), 7.32-7.34 (1H, m, Ar-H), 7.42 (1H, t, J=8.1 Hz, Ar-H); 
13
C NMR 
(ppm): 23.4 (2xCH2), 25.5 (CH2), 41.9 (CH2), 53.2 (CH2), 54.0 (2xCH2), 110.0 (CH), 115.2 (CH), 
117.4 (CH), 130.7 (CH), 141.6 (C), 143.0 (C). 
 
3-Azido-N-[2-(pyrrolidin-1-yl)ethyl]aniline 14f: The crude was purified by chromatography 
(dichloromethane:methanol 95:5). Yield 54%; 
1
H NMR (ppm): 1.80 (4H, 5q, J=3.3 Hz, 2xCH2), 
2.55 (4H, bs, 2xCH2), 2.74 (2H, t, J=6.2 Hz, CH2), 3.18 (2H, q, J=5.5 Hz, CH2), 4.46 (1H, bs, NH), 
6.23 (1H, t, J=2.2 Hz, Ar-H), 6.38 (1H, ddd, J=0.8, 2.1, 8.0 Hz, Ar-H), 6.41 (1H, ddd, J=0.7, 2.2, 
8.2 Hz, Ar-H), 7.12 (1H, t, J=8.0 Hz, Ar-H); 
13
C NMR (ppm): 22.5 (2x CH2), 41.1 (CH2), 52.9 
(2xCH2), 53.6 (CH2), 101.8 (CH), 106.5 (CH), 108.8 (CH), 129.3 (CH), 139.9 (C), 148.9 (C). 
 
1-[3-(3-Azidophenoxy)propyl]-4-methylpiperazine 14g: The crude was purified by 
chromatography (dichloromethane:methanol 9:1). Yield 63%; 
1
H NMR (ppm): 1.95 (2H, 5q, J=6.5 
Hz, CH2), 2.31 (3H, s, CH3), 2.51-2.54 (10H, m, 5xCH2), 4.00 (2H, t, J=6.5 Hz, CH2), 6.54 (1H, t, 
J=2.2 Hz, Ar-H), 6.62 (1H, ddd, J=0.8, 2.2, 8.0 Hz, Ar-H), 6.67 (1H, ddd, J=0.8, 2.2, 8.0 Hz, Ar-H), 
7.23 (1H, t, J=8.0 Hz, Ar-H); 
13
C NMR (ppm): 26.7 (CH2), 45.9 (CH2), 53.1 (2xCH2), 55.0 (CH3), 
55.1 (2xCH2), 66.4 (CH2), 105.5 (CH), 111.2 (2xCH), 130.4 (CH), 141.2 (C), 160.2 (C). 
 
2-(3-Azidophenoxy)-N,N-diethylethanamine 14h: The crude was purified by chromatography 
(dichloromethane:methanol 95:5). Yield 54%; 
1
H NMR (ppm): 1.10 (6H, t, J=7.1 Hz, 2xCH3), 2.67 
(4H, q, J=7.1 Hz, 2xCH2), 2.89 (2H, t, J=6.3 Hz, CH2), 4.06 (2H, t, J=6.3 Hz, CH2), 6.59-6.60 (1H, 
m, Ar-H), 6.66 (1H, dd, J=1.6, 7.9 Hz, Ar-H), 6.71 (1H, dd, J=1.9, 8.3 Hz, Ar-H), 7.24-7.29 (1H, m, 
Ar-H); 
13
C NMR (ppm): 11.9 (2xCH2), 47.9 (2xCH3), 51.7 (CH2), 66.8 (CH2), 105.6 (CH), 111.2 
(CH), 111.3 (CH), 130.4 (CH), 141.2 (C), 160.1 (C). 
 
1-[3-(3-Azidophenoxy)propyl]pyrrolidine 14i: The crude was purified by chromatography 
(dichloromethane:methanol 95:5). Yield 53%; 
1
H NMR (ppm): 1.78-1.80 (4H, m, 2xCH2), 2.00 
(2H, 5q, J=6.5 Hz, CH2), 2.54 (4H, bs, 2xCH2), 2.63 (2H, t, J=7.4 Hz, CH2), 4.03 (2H, t, J=6.5 Hz, 
CH2), 6.56 (1H, t, J=2.2 Hz, Ar-H), 6.63 (1H, dd, J=1.9, 7.9 Hz, Ar-H), 6.69 (1H, dd, J=2.2, 8.2 Hz, 
Ar-H), 7.23 (1H, t, J=8.2 Hz, Ar-H); 
13
C NMR (ppm): 23.5 (2xCH2), 28.8 (CH2), 53.0 (CH2), 54.2 
(2xCH2), 66.6 (CH2), 105.6 (CH), 111.2 (CH), 111.3 (CH), 130.3 (CH), 141.3 (C), 160.3 (C). 
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Synthesis of naphthalene bis triazole compounds 10a-i 
General procedure:  
Compound 13 (1 eq) was dissolved in the appropriate volume of solvent (water:tert-butanol 1:1), 
followed by the addition of required azide 14a-i (3 eq) and the catalytic mixture of copper sulfate 
pentahydrate (0.05 eq), sodium ascorbate (0.5 eq) and bathophenanthrolinedisulfonic acid disodium 
salt hydrate (click catalyst, 0.1 eq). The reaction was performed in excess of the required amine (6 
eq), to avoid elimination. The mixture was heated under microwave irradiation for 15 minutes at 
120°C. after that the reaction was evaporated in vacuo and the crude obtained was purified by 
HPLC. 
 
N1,N1'-[naphthalene-2,7-diylbis(1H-1,2,3-triazole-4,1-diylbenzene-3,1-diyl)]bis(N2,N2-
diethylethane-1,2-diamine) 10a: Diethylamine was used to avoid elimination. Yield 17%; 
1
H 
NMR: 1.03 (6H, t, J=7.1 Hz, 2xCH3), 1.16 (6H, t, J=7.2 Hz, 2xCH3), 2.56-2.67 (6H, m, 3xCH2), 
2.80 (4H, q, J=7.2 Hz, 2xCH2), 2.64 (2H, t, J=5.6 Hz, CH2), 3.37 (2H, t, J=5.6 Hz, CH2), 4.19 (2H, 
t, J=6.9 Hz, CH2), 6.71 (1H, dd, J=1.6, 8.2 Hz, Ar-H), 7.05 (1H, dd, J=1.1, 7.9 Hz, Ar-H), 7.1 (1H, 
bs, Ar-H), 7.29 (2H, m, 2xAr-H), 7.64 (1H, t, J=8.1 Hz, Ar-H), 7.72-7.74 (1H, m, Ar-H), 7.83-
7.85(1H, m, Ar-H), 7.90 (2H, dd, J=3.3, 8.5 Hz, 2xAr-H), 8.00-8.02 (2H, m, 2xAr-H),  8.24 (1H, 
bs, Ar-H), 8.33 (1H, s, Ar-H), 8.43 (1H, d, J=6.1 Hz, Ar-H), 8.48 (1H, s, Ar-H); 
13
C NMR (ppm): 
10.5 (CH2), 11.7 (2xCH2), 40.3 (CH2), 43.3 (CH2), 46.8 (2xCH3), 47.3 (2xCH3), 48.8 (CH2), 51.2 
(2xCH2), 104.1 (CH), 108.8 (CH), 111.4 (CH), 113.5 (CH), 118.1 (CH), 118.3 (CH), 118.5 (CH), 
119.2 (CH), 124.1 (CH), 124.4 (CH), 124.8 (CH), 125.0 (CH), 128.0 (C), 128.5 (C), 128.6 (CH), 
128.7 (CH), 130.4 (CH), 130.8 (CH), 133.0 (C), 133.6 (C), 137.9 (C), 138.1 (C), 143.3 (C), 147.9 
(C), 148.5 (C), 149.2 (C). 
 
N1,N1'-[naphthalene-2,7-diylbis(1H-1,2,3-triazole-4,1-diylbenzene-3,1-diyl)]bis(N3,N3-
diethylpropane-1,3-diamine) 10b: Diethylamine was used to avoid elimination . Yield 44%; 
1
H 
NMR:  1.16 (12H, t, J=7.2 Hz, 4xCH3), 1.97 (4H, 5q, J=7.4 Hz, 2xCH2), 2.75-2.84 (12H, m, 
6xCH2), 4.17 (4H, t, J=7.8 Hz, 2xCH2), 7.68 (2H, t, J=8.1 Hz, 2xAr-H), 7.76 (2H, dd, J=0.8, 8.2 Hz, 
2xAr-H), 7.95-7.98 (4H, m, 4xAr-H), 8.08 (2H, dd, J=1.1, 8.5 Hz, 2xAr-H), 8.13-8.14 (2H, m, 
2xAr-H), 8.52 (2H, s, 2xAr-H), 8.84 (2H, s, 2xAr-H); 
13
C NMR (ppm): 9.6 (4xCH2), 22.8 (2xCH2), 
41.8 (2xCH2), 45.9 (4xCH3), 49.3 (2xCH2), 110.3 (2xCH), 118.5 (2xCH), 118.6 (2xCH), 118.8 
(2xCH), 124.4 (2xC), 125.0 (2xCH), 128.2 (2xC), 128.7 (2xCH), 131.1 (2xCH), 133.2 (C), 133.7 
(C), 138.2 (2xCH), 142.7 (2xC), 148.6 (2xC). 
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4,4'-[Naphthalene-2,7-diylbis(1H-1,2,3-triazole-4,1-diyl)]bis{N-[3-(4-methylpiperazin-1-
yl)propyl]aniline} 10c: N-methylpiperazine was used to avoid elimination. Yield 12%; 
1
H NMR:  
1.82-1.88 (8H, m, 4xCH2), 2.34 (6H, s, 2xCH3), 2.53-2.56 (16H, m, 8xCH2), 3.26 (4H, t, J=6.2 Hz, 
2xCH2), 6.69-6.71 (4H, m, 4xAr-H), 7.57-7.59 (4H, m, 4xAr-H), 7.93 (2H, d, J=8.5 Hz, 2xAr-H), 
8.03 (2H, dd, J=1.4, 8.5 Hz, 2xAr-H), 8.19 (2H, s, 2xAr-H), 8.44 (2H, s, 2xAr-H); 
13
C NMR (ppm): 
25.2 (2xCH2), 43.7 (2xCH2), 46.1 (2xCH3), 53.2 (4xCH2), 55.3 (4xCH2), 57.4 (2xCH2), 112.6 
(4xCH), 118.2 (2xCH), 122.4 (4xCH), 124.2 (2xC), 124.7 (2xCH), 127.2 (2xC), 128.5 (2xCH), 
128.6 (2xCH), 132.9 (C), 133.8 (C), 147.8 (2xC), 149.3 (2xC). 
 
3,3'-[Naphthalene-2,7-diylbis(1H-1,2,3-triazole-4,1-diyl)]bis{N-[3-(4-methylpiperazin-1-
yl)propyl]aniline}10d: N-methylpiperazine was used to avoid elimination . Yield 60%; 
1
H NMR: 
1.81 (4H, 5q, J=6.6 Hz, 2xCH2), 2.45 (4H, t, J=6.6 Hz, 2xCH2), 2.58 (6H, s, 2xCH3), 2.67 (8H, bs, 
4xCH2), 2.94 (8H, bs, 4xCH2), 4.16 (4H, t, J=7.3 Hz, 2xCH2), 7.64-7.68 (2H, m, 2xAr-H), 7.75-
7.77 (4H, m, 4xAr-H), 7.93-8.03 (4H, m, 4xAr-H), 8.19 (2H, t, J=1.8 Hz, 2xAr-H), 8.46-8.48 (4H, 
m, 4xAr-H); 
13
C NMR (ppm): 23.3 (2xCH3), 41.7 (2xCH2), 43.8 (2xCH2), 50.7 (4xCH2), 53.3 
(4xCH2), 54.4 (2xCH2), 110.7 (2xCH2), 118.1 (2xCH), 118.2 (2xCH), 118.6 (2xC), 124.3 (2xC), 
125.0 (2xCH), 128.1 (2xC), 128.8 (2xC), 131.0 (2xCH), 133.3 (C), 133.6 (C), 138.0 (2xCH), 143.2 
(2xCH), 148.6 (2xCH). 
 
3,3'-[Naphthalene-2,7-diylbis(1H-1,2,3-triazole-4,1-diyl)]bis{N-[3-(pyrrolidin-1-
yl)propyl]aniline} 10e: Pyrrolidine was used to avoid elimination .Yield 18%; 
1
H NMR: 1.94 (8H, 
bs, 4xCH2), 2.02 (4H, quint, J=7.2 Hz, 2xCH2), 2.80 (4H, t, J=7.4 Hz, 2xCH2), 2.87 (8H, bs, 
4xCH2), 4.20 (4H, t, J=7.4 Hz, 2xCH2), 7.67 (2H, t, J=8.1 Hz, 2xAr-H), 7.75-7.77 (2H, m, 2xAr-H), 
7.95 (4H, d, J=8.3 Hz, 4xAr-H), 8.08 (2H, d, J=8.3 Hz, 2xAr-H), 8.14 (2H, s, 2xAr-H), 8.52 (2H, s, 
2xAr-H), 8.82 (2H, s, 2xAr-H); 
13
C NMR (ppm): 23.4 (4xCH2), 24.5 (2xCH2), 41.7 (2xCH2), 52.7 
(2xCH2), 53.6 (4xCH2), 110.5 (2xCH), 118.5 (2xCH), 118.6 (2xCH), 118.8 (2xCH), 124.3 (2xCH), 
125.0 (2xCH), 128.2 (2xC), 128.7 (2xCH), 131.1 (2xCH), 133.2 (C), 133.7 (C), 138.2  (2xC), 142.8 
(2xC), 148.6 (2xC). 
 
3,3'-[Naphthalene-2,7-diylbis(1H-1,2,3-triazole-4,1-diyl)]bis{N-[2-(pyrrolidin-1-
yl)ethyl]aniline} 10f: Pyrrolidine was used to avoid elimination .Yield 13%; 
1
H NMR (ppm): 1.92 
(8H, bs, 4xCH2), 3.00 (8H, bs, 4xCH2), 3.08 (4H, t, J=5.3 Hz, 2xCH2), 3.45 (4H, t, J=5.3 Hz, 2x 
CH2), 6.63 (2H, d, J=8.1 Hz, 2xAr-H), 6.97-7.02 (4H, m, 4xAr-H), 7.21 (2H, t, J=8.1 Hz, 2xAr-H), 
7.82 (2H, d, J=8.5 Hz, 2xAr-H), 7.93 (2H, dd, J=1.1, 8.5 Hz, 2xAr-H), 8.30 (2H, s, 2xAr-H), 8.34 
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(2H, s, 2xAr-H); 
13
C NMR (ppm): 23.3 (4xCH2), 40.4 (2xCH2), 53.8 (4xCH2), 54.0 (2xCH2), 103.6 
(2xCH), 108.7 (2xCH), 113.6 (2xC), 118.4 (2xCH), 124.2 (2xC), 124.8 (2xCH), 128.4 (2xCH), 
128.5 (2xCH), 130.4 (2xCH), 133.0 (C), 133.7 (C), 138.2 (2xC), 148.0 (2xCH), 148.9 (2xC). 
 
1,1'-[Naphthalene-2,7-diylbis(1H-1,2,3-triazole-4,1-diylbenzene-3,1-diyloxypropane-3,1-
diyl)]bis(4-methylpiperazine) 10g: N-methylpiperazine was used to avoid elimination. Yield 10%; 
1
H NMR: 2.03 (4H, 5q, J=6.4 Hz, 2xCH2), 2.34 (6H, s, 2xCH3), 2.57-2.60 (20H, m, 10xCH2), 4.12 
(4H, t, J=6.4 Hz, 2xCH2), 6.99 (2H, dd, J=2.4, 8.1 Hz, 2xAr-H), 7.26-7.36 (2H, m, 2xAr-H), 7.42-
7.46 (4H, m, 4xAr-H), 7.94 (2H, d, J=8.5 Hz, 2xAr-H), 8.02 (2H, dd, J=1.5, 8.5 Hz, 2xAr-H), 8.31 
(2H, s, 2xAr-H), 8.46 (2H, s, 2xAr-H); 
13
C NMR (ppm): 26.6 (2xCH2), 45.6 (2xCH2), 52.8 
(2xCH3), 54.7 (4xCH2), 54.8 (4xCH2), 66.7 (2xCH2), 107.0 (2xCH), 112.4 (2xCH), 115.2 (2xCH), 
118.1 (2xCH), 124.3 (2xC), 124.9 (2xCH), 128.3 (2xC), 128.6 (2xC), 130.6 (2xCH), 133.1 (C), 
133.7 (C), 138.1 (2xC), 148.2 (2xCH), 160.1 (2xCH). 
 
2,2'-[Naphthalene-2,7-diylbis(1H-1,2,3-triazole-4,1-diylbenzene-3,1-diyloxy)]bis(N,N-
diethylethanamine) 10h: Diethylamine was used to avoid elimination . Yield 24%; 
1
H NMR 
(ppm): 1.12 (12H, t, J=7.1 Hz, 4xCH3), 2.71 (8H, q, J=7.1 Hz, 4xCH2), 2.96 (4H, t, J=6.0 Hz, 
2xCH2),  4.17 (4H, t, J=6.0 Hz, 2xCH2), 7.01 (2H, dd, J=2.1, 7.9 Hz, 2xAr-H), 7.36-7.38 (2H, m, 
2xAr-H), 7.42-7.46 (4H, m, 4xAr-H), 7.94 (2H, t, J=8.4 Hz, 2xAr-H), 8.03 (2H, dd, J=1.2, 8.4 Hz, 
2xAr-H), 8.32 (2H, s, 2xAr-H), 8.46 (2H, s, 2xAr-H); 
13
C NMR (ppm): 11.7 (4xCH2), 47.8 
(4xCH3), 51.5 (2xCH2), 66.9 (2xCH2), 107.0 (2xCH2), 112.5 (2xCH), 115.1 (2xCH), 118.1 (2xCH), 
124.3 (2xCH), 124.9 (2xCH), 128.3 (2xC), 128.6 (2xCH), 130.6 (2xCH), 133.2 (C), 133.7 (C), 
138.0 (2xC), 148.2 (2xC), 160.0 (2xC).  
 
4,4'-Naphthalene-2,7-diylbis(1-{3-[3-(pyrrolidin-1-yl)propoxy]phenyl}-1H-1,2,3-triazole) 10i:  
Pyrrolidine was used to avoid elimination . Yield 40%; 
1
H NMR:  1.91 (8H, bs, 4xCH2), 2.16 (4H, 
5q, J=6.2 Hz, 2xCH2), 2.81 (8H, bs, 4xCH2), 2.87 (4H, t, J=7.5 Hz, 2xCH2), 4.15 (4H, t, J=6.2 Hz, 
2xCH2), 6.97-6.99 (2H, m, 2xAr-H),  7.37 (2H, d, J=7.8 Hz, 2xAr-H),  7.43-7.46 (4H, m, 4xAr-H), 
7.94 (2H, d, J=8.5 Hz, 2xAr-H), 8.03 (2H, d, J=8.5 Hz, 2xAr-H), 8.34 (2H, s, 2xAr-H),  8.46 (2H, s, 
2xAr-H); 
13
C NMR (ppm): 23.5 (4xCH2), 27.7 (2xCH2), 52.8 (2xCH2), 53.8 (4xCH2), 66.4 
(2xCH2), 107.1 (2xCH), 112.5 (2xCH), 115.0 (2xCH), 118.1 (2xCH), 124.3 (2xCH), 124.9 (2xCH), 
128.3 (2xC), 128.6 (2xCH), 130.6 (2xCH), 133.1 (C), 133.7 (C), 138.1 (2xC), 148.2 (2xC), 159.9 
(2xC). 
 
112 
 
Synthesis of 5,5'-benzene-1,3-diylbis(1,3-oxazole) 24 
Compound 24 was prepared according to literature procedure. [41] Analytical data and 
1
H and 
13
C 
NMR spectra matched literature values. 
 
Synthesis of 5,5'-naphthalene-2,7-diylbis(1,3-oxazole) 27 
An oven dried microwave vial was charged with palladium acetate (0.1 eq), potassium carbonate (3 
eq), ligand (2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2’,4’,6’-triisoproppyl-1,1’-biphenyl) (0.2 
eq), compound 26 (1 eq) and compound 25 (2.2 eq). The microwave vial was capped, evacuated 
and backfilled with argon and then pivalic acid (0.4 eq) and dimethylacetamide were added. The 
vial was heated at 110°C for 72 hours. After cooling to room temperature, the reaction mixture was 
concentrated and purified via HPLC. 
Yield 50%; 
1
H NMR: 6.81-6.88 (2H, m, 2xAr-H), 7.38 (2H, t, J=7.9 Hz, 2xAr-H), 7.68-7.73 (2H, 
m, 2xAr-H), 8.01 (2H, s, 2xAr-H), 8.68 (2H, s, 2xAr-H); 
13
C NMR (ppm): 124.4 (2xCH), 125.4 
(2xCH), 126.5 (2xCH), 128.5 (2xCH), 133.6 (2xC), 133.9 (C), 134.6 (2xC), 138.1 (C), 150.0 
(2xCH). 
 
Synthesis of N-substituted 3-bromoaniline compounds 29a-c 
General procedure: 
To a solution of the chloro-compound 20b,d,e (1 eq) in acetonitrile in an oven dried microwave 
vial, potassium iodide (0.2 eq) and 3-bromoaniline 28 (3 eq) were added. 
The vial was heated under microwave irradiation for 10 minutes at 110°C. The cooled reaction 
mixture was diluted with dichloromethane, washed with aqueous saturated sodium hydrogen 
carbonate, dried over MgSO4, concentrated in vacuo and purified via column chromatography.   
 
N'-(3-bromophenyl)-N,N-diethylethane-1,2-diamine 29a: The crude was purified by 
chromatography  (dichloromethane:methanol 9:1). Yield 83%,  
1
H NMR (ppm): 1.17 (6H, t, J=7.12 
Hz, 2xCH3), 2.8 (4H, q,  J=7.12 Hz, 2xCH2), 2.91 (2H, t, J=5.7 Hz, CH2), 3.29 (2H, bs, CH2),  6.58 
(1H, dd, J=2.1, 8.0, Ar-H), 6.76 (1H, t, J=2.1, Ar-H), 6.80 (1H, dd, J=2.1, 8.0, Ar-H), 7.00 (1H, t, 
J=8.0, Ar-H); 
13
C NMR (ppm): 10.4 (CH2), 39.9 (CH2), 47.0 (2xCH3), 51.4 (2xCH2), 111.9 (CH), 
115.1 (CH), 120.2 (CH), 123.3 (C), 130.6 (CH), 149.2 (C). 
 
3-Bromo-N-[3-(4-methylpiperazin-1-yl)propyl]aniline 29b: The crude was purified by 
chromatography (dichloromethane:methanol 9:1).Yield 20%,  
1
H NMR (ppm): 1.79 (2H, 5q, J=6.4 
Hz, CH2), 2.35 (3H, s, CH3), 2.50-2.55 (10H, m, 5xCH2), 3.16 (2H, t, J=6.4 Hz, CH2), 4.88 (1H, bs, 
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NH), 6.49 (1H, ddd, J=0.75, 2.2, 8.0 Hz, Ar-H), 6.71 (1H, t, J=2.2 Hz, Ar-H), 6.77 (1H, ddd, 
J=0.75, 2.2, 8.0 Hz, Ar-H), 6.99 (1H, t, J=8 Hz, Ar-H); 
13
C NMR (ppm): 25.4 (CH2), 43.3 (CH2), 
45.9 (CH3), 53.0 (2xCH2), 55.2 (2x CH2), 57.1 (CH2), 111.5 (CH), 114.9 (CH), 119.6 (CH), 123.3 
(C), 130.4 (CH), 150.0 (C). 
 
3-Bromo-N-[2-(pyrrolidin-1-yl)ethyl]aniline 29c: The crude was purified by chromatography 
(dichloromethane:methanol 95:5). Yield 46%, 
1
H NMR (ppm): 1.89 (4H, bs, 2xCH2), 3.04-3.05 
(6H, m, 3xCH2), 3.36 (2H, q, J=5.65 Hz, CH2), 6.66 (1H, dd, J=1.7, 8.1 Hz, Ar-H), 6.75 (1H, dd, 
J=1.0, 7.8 Hz, Ar-H), 6.83 (1H, t. J=1.7 Hz, Ar-H), 7.08 (1H, t, J=8.1 Hz, Ar-H); 
13
C NMR (ppm): 
22.7 (4xCH2), 53.3 (2xCH2), 111.2 (CH), 114.1 (CH), 118.3 (C), 122.4 (CH), 130.7 (CH), 149.9 
(C). 
 
Synthesis of O-substituted 3-bromophenol compounds 29d,e 
General procedure: 
3-Bromo-phenol 30 (1 equiv), 1-(2-chloro-ethyl)-amino compound 20d,e (1 equiv) and potassium 
carbonate (8 equiv) were diluted with dimethylformamide and stirred for 2 days. The contents were 
poured onto ethyl acetate water mixture and extracted. The organic layer was separated, washed 
with brine and dried over MgSO4,  concentrated in vacuo and purified via column chromatography 
to give the desired compound. 
 
1-[2-(3-Bromophenoxy)ethyl]pyrrolidine 29e: The crude was purified by chromatography  
(dichloromethane:methanol 98:2). Yield 48 %; 
1
H NMR:  1.81 (4H, quint, J=3.1 Hz, 2xCH2), 2.61-
2.64 (4H, m, 2xCH2), 2.90 (2H, t, J=5.9 Hz, CH2), 4.08 (2H, t, J=5.9 Hz, CH2), 6.83-6.86 (1H, m, 
Ar-H), 7.05-7.15 (3H, m, 3x Ar-H); 
13
C NMR (ppm): 23.5 (2xCH2), 54.7 (2xCH2), 54.9 (CH2), 67.4 
(CH2), 113.6 (CH), 118.0 (CH), 122.8 (C), 123.8 (CH), 130.5 (CH), 159.7 (C). 
 
2-(3-Bromophenoxy)-N,N-diethylethanamine 29d: The crude was purified by chromatography  
(dichloromethane:methanol 9:1). Yield 78 %; 
1
H NMR:  1.06 (6H, t, J=7.2 Hz, 2xCH3), 2.64 (4H, 
q, J=7.2 Hz, 2xCH2), 2.86 (2H, t, J=6.2 Hz, CH2), 4.02 (2H, t, J=6.2 Hz, CH2), 6.83 (1H, ddd, 
J=1.2, 2.3, 8.1 Hz, Ar-H), 7.05-7.07 (2H, m, 2x Ar-H), 7.12 (1H, t, J=8.1 Hz, Ar-H); 
13
C NMR 
(ppm): 11.9 (2xCH3), 47.9 (2xCH2), 51.7 (CH2), 66.9 (CH2), 113.6 (CH), 117.9 (CH), 122.8 (C), 
123.7 (CH), 130.5 (CH), 159.7 (C). 
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Synthesis of benzene bis oxazole compounds 11a-e 
General procedure: 
An oven dried microwave vial was charged with palladium acetate (0.1 eq), potassium carbonate (3 
eq), ligand (2-dicyclohexylphosphino-2’,6’-diisopropoxybiphenyl) (0.2 eq), compound 24 (1 eq) 
and compound 29a-e (2.2 eq). The microwave vial was capped, evacuated and backfilled with 
argon and then pivalic acid (0.4 eq) and toluene were added. The vial was heated at 110°C for 72 
hours. After cooling to room temperature, the reaction mixture was concentrated and purified. 
 
N1,N1'-[benzene-1,3-diylbis(1,3-oxazole-5,2-diylbenzene-3,1-diyl)]bis(N2,N2-diethylethane-
1,2-diamine) 11a: The crude was purified by chromatography (dichloromethane:methanol 95:5). 
Yield quantitative;  
1
H NMR (ppm): 1.05 (12H, t, J=7.1 Hz, 4xCH3), 2.64 (8H, q, J=7.1 Hz, 
4xCH2), 2.68 (4H, t, J=6.9 Hz, 2xCH2), 3.24 (4H, q, J=6.9 Hz, 2xCH2), 5.85 (2H, bs, 2xNH), 6.81-
6.84 (2H, m, 2xAr-H), 7.31 (2H, t, J=7.7 Hz, 2xAr-H), 7.37-7.40 (4H, m, 4xAr-H), 7.69 (1H, t, 
J=7.9 Hz, Ar-H), 7.87 (2H, dd, J=1.5, 7.9 Hz, 2xAr-H), 8.01 (2H, s, 2x Ar-H), 8.28 (1H, t, J=1.5 
Hz, Ar-H); 
13
C NMR (ppm): 11.6 (2xCH2), 46.5 (4xCH3), 51.1 (2xCH2), 4xCH2 is hidden 
underneath DMSO peak, 108.9 (CH), 113.6 (2xC), 114.6 (2xC), 119.1 (2xC), 119.1 (2xC), 123.7 
(2xC), 125.0 (CH), 127.3 (2xCH), 128.4 (2xCH), 129.7 (2xCH), 130.0 (CH), 149.2 (CH), 149.8 
(2xCH), 161.3 (2xCH). 
 
3,3'-(Benzene-1,3-diyldi-1,3-oxazole-5,2-diyl)bis{N-[3-(4-methylpiperazin-1-yl)propyl]aniline} 
11b: The crude was purified by prep-HPLC. Yield 12%; 
1
H NMR (ppm): 1.26 (4H, s, 2xCH2), 1.65 
(4H, bs, 2xCH2), 1.85 (4H, 5q, J=6.3 Hz, 2xCH2), 2.31 (6H, s, 2xCH3), 2.51-2.55 (12H, m, 6xCH2), 
3.30 (4H, t, J=6.3 Hz, 2xCH2), 6.72 (2H, dd, J=1.6, 8.1 Hz, 2xAr-H), 7.29 (2H, t, J=7.8 Hz, 2xAr-
H), 7.35 (2H, t, J=1.6 Hz, 2xAr-H), 7.46 (2H, d, J=7.8 Hz, 2xAr-H), 7.49-7.53 (3H, m, 3xAr-H), 
7.69 (2H, dd, J=1.5, 7.8 Hz, 2xAr-H), 8.01 (1H, bs, Ar-H); 
13
C NMR (ppm): 25.6 (2xCH3), 43.5 
(2xCH2), 46.0 (2xCH2), 53.2 (4xCH2), 55.3 (4xCH2), 57.2 (2xCH2), 109.8 (2xCH), 115.2 (2xCH), 
115.3 (CH), 119.7 (2xC), 124.0 (2xC), 124.1 (2xC), 128.1 (2xCH), 129.0 (2xCH), 129.6 (2xC), 
129.7 (2xCH), 149.1 (2xCH), 150.4 (CH), 162.1 (2xC). 
 
3,3'-(Benzene-1,3-diyldi-1,3-oxazole-5,2-diyl)bis{N-[2-(pyrrolidin-1-yl)ethyl]aniline} 11c: The 
crude was purified by prep-HPLC. Yield 32%; 
1
H NMR (ppm): 1.83 (8H, bs, 4xCH2), 2.62 (8H, bs, 
4xCH2), 2.83 (4H, t, J=6.0 Hz, 2xCH2), 3.32 (4H, t, J=6.0 Hz, 2xCH2), 6.76 (2H, dd, J=1.7, 8.0 Hz, 
2xAr-H), 7.30 (2H, t, J=7.9 Hz, 2xAr-H), 7.39 (2H, bs, 2xAr-H), 7.46-7.54 (5H, m, 5xAr-H), 7.69 
(2H, dd, J=1.4, 7.9 Hz, 2xAr-H), 8.0 (1H, s, Ar-H); 
13
C NMR (ppm): 23.5 (4xCH2), 42.2 (2xCH2), 
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53.9 (4xCH2), 54.7 (2xCH2), 110.0 (2xCH), 115.3 (2xCH), 115.4 (2xCH), 119.7 (2xC), 124.0 
(2xCH), 124.1 (2xCH), 128.1 (2xC), 128.9 (2xC), 129.6 (2xC), 129.7 (2xCH), 148.9 (CH), 150.4 
(CH), 162.1 (2xC). 
 
2,2'-[bBenzene-1,3-diylbis(1,3-oxazole-5,2-diylbenzene-3,1-diyloxy)]bis(N,N-
diethylethanamine) 11d: The crude was purified by column chromatography 
(dichloromethane:methanol 8:2). Yield 50%;  
1
H NMR (ppm): 1.14 (12H, t, J=7.15 Hz, 4xCH3), 
2.75 (8H, q, J=7.15 Hz, 4xCH2), 3.00 (4H, t, J=5.9 Hz, 2xCH2), 4.20 (4H, t, J=5.9 Hz, 2xCH2), 7.02 
(2H, dd, J=1.96, 8.1 Hz, 2xAr-H), 7.39 (2H, t, J=8.0 Hz, 2xAr-H), 7.49-7.54 (3H, m, 3xAr-H), 
7.65-7.72 (6H, m, 6xAr-H), 7.96 (1H, s, Ar-H); 
13
C NMR (ppm): 11.4 (4xCH2), 47.8 (4xCH3), 51.6 
(2xCH2), 66.2 (2xCH2), 112.0 (2xCH), 117.3 (CH), 119.1 (CH), 119.7 (2xC), 124.1 (2xCH), 124.2 
(2xCH), 128.5 (2xC), 128.8 (2xC), 129.6 (2xC), 130.0 (2xCH), 150.7 (2xCH), 159.0 (2xCH), 161.3 
(2xC). 
 
5,5'-Benzene-1,3-diylbis(2-{3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-1,3-oxazole) 11e: The crude 
was purified by column chromatography (dichloromethane:methanol 8:2). Yield 75%; 
1
H NMR 
(ppm): 1.90 (8H, bs, 4xCH2), 2.83 (8H, bs, 4xCH2), 3.08 (4H, t, J=5.6 Hz, 2xCH2), 4.31 (4H, t, 
J=5.6 Hz, 2xCH2), 7.05 (2H, ddd, J=0.75, 2.5, 8.3 Hz, 2xAr-H), 7.41 (2H, t, J=8.1 Hz, 2xAr-H), 
7.51-7.55 (3H, m , 3xAr-H), 7.67-7.74 (6H, m, 6xAr-H), 7.98 (1H, t, J=1.42, Ar-H); 
13
C NMR 
(ppm): 23.5 (4xCH2), 54.7 (4xCH2), 54.8 (2xCH2), 66.5 (2xCH2), 112.2 (2xCH), 117.2 (CH), 119.1 
(2xC), 119.2 (2xC), 119.8 (2xC), 124.2 (2xCH), 128.5 (2xCH), 128.8 (CH), 129.7 (2xC), 130.1 
(2xCH), 150.7 (2xCH), 158.9 (2xCH), 161.3 (2xC). 
 
Synthesis of naphthalene bis oxazole compounds 12a,b 
General procedure:  
An oven dried microwave vial was charged with palladium acetate (0.1 eq), potassium carbonate (3 
eq), ligand (2-dicyclohexylphosphino-2’.6’-diisopropoxybiphenyl) (0.2 eq), compound 27 (1 eq) 
and compound 29a,b (2 eq). The microwave vial was capped, evacuated and backfilled with argon 
and then pivalic acid (0.4 eq) and toluene were added. The vial was heated at 110°C for 72 hours. 
After cooling to room temperature, the reaction mixture was concentrated and purified.  
 
N1,N1'-[naphthalene-2,7-diylbis(1,3-oxazole-5,2-diylbenzene-3,1-diyl)]bis(N2,N2-
diethylethane-1,2-diamine) 12a: The crude was purified by column chromatography 
(dichloromethane:methanol 95:5). Yield 86%; 
1
H NMR : 1.06 (12H, t, J=7.1 Hz 4xCH3), 2.61 (8H, 
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q, J=7.1 Hz, 4xCH2), 2.68 (4H, t, J=7.3 Hz, 2xCH2), 3.23 (4H, q, J=7.3 Hz, 2xCH2), 5.85 (2H, t, 
J=5.5 Hz, 2xNH), 6.83-6.85 (2H, m, 2xAr-H), 7.33 (2H, t, J=7.9 Hz, 2xAr-H), 7.38-7.42 (4H, m, 
4xAr-H), 8.01 (2H, s, 2xAr-H), 8.03 (2H, dd, J=1.6, 8.5 Hz, 2xAr-H), 8.12 (2H, d, J=8.5 Hz, 2xAr-
H), 8.5 (2H, s, 2xAr-H); 
13
C NMR (ppm): 11.8 (4xCH3), 41.1 (2xCH2), 46.6 (4xCH2), 51.3 
(2xCH2), 108.9 (2xC), 113.4 (2xC), 114.6 (2xC), 122.4 (2xCH), 122.6 (2xC), 125.1 (2xCH), 125.8 
(2xCH), 127.3 (2xCH), 128.8 (2xC), 129.7 (2xCH), 132.1 (C), 133.1 (C), 149.3 (2xCH), 150.2 
(2xCH), 161.4 (2xCH). 
 
3,3'-(Naphthalene-2,7-diyldi-1,3-oxazole-5,2-diyl)bis{N-[3-(4-methylpiperazin-1-
yl)propyl]aniline} 12b: The crude was purified by HPLC. Yield 10%; 
1
H NMR: 1.91 (4H, quint, 
J=6.6 Hz, 2xCH2), 2.54 (6H, s, 2xCH3), 2.71 (4H, t, J=6.6 Hz, 2xCH2), 2.82-2.92 (16H, m, 8xCH2), 
3.31 (4H, t, J=6.6 Hz, 2xCH2), 6.73 (2H, dd, J=1.6, 8.1 Hz, 2xAr-H), 7.30 (2H, t, J=7.9 Hz, 2xAr-
H), 7.38 (2H, bs, 2xAr-H), 7.50 (2H, d, J=7.9 Hz, 2xAr-H), 7.56 (2H, s, 2xAr-H), 7.78 (2H, dd, 
J=1.3, 8.6 Hz, 2xAr-H), 7.89 (2H, d, J=8.6 Hz, 2xAr-H), 8.25 (2H, s, 2xAr-H), 8.43 (2H, bs, 
2xNH); 
13
C NMR (ppm): 25.4 (2xCH2), 42.1 (2xCH2), 44.1 (2xCH2), 50.9 (4xCH2), 53.2 (4xCH2), 
55.6 (2xCH2), 109.7 (2xC), 115.4 (2xC), 115.5 (2xC), 123.0 (2xC), 124.2 (2xC), 126.3 (2xCH), 
128.2 (2xCH), 128.7 (2xCH), 129.8 (2xCH), 132.6 (C), 133.5 (C), 148.7 (2xCH), 150.9 (2xCH), 
162.0 (2xCH), 167.2 (2xCH). 
 
BIOPHYSICAL STUDIES: FRET 
 
All oligonucleotides and their fluorescent conjugates were purchased from Eurofins. DNA was 
initially dissolved as a stock 20 µM solution in purified water; further dilutions were carried out in 
the relevant buffer. The ability of the compounds to stabilise G-quadruplex DNA was investigated 
using a FRET assay modified to be used as a high-throughput screen in a 96-well format. 
The labelled DNA were diluted from stock to the correct concentration in a 60 mM potassium 
cacodylate buffer and then annealed by heating to 95°C for 10 min, followed by cooling to room 
temperature in the heating block. Compounds were stored at -20°C as 1 mM stock solution in 90% 
water and 10% DMSO, further dilutions were carried out using the potassium cacodylate buffer. All 
experiment values were determinated in triplicate. 96-well plates (MJ Research, Waltham, MA) 
were prepared by aliquoting 50 µl of the compounds solutions into each well, followed by 50 µl of 
the annealed DNA. Measurements were made on a DNA Engine Opticon  (MJ Research) with 
excitation at 450-495 nm and detection at 515-545 nm. Fluorescence readings were taken at 
intervals of 0.5°C over the range 30-100°C, with a constant temperature being maintained for 30 
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seconds prior to each reading to ensure a stable value. Final analysis of the data was carried out 
using a script written in the program Origin 7.0 (OriginLab Corp., Northampton, MA). In brief, the 
raw data from the fluorescence detector was first smoothed using a 10-point running average and 
subsequently normalised. For the determination of the melting temperature, the first derivative of 
the smoothed melting curve was then calculated, and the resulting value plot against compound 
concentration as ∆Tm with respect to the native melting profile of the sequences. 
 
IN VITRO CELL ASSAY 
 
The cell lines MCF7, A549, MIA-Pa-Ca-2, RCC4, 786-0 (European Collection of Cell Cultures) 
and WI38 were maintained in monolayer culture in 75 cm
2
 flasks (TPP, Switzerland) under a 
humidified 5 % CO2 atmosphere at 37 °C. Incubations were also done under these conditions, 
unless specified otherwise. For the cell lines MCF7 and A549, the medium Dulbecco’s MEM 
(GIBCO 21969, Invitrogen, UK) supplemented with L-glutamine (2 mM, GIBCO 25030, 
Invitrogen, UK), essential amino acids (1 %, GIBCO 11140, Invitrogen, UK), foetal bovine serum 
(10 %, S1810, Biosera, UK) was used. The medium MEM (M2279, Sigma, UK) with added L-
glutamine (2 mM), essential amino acids (1 %) and foetal calf serum (10 %) was used for the cell 
line WI38. Cells were sub-cultured every 3 to 4 days by washing with phosphate buffered saline ( 
Gibco, Invitrogen, UK), followed by tripsinisation (Gibco, Invitrogen, UK) and re-seeding into 
fresh medium. 
In a 96 well plate the required number of cells was seeded in 160 l of the appropriate media and 
incubated overnight at 37°C. The drugs were stored at 4°C as 10 mM stock solution in DMSO, this 
solution was first diluted with a 1 mM aqueous solution of HCl to 1mM concentration and further 
diluitions were performed in the required media. 
Then 40 l of the stock solution of the drug were added to the cells, which were incubated for 96 
hours. For positive and negative controls 40 l of media was added instead. 
After 96 hours the plates were emptied and the cell fixed with trichloroacetic acid solution (10 g 
TCA in 100 ml H2O, 160 l per well; Sigma-Aldrich, UK) for 30 minutes in ice. The supernatant 
was then removed the plates were washed with water and dried at 60°C for one hour. The plates 
were then stained with SRB (0.4% stain in 1% acetic acid w/v, 80 l per well; Sigma-Aldrich, UK) 
for 15 minutes. 
The excess of SRB was removed with 1%5 acetic acid, the plates were wiped and dried at 60°C. 
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The dye was extracted with 10 mM Tris base (100 l per well; Sigma-Aldrich, UK) for 
determination of optical density in a computer-interfaced, 96-well microtiter plate reader (Anthos 
2010, Anthos Labtec, Austria) at 540 nm. 
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